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The growing use of decision analytic modelling (DAM) to aid decision making in healthcare has 
triggered the need for increased scrutiny of the methods used and the assessment of 
compliance with these methods. The assessment of structural uncertainty surrounding the 
choice of model structure and model external validity represent some of most frequent 
challenges faced by researchers.  
This thesis used systematic reviews and two case studies focused on the self-management of 
hypertension in patients at high risk and thrombolysis in acute stroke to critically examine all 
available guidelines and statements of good practice and the adherence of current research 
to good practice guidelines. Two case studies were developed to assess structural uncertainty 
surrounding the choice of model structure and the impact of the exclusion of secondary 
events.   
The results here indicate that DAM guidelines lack practicality due to the extensive amount of 
information available and their complexity; furthermore, researchers are failing to identify 
and correctly assess model structural uncertainty. This thesis makes an important contribution 
to current knowledge by developing and proposing the use of a practical five-dimension 
framework to improve the current standards of reporting results of DAM and by illustrating, 
through case studies, the assessment of structural uncertainty arising from the choice of 
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CEA compares the relative costs and outcomes (consequences or effects) of different courses 
of action. The differences between the costs and consequences of the various alternatives are 
presented in the form of a ratio or the cost per unit of health effect. Cost-effectiveness results 
are usually presented as incremental costs, incremental effects and the incremental cost-
effectiveness ratio (ICER)1. For example, given two options x and y, first their respective costs 
and effects are estimated; then the difference in costs and difference in effects are calculated; 
then the existence of dominance is checked (the intervention costs less and is at least as 
effective as the comparator); and, only if dominance is not found, the ICER is estimated as the 
difference in costs divided by the difference in effects: 







Consequences or the effects of alternative interventions are estimated using different types 
of measurement units, for example, the effect of a blood pressure intervention can be 
measured by the cost per 1 mmHg reduction in systolic blood pressure. The choice of the 
measure of effect used in cost-effectiveness analysis is limitless, examples include cost per 




A broader measure of the effect of a health care intervention is utility. Utility is viewed as a 
useful measure because it allows for health-related quality of life adjustments to a given set 
of treatment outcomes and at the same time provides a generic outcome measure for the 
comparison of costs and outcomes2. 
CUA allows the comparison of different health outcomes (prolongation of life, prevention of 
blindness or relief of suffering) by measuring them in terms of a single unit. This is most 
commonly the quality-adjusted life-year (QALY) although other generic outcome measures 
including the disability-adjusted life-year (DALY) and the healthy-years equivalent (HYE) have 
been proposed2. In general terms, any state of health or disability is assigned a utility on a 
scale ranging from 0 (equivalent to immediate death) to 1 (a state of perfect health). The 
outcome of any health intervention can then be calculated as the product of the increase in 
utility that it may cause and the time in years over which it may be enjoyed. When allocating 
scarce resources, those interventions that are expected to produce fewer QALYs for any given 
cost are given a lower priority and vice-versa. 
The ability to compare directly costs of different health outcomes in monetary terms is 
attractive to the decision-maker. CUA has been at times termed as controversial because it is 
difficult to put a value on health status or on an improvement in health status as perceived by 





 “Cost-benefit analysis purports to be a way of deciding what society prefers. Where only one 
option can be chosen from a series of options, CBA should inform the decision maker as to 
which option is socially most preferred” (Dasgupta and Pearce3, 1978. p. 46). Key to this 
definition is the identification of, measurement and valuation of benefits and costs arising 
from a change in the provision of a service or a good.  
While economic evaluation is about assessing costs and consequences of competing uses of 
scarce resources, a new bridge, a new intervention, or a new drug, at root of applied CBA is 
the theory of welfare economics. Welfare economics allows the development of a social 
ordering where trade-offs are made between rankings of ‘better than’, ‘worse than’ or ‘equally 
as good as’.  
The trade-offs that people make as they choose less of one good and substitute more of some 
other good reveal something about the value people place on these goods. Value measures 
based upon such substitutability are calculated in a number of ways, including the willingness 
to pay (WTP) and willingness to accept (WTA) measures. 
CBA place monetary values on the gains and losses to those affected by a change in the level 
of provision of a good for which there is often no market, for example, health care. It allows 
the calculation of net gain or loss from a policy change, and determination of whether the 
change is potentially Pareto-improving4 (meaning that the gainers from the change could 
hypothetically compensate the losers from the change). 
  
Cost-effectiveness analyses and cost-utility analyses are techniques that aim to determine the 
best allocation of an existing budget2. However, CEA or CUA are not the appropriate 
instruments to give answer to questions, for example, what is the underlying value to society 
of gaining additional QALYs or how much in total is it worth spending on health care rather 
than on other social objectives (for example, education or defence).  
CBA allows answering, for example, if a procedure reduces mortality, whether the monetary 
value of each death averted (benefits) was greater or less than the costs of obtaining these 
benefits. In addition, CBA, by having a common denominator expressed in monetary terms, 
permits comparisons not just within the health care budget but across different areas of 
spending1. 
 
Net monetary benefit 
Net monetary benefit (NMB) of an intervention is calculated as the total health effects, for 
example, quality-adjusted life years (QALYs), multiplied by the willingness to pay (WTP) for a 
QALY minus the total costs of the intervention:  
𝑁𝑀𝐵 = QALY*WTP - C 
Expected net monetary benefit is defined as the mean of the net monetary benefits across all 
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CHAPTER 1. INTRODUCTION 
 
Economic evaluation in health care has been increasingly used to allocate scarce health 
resources. The financial resources available for the provision of health care interventions 
are never sufficient to fund all health care needs, leaving those who plan, provide, or pay 
for health care services with the challenge of choosing how best to allocate scarce 
resources1. 
 Decision Analytic Modelling (DAM) has been increasingly used in economic evaluation of 
health care to aid decision making, which has led to greater scrutiny of the methods used. 
The increasing use of DAM requires the use of sound analytic methods and consideration 
of the requirements of good practice.  
Stroke is the fourth single largest cause of death in the UK and second in the world5. By 
2020, cardiovascular disease is expected to become the leading cause of death and 
disability worldwide6. Hypertension is a leading risk factor for cardiovascular mortality and 
morbidity worldwide7, 8. 
This chapter introduces the concepts relevant to the development of this research work, 
specifies the aims and objectives, and outlines the structure of the thesis. 
 
2 
1.1. Economic evaluation 
Economic evaluation2, 9 offers a coherent and theoretically based approach to identifying, 
measuring and valuing resource use, costs and outcomes in a health care setting and 
handling uncertainty1. Furthermore, economic evaluation seeks to identify criteria useful 
in deciding between the competing uses of scarce resources2. In other words, it is not 
possible to establish the economic value of an intervention unless its costs and outcomes 
are compared with at least one other alternative option2.  
There are two main features that characterise an economic evaluation2: i) it considers both 
costs and consequences; and ii) choices: resource scarcity and the inability to produce all 
desired outputs necessitates that choices are made between competing alternatives in the 
allocation of resources. These two characteristics define economic evaluation as “the 
comparative analysis of alternative course of action in terms of both their costs and 
consequences”2.  
In economic evaluation the measurement of different types of costs is made in monetary 
units. Costs may be divided into direct medical costs (costs to the NHS), direct non-medical 
costs (family expenditure, social services) and indirect costs or productivity costs (changes 
associated with treatment such as time off work, earlier return to work).2 The 
measurement of consequences in economic evaluation may differ considerably due to the 
nature of what is identified as an outcome2. Methods of economic evaluation currently in 
use include cost-effectiveness analysis (CEA), cost-benefit analysis (CBA) and cost-utility 
analysis (CUA). These are terms which should be understood, and it is important to realise 
that methods of economic evaluation are only an adjunct to decision making. 
3 
 
1.2. Decision analytic modelling in health care 
Economic evaluations are often conducted alongside randomised controlled trials (RCTs), 
using patient level data describing costs and outcomes to estimate the cost-effectiveness 
of a specific health care technology or intervention. However, it has been argued that cost-
effectiveness analysis based only on data from clinical trials does not provide a sufficient 
basis to inform regulatory or reimbursement decisions10. The design of clinical trials may 
not compare all the available options, or provide evidence on all relevant inputs or follow 
up patients over a period long enough to capture differences in economic outcomes. In 
addition, by relying on data from a single clinical trial, other sources of data, such as other 
trials or results of meta-analyses and data from observational studies may be ignored. 
Under these circumstances, DAM provides an alternative framework for economic 
evaluation10. 
Since the 1980s, DAM has been widely used in health care to synthesise clinical and 
economic evidence and to inform resource allocation decisions for the purpose of allowing 
scarce health care resources to be allocated more efficiently9. In the UK, the National 
Institute for Health and Care Excellence (NICE) recommends using the results of decision 
analysis as a basis for estimating cost-effectiveness and informing the allocation of health 
care resources9, 11. 
Decision analytic modelling has been defined as a systematic approach to the analysis of a 
decision problem under uncertainty12. In this thesis DAM is defined as a method that “uses 
4 
mathematical relationships to define a series of possible consequences that would flow 
from a set of alternative options being evaluated”9 (p.6).  
It has been emphasised that, when selecting the appropriate approach to DAM, care 
should be taken over identifying an appropriate model structure for the clinical question 
that is being considered13, 14. For example, cohort models examine the proportions of the 
population undergoing different events associated with costs and effects whilst patient or 
individual level models sample individuals with specific attributes and follow their progress 
over time14. In practice, model structure has usually been defined after considering the 
relationship between inputs and outputs required by the decision maker. The most 
common types of cohort models are decision trees and Markov models9, 13, 14. 
The decision tree is considered to have the simplest of the structures. Patient pathways 
are shown explicitly on a decision tree with associated probabilities and outcome 
measures. From Barton et al13, “if the time frame is short and if the mortality of patients 
does not differ across strategies, a simple decision tree is usually appropriate” (p.111). 
Decision trees are particularly suited for acute care problems, once-only diseases and 
short-term diagnostic or screening decisions. 
Markov models are recursive (repetitive) decision trees that are used for modelling 
conditions that have events that may occur repeatedly over time or for modelling 
predictable events that occur over time (screening for disease at fixed intervals). Markov 
models are suitable to handle the added complexity of modelling options such as the 
representation of progression of chronic disease, recurrent events and assessment of long 
term costs and effects. Some of the commonly identified limitations of Markov models 
5 
include the lack of memory with no account taken of history and the fact that they assume 
a uniform population and equal and constant risk. These limitations may be overcome by 
using a larger number of states or alternatively, by using other types of method (individual 
sampling model - ISM, discrete event simulation - DES)14-16. 
When it is important that a model captures interaction between individuals such as in the 
case of infectious diseases or models that focus on constraints on resources – discrete 
event simulation (DES) or system dynamic models are the recommended strategies14, 15. 
DES allows the representation of each individual’s history and the interaction between 
specific individuals. 
The ISM is used to represent individuals without interactions; the ISM tracks specific 
individuals with potentially heterogeneous characteristics that affect their progression 
through the model14. One of the key advantages of this type of model is that it allows 
modelling multiple co-morbidities which depend on multiple attributes or covariates14, 15. 
The growing use of modelling in economic evaluations, and increased need for the scrutiny 
of the methods used, has led to the emergence of best practice guidelines in the literature. 
Since 1985, guidelines for good practice in DAM have been developed; however, to date, 
there is no agreed standard on what constitutes a good model or how models should be 
formally assessed17. The International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Task Forces have provided leadership in producing and updating sets of 
guidelines16, 18-25 while other authors have made great efforts to synthesise the available 
ones17, 26. 
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To greater or less extent, DAM guidelines have all been concerned with some common 
aspects in the modelling process including the need to identify and synthesise evidence, 
consider all relevant comparators, adopt an appropriate time horizon and reflect 
uncertainty in evidence when presenting results. Each of these factors is considered in turn 
below. 
 
1.2.1. Identifying and synthesising evidence 
Model-based economic evaluations are expected to use all relevant and available sources 
of evidence including parameters relating to the effectiveness of interventions, resource 
use and utilities. Evidence cannot usually be found in a single source and instead needs to 
be drawn from a range of sources. Under these conditions, it has been suggested that a 
framework be adopted to ensure that all available evidence is properly used in 
characterising the decision problem2, 9. 
 
1.2.2. Inclusion of relevant comparators 
An economic evaluation is expected to consider all relevant comparators related to 
different sequences of treatments or interventions. This requirement poses a challenge to 
researchers in terms of bringing together data from several clinical studies using 
appropriate statistical synthesis methods (in consideration of the fact that clinical trials will 
not always compare all the relevant alternatives)9. 
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1.2.3. Time horizon 
An economic evaluation should adopt a time horizon that is sufficiently long to reflect all 
the key differences in costs and outcomes between the alternative treatments being 
compared. For many interventions with a potential mortality effect and where survival 
curves are required to estimate life expectancy, extended time horizons (sometimes 
lifetime) are needed9. However, because the time horizon from trials usually does not 
reflect the full duration of the impact of interventions, decision modelling is needed as a 
framework to extend the results from a short-term trial over a longer time horizon9. 
 
1.2.4. Uncertainty 
The results from an economic evaluation should indicate how uncertainty in the available 
evidence used to parameterise the model translates into decision uncertainty; this includes 
indicating the probability that a given decision is the correct one9. These results are most 
helpful when they are unbiased and the uncertainty about the estimated costs and 
outcomes is properly specified27, 28. The main sources of uncertainty in model predictions 
are related to the model input values and model structure20, 28-30.  
In order to quantify input uncertainty (which can lead to uncertainty in the model output), 
health economists use two main methods. Deterministic sensitivity analysis (DSA) which 
consists of varying manually individual input parameters to test the sensitivity of the 
model’s results to specific parameters or sets of parameters20, and probabilistic sensitivity 
analysis (PSA) where probability distributions are specified for the true values of the inputs 
8 
and then these distributions are propagated through the model using Monte Carlo 
sampling 20, 31-33. In recent years, expected value of perfect information (EVPI) and expected 
value of perfect partial information (EVPPI) analysis have been increasingly used as an 
extension of PSA. These provide important information to policy makers on the 
consequences of adopting the wrong treatment strategy34 - the decision to adopt and 
reimburse the strategy with the highest expected net monetary benefit is based on the 
information available at the time the decision is made with its accompanying uncertainty, 
and, as long as there is uncertainty, there will always be a chance the wrong decision is 
made34.  
Representing uncertainty in the model structure (or about the costs and health effects of 
the various decision options) is difficult since it requires judgements about the ability of a 
model to represent a complex real life decision problem faithfully28. Uncertainty related to 
a model structure is often difficult to handle since it requires judgements about the ability 
of a model to represent a complex real life decision problem faithfully28.  
 
1.3. Cardiovascular disease and decision analytic modelling 
A disease area where DAM is commonly used to extend the results of clinical trials over a 
longer time horizon is cardiovascular disease. Cardiovascular disease is the main cause of 
death worldwide35. Self-management of hypertension can lead to significant reductions in 
blood pressure, thereby reducing the risk of cardiovascular disease36, 37. Cerebrovascular 
accident (commonly known as stroke) is the fourth single largest cause of death in the UK 
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and second in the world5. Treatment with thrombolytic therapy in patients presenting to 
hospital with a recent acute stroke increases the proportion of patients who are free of 
disability38. 
Due to the high morbidity and mortality burden of CVD and its equally important economic 
impact at the level of health systems and families, this is a clinical area where a large 
number of model-based economic evaluations covering both primary prevention of 
cardiovascular disease and acute care interventions for stroke have been undertaken37, 39, 
40. 
 
1.4. Aim and objectives of this doctoral research 
The increasing use of DAM in the economic evaluation of health care interventions requires 
the use of sound analytic methods and consideration of the requirements of good practice. 
Furthermore, there is a need to clarify what is understood by good practice in DAM, how 
existing DAM guidelines have been used, and most importantly, to what extent DAM 
guidance is lacking. 
Which elements of the guidelines pose the greater challenges for modellers or correspond 
to deviances from guidelines in current practice are elements that need to be identified 
and investigated. To date few attempts have been pursued in this line of research.  
It has been argued that alternative model structures can lead to variations in model 
predictions and that inappropriate model structures may lead to poorly informed policy 
decisions, resulting in the inefficient allocation of scarce resources. Therefore, assessing 
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the extent to which model predictions are influenced by choices made during the model 
development process is of utmost importance. 
The analysis of uncertainty and structural uncertainty still seem to pose challenges, starting 
by the many issues that have been defined as structural uncertainty and the methods 
available to pursue such an assessment. No previous research has attempted to assess the 
extent to which structural uncertainty is considered as part of current practice in DAM. 
Therefore, the overall aim of this thesis is to examine the contemporary understanding of 
‘good practice’ in DAM, to assess the extent to which economic evaluations in primary 
prevention of cardiovascular disease and acute care interventions for stroke have adhered 
to good practice guidelines and to examine structural uncertainty arising from the choice 
of a model structure in applied studies. 
The specific objectives are to: 
• identify and critically assess good practice DAM guidelines, and highlight areas in 
which guidelines have failed to provide recommendations  
• identify the extent to which recent model-based economic evaluations of 
interventions focused on lowering the blood pressure of patients with hypertension 
conform to published guidelines for DAM in health care  
• assess the structural uncertainty surrounding the choice of model structure in 
previously published cost-effectiveness analyses in cardiovascular disease, and 
thereby gain insights into the optimum model structure in this setting 
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1.5. Thesis structure 
Following this introductory chapter, Chapter 2 presents the results of a systematic review 
which aimed to identify and critically assess the best practice guidelines available to 
researchers undertaking DAM. Chapter 3 identifies and provides evidence on the 
adherence to best practice guidelines of contemporary economic evaluations using DAM 
in primary prevention of cardiovascular disease, with particular emphasis on the model 
structure and the assessment of structural uncertainty. Chapter 4 outlines the ways in 
which structural uncertainty has been described and understood within the decision 
analytic modelling process. Chapters 5 and 6 examine the impact of model structure on 
cost-effectiveness results through the use of case-studies: 
The case study in Chapter 5 uses a model based economic evaluation of a primary 
prevention intervention aiming to reduce the risk of cardiovascular disease. The second 
case study in Chapter 6 explores whether the cost-effectiveness results for an acute care 
intervention after stroke would have been different if an alternative model structure had 
been used or if other elements pertaining to structural uncertainty had been explicitly 
considered.  
Chapter 7 brings the study main results together, specifically it highlights the key findings 
of this study, interprets and discusses the results in light of methodological and theoretical 
strengths and weaknesses, and formulates recommendations for further research. Chapter 
8 draws conclusions. 
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CHAPTER 2. A SYSTEMATIC REVIEW OF RESEARCH 
GUIDELINES IN DECISION ANALYTIC MODELLING 
 
2.1. Introduction 
Decision analytic modelling (DAM) in health care has been widely used to synthesise clinical 
and economic evidence and to inform resource allocation decisions for the purpose of 
allowing scarce health care resources to be allocated more efficiently2. In simple terms, in 
DAM, a model is structured to represent clinical pathways to examine whether an 
intervention, compared for example to current practice, is cost effective10. Building a 
model requires consideration of important elements including the complexity of the 
clinical area and the available evidence related to the disease, as well as other issues such 
as the scope or boundaries of the model, the appropriate time horizon, the perspective of 
the analysis, the availability of data and a formal synthesis of evidence within the model10, 
41. The increasing use of DAM in the economic evaluation of health care interventions and 
health technology assessments (HTAs) requires the use of sound analytic methods and 
consideration of the requirements of good practice.  
The aim of this chapter is twofold: to perform a review to identify and critically assess good 
practice guidelines, highlighting areas in which these have failed to provide 
recommendations, with emphasis being given to more recent developments, and to 
develop a practical framework to assess adherence to guidelines in DAM. 
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2.2. Methods 
A systematic review of articles written in English was undertaken with the aim of identifying 
published guidelines on DAM in healthcare. The following types of studies were included: 
guidelines for DAM or HTA and other published articles on good practice in DAM. On the 
basis of an assessment of their title and abstract (if available), papers were deemed 
potentially relevant for inclusion if they: 1) provided general guidance in DAM for health 
care or HTA; or 2) provided general criteria against which to assess good practice in DAM 
(e.g., a checklist).  
For the purpose of this review the following were excluded: 1) trials or economic 
evaluations alongside clinical trials; 2) other non-DAM studies including statistical or 
econometric models; and 3) conference abstracts or other non-DAM papers. 
 
2.2.1. Search Strategy 
An initial exploratory approach was utilized which employed search terms used in a 
previous systematic review26 and this helped inform the final search terms identified for 
this review (see Appendix 1, Appendix 2). Further relevant literature was obtained by 
checking the references of the included articles.  
The following bibliographic databases were searched: The Cochrane Library, Cochrane 
Methodology Register (CMR), Cochrane Health Technology Assessments, NHS Economic 
Evaluation Database, Embase, and MEDLINE via Ovid. To avoid duplication, the PROSPERO 
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database of prospectively registered systematic reviews in health and social care was 
searched for any existing or ongoing reviews that addressed similar topics, and none were 
identified. This review covered the period from January 1990 to March 2014, a period that 
has seen the development of guidelines for DAM in healthcare and the consolidation of 
good practice guidelines. 
 
2.2.2. Data extraction 
All studies were manually searched and data extracted from each paper using a data 
extraction form developed to retrieve and organise information from each paper on the 
basis of its main topic, model structure, model uncertainty, model transparency, and 
validation. The data extraction form was developed through a process in which the content 
of the articles informed the “areas” that the data were extracted under. This approach was 
used to ensure that the review did not miss any information related to the model-building 
process. Data were extracted as free text and in the form of a ‘yes/no’ response.  
 
2.3. Results 
Titles and abstracts (if available) were screened using the inclusion and exclusion criteria 
to identify potentially relevant articles. The database search yielded 4,150 studies and 11 
additional studies were identified through other sources totalling 4,161 studies left for 
screening. A total of 3,976 records were excluded because they were economic evaluations 
alongside clinical trials, other non-DAM studies, conference abstracts or duplicates. One-
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hundred and seventy eight full-text articles were assessed for eligibility, of which 145 were 
excluded on the basis of not providing criteria against which to assess good practice in 
DAM.  
In total, thirty-tree studies, corresponding to general guidance or elements of good 
practice in DAM, were included in this review. A flow chart showing the study selection 
process is shown in Figure 2-1. The methodological quality of the articles included in this 
study was not comprehensively assessed using formal checklists because of the diversity 
of the literature included and the nature of the review. 
Of the 33 articles included in this review, 15 studies provided general guidelines for good 
practice or criteria in the form of a checklist. Eighteen articles were focused on particular 
elements of good practice, for example, model structure or uncertainty, or model 

















Figure 2-1 Flow Chart of DAM guidelines using the PRISMA statement  
 
 
# of additional records identified 
through other sources (11) 
# of records identified through 
database searching (4,150) 
 
# of records screened (178) 
# included for review (33) 
# of records excluded after sifting (3976) 
# of records excluded after 
initial categorization (145) 
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2.3.1. Elements of good practice for DAM 
Fifteen studies provided general guidelines for good practice; 8 of the 15 guidelines were 
released before 201217, 18, 26, 42-47, with the remainder making up the ISPOR-SMDM16, 20-25 
set of guidelines. Table 2-1 presents a breakdown of the elements of good practice based 
on the main themes of the guidance, that is, model structure, identifying and synthesizing 
evidence, and model validity. These studies provided a source of complete information on 
the various stages that need to be covered in DAM. Some of the studies constituted a list 
of topics that need to be checked, or questions that modellers need to answer prior to 
constructing a model. Most commonly, guidelines have been presented as a series of good 
practice statements, starting with Weinstein et al18, then Philips et al17, 26 and more recently 
ISPOR-SMDM16, 20-25. DAM guidelines provide a set of principles that might lead, for 
example, to an appropriate model structure or else indicators of areas that require 
consideration in decision modelling17.  
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Table 2-1 General guidelines  




































✓   ✓ ✓   ✓ ✓ ✓   










  ✓ ✓     ✓ ✓ ✓ ✓
Philips et al26 General 
guidelines  
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Philips et al17  Framework 
for quality 
assessment 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓   
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✓ ✓   ✓ ✓ ✓       
















✓ ✓  ✓ ✓  ✓  ✓ ✓ ✓  ✓  
Note: Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines 
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Table 2-1 General guidelines (continuation) 
Paper ID Identifying and synthesizing evidence 






























































































































Sonnenberg et al46  Framework        ✓   ✓✓   ✓ ✓       ✓
Sculpher et al45 Framework        ✓ ✓                   
Soto47  Checklist      ✓ ✓ ✓   ✓ ✓ ✓     ✓  ✓
Weinstein et al18  Good modelling 
practice 
✓       ✓ ✓✓               
Philips et al26 General guidelines  ✓ ✓ ✓ ✓ ✓ ✓✓  ✓ ✓ ✓   ✓✓ ✓
Philips et al17  Framework  ✓   ✓ ✓ ✓ ✓✓ ✓ ✓     ✓✓ ✓
HTA, Canada42  General guidelines      ✓ ✓     ✓   ✓ ✓       ✓
Karnon et al44 Modelling issues             ✓               





 ✓ ✓  ✓  ✓  ✓  ✓
  
✓  ✓ ✓  ✓ ✓ ✓✓  ✓
  
Note: Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines 
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Table 2-1 General guidelines (continuation) 
Paper ID Model validity 
Author(s) / year Topic Face/Internal/technical 










Framework to judge 
adequacy 
✓
   









Weinstein et al 
18  
Methodology regarded as 
good modelling practice 
✓ ✓ ✓ ✓
Philips et al26 General guidelines  ✓
 
✓ ✓




HTA, Canada42  General guidelines in Canada  
    
Karnon et al44 Modelling issues 
    
Earnshaw et al43 Guidelines for economic 
evaluation 
✓
   
ISPOR-SMDM16, 
20-25 
Good research practices ✓ ✓ ✓ ✓
Note: Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines  
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To inform model construction and increase model credibility and validity, these guidelines 
provide a set of principles, checklists, or have stated the agreement of a common 
application16, 21-23, 25, 44-47. For example, guidelines have stated that model construction is 
likely to be influenced by the adoption of simplifying assumptions reflecting issues such as 
data availability, and that the design of a model should not be driven by the data at hand. 
Under these circumstances the identification of the explicit characteristics of the disease 
area that affect model selection, for example, the unit of representation, is considered 
important16, 23, 25, 46, 47. Other aspects in model construction that arise from the application 
of models to specific groups of patients or specific settings include the scope of the model, 
the model perspective, choice of model type, choice of utility structure (e.g. quality 
adjusted utility scale) and the interventions to be included in the model16, 23, 25, 45-47. These 
guidelines identify the characteristics of individuals as a key element aiding the process of 
model selection, that is, whether a model needs to represent individuals or groups or 
interactions between individuals16. Furthermore, guidelines recommend that ‘the 
appropriate model type is determined by purpose, level of detail and complexity’ (p.809)16, 
and ‘explicit processes’ involving expert consultation, influence diagrams or similar should 
be used to convert the conceptualization of the problem into an appropriate model 
structure16.  
ISPOR-SMDM16, 20-25 recognised the difficulty for all models in achieving all the 
recommended best practice for model validation, that is, face validity, internal validity, 
cross validity, external validity and predictive validity. Instead of establishing a minimum 
quality standard, guidelines recommend the adoption of optimal practices that all models 
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should aim for22. Among these, model transparency was identified as a key area of optimal 
practice that should be achieved by all models and is reflected by providing clear 
information on how the model was built, that is, describing its structure, parameter values, 
and assumptions22.  
ISPOR-SMDM16, 20-25 reiterated statements of good practice emphasizing its appropriate 
conduct and furthermore establishing grounds for usage, for example, the use of time 
horizons sufficiently large to capture all health effects and costs relevant to the decision 
problem in cohort simulations16, 20-25; or insisting on the value of model simplicity as long 
as the model’s face validity is not compromised16. 
 
2.3.2. Model structure 
Good practice for selecting a model or the use of alternative model structures was 
discussed in ISPOR-SMDM16, 21, 23 and in 4 of the 18 individual articles included in this 
review13, 14, 48, 49. Model structure should be considered in the initial stages in the process 
of model building (Table 2-2). Guidelines have suggested that before model building, 
researchers should identify the problem and objective of the project, the analytical 
perspective of the model, the scope, the rationale for selecting the particular structure, the 
target population, and the strategies and comparators and then give justification for 
choosing the model type, the time horizon and the disease states13, 14, 16, 49. These initial 
steps are important and will have important implications for the model structure, data 
requirements, and the reporting of the final results obtained from the model.  
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powerful tools to guide 
decision in health care 
Decision tree 
has limited 
ability to reflect 
time; then STM 
seems the 
simplest option 
Markov model if 
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manageable number of 
health states; if not, 
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A good choice if 
individuals are subject 
to multiple or 
competing risks 
Bentley 


















The ability to 
incorporate past 
history is restricted to 




bias and model 
complexity 
Failing to incorporate 
prior event history 
would overestimate 
the impact of an 
intervention; add 
dependency by using 
states that track event 
history; make event 
risks dependent on this 
history 
Brennan 









from taxonomy of 
model structures 
Comparison of health 
technologies and 
synthesising evidence 








developers to select 
the most appropriate 
modelling approach; 


























Two distinct and 
independent aspects: 
mean estimate of cost-
effectiveness and 
exploration of 
uncertainty in the 
model inputs 
Simplicity 
(relates to the 
size of the 
model) is seen 
as an advantage 
Check dependence or 
independence among 
individuals; model 
simplicity is an 
advantage; model 
validation; challenge 













and analytic input 
(complexity of 
model building) 
Choice depend on 
flexibility vs. time 
availability; there may 
be circumstances 
where DES provides a 
more accurate 
representation of the 
data 
A simpler model 
was the optimal 
technique as 
compared to a 
complex DES 
model 
Results of different 
models (Markov or 
DES) may produce 
likely results; model 
flexibility (DES) may be 
outweighed by greater 
time required to 
evaluate its results 
Note: DES= Discrete Event Simulation; STM= State Transition Model 
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Guidelines for conceptualizing a model’s structure have evolved from statements of 
general principles, for example by stating that the structure of a model should be 
consistent with the theory of the health condition and the available evidence18, to more 
systematic processes describing how to select a model from competing alternatives13, 14, 48, 
49. ISPOR-SMDM16, 21, 23 described the development and construction of a model as a 
process that starts with model conceptualization16 which consists of a two-step process: 
problem conceptualization and model conceptualization. Problem conceptualization in this 
context is transforming knowledge of the healthcare process into a representation of the 
decision problem. Model conceptualization is the representation of the components of the 
problem using a particular decision analytic method (Table 2-2). The nature of the problem 
and the project objectives are decisive in selecting the structure of a model. Furthermore, 
ISPOR-SMDM16, 21, 23 has suggested that the early specification of the decision problem and 
project objectives will improve model-building and the structure of the model (data 
requirements, analytic strategy and reporting)16.  
The importance of the choice of model structure stems from the fact that alternative model 
structures can have an impact on model results and thereby affect decision making13, 14, 16. 
The appropriate model type should be determined according to its purpose, level of detail 
required, and complexity16. As previously demonstrated, guidelines aid the selection of an 
appropriate modelling approach by providing an overview of competing approaches and 
highlighting examples of where each alternative technique should be employed13, 14, 16. The 
most common issues affecting a model’s selection are16, 21, 23: 1) the unit of representation, 
does a model represent individuals or groups? This affects the level of detail required for 
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the variables that predict outcomes16; 2) whether the decision problem requires the 
modelling of the effect of an intervention on disease spread or use of limited resources, in 
other words, if interactions among individuals need to be represented, then models 
designed for patient interactions are necessary16; and 3) the time horizon is dictated by the 
problem scope. For example, decision trees are considered appropriate for models with 
very short time horizons, while longer horizons require the use of models such as State-
Transition (for example a Markov) or Discrete Event Simulation DES16. 
Among the most difficult stages in the conceptualization of a model is the selection of the 
appropriate level of model complexity, as very simple models may lose face validity if they 
do not incorporate all the aspects that experts feel are required; whereas complex models 
may be difficult to build, debug, analyse, understand and communicate16. Guidelines have 
generally supported the choice of simpler models as ‘model simplicity is desirable for 
transparency, ease of analysis, validation and description’16, while at the same time it is 
recognised that under certain circumstances, more complex models may be needed. 
Consensus-based guidelines, stating common grounds for the application of more complex 
model structures, have been developed, that is, state-transition models, discrete event 
simulation and dynamic transmission models23-25.   
 
2.3.3. Model uncertainty and synthesis of information  
ISPOR-SMDM20 and an additional eleven individual papers27, 28, 31, 50-57 provided 
methodological guidelines for the analysis of model uncertainty (methodological, 
structural, parameter, heterogeneity and stochastic), and the use of sensitivity analysis. 
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Step by step guidelines and checklists have been developed (Table 2-3) to aid researchers 
in accounting for uncertainty or to identify how uncertainty is incorporated in a model or 
to address special model circumstances, for example where the evidence is insufficient to 
give a clear representation of the uncertainty through parameter distributions20, 31. The 
view presented by some of the studies included in this review is that many published 
models still fail to account correctly for the major sources of uncertainty, in particular 
structural uncertainty, indicating that a gap may still exist between techniques, guidelines, 
and what is done in practice31, 54. 
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Table 2-3 Model uncertainty and synthesis of evidence 
Author(s)  Area of 
guideline 










Responsible reporting; use 
of terminology; justify its 
omission; decision 
maker’s role; preferable 
parameterize uncertainty 
from structural 
assumptions if possible 
Use tornado 
diagrams, threshold 
plots, or statements 
of threshold 















For structural uncertainty, 
calibration approaches; for 
parameter uncertainty  DSA or 
PSA; for point and interval 
estimates use CI or 







checklist   
Formulate decision-
problem; specify sources 
of uncertainty; obtain 
information and evidence; 
report results; apportion 
uncertainty to sources 
Report choices of 
normative 
approach(es); 
present sources of 
uncertainty; use 
distributions; assess 
the most influential 
sources of 
uncertainty; report 





State if there are more than 
one approach that can be 
used; use distributions; assess 
the most influential sources of 
uncertainty; global sensitivity 
analysis; PSA  
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Author(s)  Area of 
guideline 
General principles Way of reporting Methodological 
issues 
Methods /recommendations 
Jain et al54  Sensitivity 
Analysis  
Report all sources of 
uncertainty; Strengths and 





If long term analysis 
is needed, conduct 
CEA under various 
time horizons; use for 
instance, tornado 
diagrams, or 









can be addressed by providing 
results for a 'reference case'; 
DSA or PSA.  
Koerkamp 




Consider range of 
assumptions for the 
natural course of a 
disease; provide model for 
every set of assumptions 
instead of using the single 
best model; trade-off 
between the realism of a 







uncertainty; if the 
purpose of the PSA is 












PSA joint uncertainty; 
parameterisation model 
structure uncertainty; first-
order Monte Carlo analysis for 
stochastic; DSA for parameter 





Various sources: statistical 
models, evidence used, 
states or clinical events 








Reference case model; assign 
distributions; use PSA; for 
non-parameterised 
uncertainties use global 
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Author(s)  Area of 
guideline 
General principles Way of reporting Methodological 
issues 
Methods /recommendations 







Uncertainty in model 
structure is complex; it 
involves making 
judgements about 
model's ability to 
accurately represent a 
decision problem  
Most commonly by 
PSA, however, it will 
only quantify 
uncertainty about the 
costs and 
consequences; 
problem when a 






To properly represent 
uncertainty about the costs 
and outcomes, structural 
uncertainty must be 
presented; structural 
uncertainty measured with 






Impossible to accurately 
predict mean costs and 
outcomes; sources are 
treatment effects and 






uncertainty can be 
parameterised, then 









Model selection (not 




representing uncertainty by 






If there is a need to 
specify a distribution over 




performing SA if 
a node has 2 or 
Use Dirichlet distribution, a 
multivariate equivalent of the 
beta distribution 
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Author(s)  Area of 
guideline 





multiple branches at a 
chance node 
multiple branches at 
a chance node? 
more branches 
and the sum of 
the branch 
probability is 





Cohorts are defined based 
on population 
characteristics; sometimes 
other characteristics may 
be overlooked (disease 
incidence or progression), 
causing heterogeneity  
Heterogeneity bias 
may be evaluated as 




disease; RR of disease 
with vs. without the 
factor; iii) baseline 
prevalence of the 
factor 
The assumption 
that each health 
state contains a 
homogenous 
population 
group does not 
always hold: for 
instance, in the 
presence of risk 
factors affecting 
the risk of 
developing 
disease  
Adjust by introducing an 
heterogeneity factor; 
probability of transitioning to 
disease dependent on 
heterogeneity factor; 
transition probabilities 




Uncertainty Study designs included 
were modelling-type 
based approaches 
The majority included 











Reference case (comparability 
of results); potential for ICER 
to vary; avoid selective 
comparison; uncertainty; 
interval estimates; SA; 
probabilistic nature of 
reported range; descriptive 
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Author(s)  Area of 
guideline 







statistics; estimate CI; present 
CEAC  
Andronis 
et al58  
Sensitivity 
analysis 
DSA requires variables 
and sources to be 
justified; for PSA 
distributions should be 
placed around all 
parameters (excluded 
parameters should be 
justified) 
Repeated analysis 
should be run using 
different models and 
methods where 




Univariate, multivariate, PSA 
and DSA; distributions in line 
with logical bounds; if 
correlation is expected, use 








multivariate SA to assess 
robustness; however, SA 
does not inform joint 
uncertainty  
Alternative 
approaches as a 
result of the 
intractability of the 
ICER: Net Health 
Benefit (NHB) and 
CEAC 
ICER difficulty 
apparent if a 
distribution 
extends over 
more than one 
quadrant 
NHB, however, a problem if 
lambda is unknown; CEAC, 
however, same problem with 
lambda; uncertainty can be 
accounted for using Bayesian 
methods 
Note: DSA= Deterministic Sensitivity analysis; PSA= Probabilistic Sensitivity Analysis; EVPI= Expected Value of Perfect Information; CI= Confidence 
Intervals; SA= Sensitivity Analysis; CEA= Cost-Effectiveness Analysis; RR= Risk Ratio; ICER= Incremental Cost-Effectiveness Ratio; CEAC= Cost-
Effectiveness Acceptability Curve; NHB= Net Health Benefit 
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Assumptions adopted in decision models determine their final structure and can consider 
the choice of relevant comparators and health states, or available clinical evidence that 
determines the type of adverse events, duration of treatment effects, time dependency of 
probabilities and prognostic implications of surrogate end points or the clinical events 
included20. Structural uncertainties arise when these structural assumptions are not 
formally quantified and it is uncertain whether they accurately reflect reality20. Current 
methods for addressing structural uncertainty include scenario analysis (presenting the 
results under different model structures); model averaging (presenting results of different 
models using different assumptions and an average across these models); 
parameterisation of structural uncertainty; and in the absence of data or presence of weak 
data, expert elicitation to translate expert beliefs into probability distributions27. Model 
structure plays an important role in defining the relationship between inputs and outputs 
to the point that it has been recognised that structural uncertainty may be at least as 
important, in terms of its impact on results, as parameter uncertainty20. ISPOR-SMDM20 
highlighted the emerging interest in calibration methods as an aid to ensure consistency of 
inputs and outputs in a model. Calibration is used when data are available to match model 
outputs rather than model inputs: it is then necessary to determine parameter values 
which give model results that match the data20.  
Many techniques that aim to capture the various sources of DAM uncertainty have been 
developed and have evolved. However, there still remains some areas in which more 
research is needed, such as: accounting for uncertainty surrounding quality of evidence for 
particular structural aspects; generalisability from one setting to another; and the way 
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multiple sources of evidence should be combined (heterogeneity of parameter values from 
different sources)31. ISPOR-SMDM20 proposed the parameterisation of structural 
uncertainties into a model as an approach to deal with issues around the quality of 
evidence; however, this approach seems to become complex if a complete 
redesign/rebuilding of the model is required (nested structures)20. Under these 
circumstances, guidelines have stated that “where it is impossible to perform structural 
uncertainty analysis, it is important to be aware that this uncertainty may be at least as 
important as parameter uncertainty” and analysts are encouraged to be explicit about the 
structural assumptions that might impact their findings and suggest alternative 
assumptions for future modelling exercises20. 
  
2.3.4. Model transparency and validation  
Four articles discussed methods to assess the consistency or validity of models and model 
transparency, (Table 2-4)22, 59-61. Model transparency reflects the extent to which a model’s 
structure, equations, parameter values and assumptions can be reviewed, and a model is 
considered transparent if any interested reader with the necessary expertise who wants to 
evaluate the model is able to reproduce it22. Model validation has been recommended to 
enhance the credibility of models and as an indicator of reliability in practice guidelines17, 
22, 59-61. Model transparency does not equal the accuracy of a model in making relevant 
predictions; a transparent model may yield the wrong answer, and vice versa, while a 
model may be correct and lack transparency. Thus, transparency and validation are both 
necessary for good practice in modelling22. 
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sufficient detail to 
enable the reader 
to evaluate it 







Models are instruments to help 
decision makers answer complex 
questions; model confidence and 
credibility is demonstrated by clarity 
in model structure, equations, 
parameters, and assumptions, and by 



















Widespread of model calibration 
(probabilistic calibration); a process 
of validation against more 
theoretically grounded approaches is 







Literature review  
Comparing model 
to independent 
data not used in 
the model 
Heterogeneity in 
how results of 
model evaluation 
are reported 
Evaluation via comparison(s) to 
independent studies; structured 
reporting format: empirical study 
description, baseline characteristics, 
study protocol, study outcomes, 






















A model should be 
generated which 
fits all available 
data  
Model based on limited data may not 
be generalisable; uncertainty from 
model assumptions as important as 
parameter uncertainty; new model 
should be generated which fits all 
available data; model validation 
should assess: key events, rate of 
accrual of events and absolute and 
incremental costs and effects 
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Validation involves a set of methods for judging the accuracy of models when making 
predictions. More recent guidelines have used the terms ‘model consistency’ or ‘model 
validation’ to refer to five types of model validity:  
• face validity (evaluation of model structure, data sources, assumptions and results) 
• internal validity (the practical model should behave as the theoretical model 
predicts) 
• cross validity (comparison of results with other models),  
• external validity (comparing model results and real-world results)  
• predictive validity (comparing model results with prospective observed events)17, 
22.  
Principles and methods to enable researchers to assess model validity have been discussed 
and in some cases demonstrated22, 60, 61. However, Kim et al61 established that health 
economic models based on limited follow-up data from one source may not be 
generalisable to longer follow-up periods or other contexts. Furthermore, in addition to 
the standard considerations of uncertainty about parameter estimates, it is important to 
assess the implications of model uncertainty on results, in other words, to undertake 
independent model validation22. 
Best practice recommends that face validity (due to its subjective nature) should be judged 
by people who have expertise in the problem area, but who are impartial and preferably 
blinded to the results22. Internal validity verifies that mathematical calculations are 
performed correctly and are consistent with the specification of the model. Methods to 
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assess internal validity will depend on the model’s complexity, but two main stages of 
internal validity involve the verification of individual equations and their accurate 
implementation. It should be noted that internal validity does not evaluate the accuracy of 
a model’s predictions22. Cross validity involves examining different models and comparing 
their results to then identify and analyse the causes of differences and similarities in these 
results. External validation compares the results of a model with actual data; however, the 
difficulty in identifying ‘alternative data’ has been noted22. Best practice to undertake 
external validation recommends following a formal process to compare a model’s results 
to actual event data. Guidelines provide awareness of the important limitation that 
external validation can only address the parts covered by data sources22. Predictive validity 
remains a highly desirable type of independent model validation due to its potential ability 
to demonstrate the accuracy of the results obtained from the DAM. Its results, however, 
are potentially limited if there are changes in the design of the study or other factors 
outside the control of the study design change during the development of the study22. 
Even though the latest guidelines22 have provided more detailed guidance on how best to 
ensure model transparency and undertake validity checks, which reflect the value of 
concise reporting of a model and advocate the quantification of uncertainties arising from 
differences in assumptions22, some quandaries seem to prevail. For example, to examine 
external validity, modellers are advised to use actual event data. However, that same data 
in many instances will already have been used to parameterise the model – as guidelines 
suggest that the most representative data sources should be used in developing a model. 
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2.4. Development of a new decision-analytic modelling framework 
This review demonstrates that although guidelines have been developed and are available 
to aid researchers to inform the results of their studies and, most importantly, to increase 
the credibility of their results, these guidelines lack practicality due to the extensive 
amount of information available and its complexity.  
The data extraction instrument used in this Chapter was developed through a process in 
which the content of guidelines informed the areas that the data were extracted under. 
This is, the data extraction instrument is a reflection of the key areas of interest in the DAM 
process and consequently, each one of these areas should be considered as an integral 
element in the model-building process. 
This review found that general guidelines concerned with the quality and adequacy of a 
model structure (see Table 2-1) indicated that the conceptualization of a model should at 
least comprise of two elements. Firstly, the conceptualization of the decision problem, 
including the knowledge of the healthcare process that is being represented (analytical 
perspective, target population, outcomes, comparators and time horizon) and secondly, 
the conceptualization of the model that matches the characteristics of a model type with 
the needs of the problem concept (model structure).  
Other areas of guidelines identified through the data extraction instrument were synthesis 
of evidence and model uncertainty (see Table 2-3). In particular, the findings of this review 
indicate that, model uncertainty seems of utmost relevance as published models still fail 
to correctly account for the major sources of uncertainty, in particular structural 
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uncertainty. Finally, another area of relevance identified by this review was model 
transparency and validation which guidelines have agreed are both necessary and 
considered good practice in DAM.   
Current standards of reporting could be improved if a single, comprehensive, user friendly 
and practical instrument is made available to direct researchers towards the key elements 
of good research practice in DAM, which should be assessed and reported to increase the 
credibility of their results. This single instrument should incorporate, as a minimum, the 
previously identified five areas of interest in DAM: problem concept, model concept, 
synthesis of evidence, model uncertainty and model transparency and validation. 
Furthermore, the availability of a single ‘five-dimension’ framework would allow modellers 
and researchers to assess adherence to guidelines in DAM.  
 
2.5. Five-dimension framework 
As previously discussed, the five-dimension framework proposed here incorporates and 
reflects much of the evidence from this systematic review, that is, it has synthesised all 
contemporary guidelines in a checklist instrument. To ensure its consistency, it adopted 
the most up to date and agreed guideline statement when components in each dimension 
were superseded or contradictory. For example, the attributes of good practice as stated 
by Philips et al26 indicate that “the appropriate model type will be dictated by the stated 
decision problem and the choices made regarding the causal relationships within the 
model”. This statement has been replaced by a more systematic process where the 
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appropriate model type is determined by its purpose, level of detail and complexity (see 
section 2.3.1). Therefore, the characteristics that affect model selection are the unit of 
representation, whether or not interactions between individuals are relevant, and the time 
horizon13, 14, 16.  
The five-dimension framework uses the following five-dimension checklist:  
• Dimension 1: Problem concept;  
• Dimension 2: Model concept;  
• Dimension 3: Synthesis of evidence;  
• Dimension 4: Analysis of uncertainty; and  
• Dimension 5: Model transparency and validation  
This framework does not attempt to replace the guidelines provided by ISPOR-SMDM 2012 
or any other contemporary guidelines; instead it attempts to serve as a reference point 
and checklist for the thorough consultation of good practice guidelines (Table 2-5).   
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Table 2-5 Framework to assess adherence to good practice guidelines in decision analytic 
modelling (DAM) 













Is there a written 
statement of the 
decision problem 
and scope of the 
study?  
  
A clear statement of the decision 
problem and scope would determine 
the interventions and health 
outcomes to be measured 
Are the 
objective(s) of the 
















Most common perspectives are: 








Target population should be defined 
in terms of features relevant to the 
decision (geography, patient 
characteristics, including co-morbid 




Are the outcomes 




scope and overall 
objective(s) of the 
model?  
  
Health outcomes may be events, 
cases of disease, deaths, life-years 
gained, quality-adjusted life-years, 
disability-adjusted life-years or other 
measures important to stakeholders 
and should be directly relevant to the 
question being asked 
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Have any adverse 




Interventions may cause negative 
health consequences that need to be 
modelled and discussed as part of the 
study's results. The impact of 
assumptions regarding adverse 
effects of interventions should be 
assessed as part of the structural 
uncertainty analysis 
Comparators 
Is there a clear 





Usually the choice of comparators is 
governed by the scope of the model. 
Impact of assumptions adopted when 
deciding upon comparators should be 
assessed as part of the structural 
uncertainty analysis 
Is there a 
discussion around 
feasible options 
or justification for 
the exclusion of 
feasible options? 
  
The choice of comparators affects 
results and should be determined by 
the decision problem, not by data 
availability. All feasible and practical 
strategies as determined by the scope 
of the model should be considered. 
Constraining the range of strategies 
should be justified 
Time 
horizon 
Is the time 
horizon of the 
model justified 






Time horizon of the model should be 
long enough to capture relevant 
differences in outcomes across 
strategies (lifetime). Time horizon is 




















Usually stated in terms of groups or 
individuals. If groups are being 
modelled most frequently decision 
trees, Markov processes or infectious 
disease models are the correct choice; 
if individuals are being modelled then 
the choice is between DES, dynamic 
transmission models or agent-based 
models 
Is there a need to 
model the 
interaction between 
individuals in this 
model? Has this 
been discussed? 
  
If interactions between individuals is 
required (when the disease or 
treatment includes interactions 
between individuals) then DES, 
dynamic-transmission, or agent-based 
models may be the correct choice 
Does the decision 
problem require a 
short time horizon? 
  
For simple models or problems (short 
time horizon, few outcomes) a decision 
tree may be appropriate; time horizon 
should be large enough to capture all 
health effects and costs directed 
related to the decision problem 
Is it necessary to 
model time in 
discrete cycles?  
  
Continuously for Individual STM or in 
discrete cycles for Markov STM; if the 
assumption that transition 
probabilities do not depend on history 
is not required, then individual STM 
are an alternative; If disease or 
treatment process need to be 
represented as health states, STM are 
appropriate (Markov type) 
Is there a need to 
model competition 
for resources or the 
development of 
  
If the problem requires the ability of a 
model to incorporate interactions 
between individuals and other model 
parts for example to answer questions 
on resource allocation i.e., organ 
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waiting lists or 
queues? 
allocation for transplantation, 
distribution of antiretroviral 
medications in resource-poor 
environments, then a DES may be 
appropriate 
Has a type of model 
been chosen and 
discussed?   
  
It is expected that studies report on 




Has the starting 
cohort been defined 





probabilities or state 
values?  
  
If results may vary by subgroups (age, 
sex, risk factors) it is advisable to 
report results for different cohorts 




understanding of the 
disease or condition 
been modelled? 
  
States should adequately capture the 
type of intervention (prevention, 
screening, diagnostics, and treatment) 
as well as the intervention's benefits 
and harms. States need to be 
homogeneous with respect to both 
observed and unobserved 



















been derived from 
representative data 
sources for the 
decision problem? 
  
Most common sources of data include 
population-based epidemiological 
studies, control arms of trials or 
literature 
Has (all) methods 
and assumptions 







Attention should be given to the use of 
transition probabilities and rates; 
conversion of transition probabilities 
from one time unit to another should 
be done through rates and never 
presented as percentages 
Has parameters 









If results of meta-analyses are used 
consider how confounders are 
addressed and the likelihood of 
increased heterogeneity resulting from 
residual confounding and from other 
biases across studies. Efficacy derived 
from RCT may have to be adjusted for 
compliance to reflect real-world 
effectiveness. Effectiveness derived 
from observational studies must be 
adjusted for confounding. Adjustment 
for time-varying confounding 
(confounders that simultaneously act 
as intermediate steps in the pathway 
between intervention and outcome) 
require special methods such as 
marginal structural analysis or g-
estimation. When results from 
observational studies are used in the 
model, causal graphs can be used to 
explicitly state causal assumptions 
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Has the quality of 




Sources of data and data limitations 
are expected to be discussed 
Has expert opinion 




An expectation that strengths and 
limitations of assumptions adopted 
should be included 
Utilities  





Methods used to obtain utility weights 
and methodology used to transform 
health estate estimates into quality of 
life scores 
Is the source for 
the utility weights 
referenced? 
  
Sources of data and data limitations 
are expected to be discussed 
Cycle length 
and half cycle 
correction 
Has the choice of 
cycle length been 
justified? 
  
It should be based on the clinical 
problem and remaining life expectancy 









Are the costs 
incorporated into 




Sources of data and data limitations 
are expected to be discussed 
Has discount rates 
been reported and 






















For example, in a cohort model states 
need to be homogeneous to observed 
or unobserved characteristics affecting 
transition probabilities to observed or 




Has mean values 
and distributions 
around the mean 
and the source and 




for each parameter 
included in the 
model? 
  
Sources of data and data limitations 
are expected to be discussed 
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Has analyses of 
uncertainty 
pertaining to the 
decision problem 
been included and 
reported? If not, 
has the reasons 
been explained for 
its omission? 
  
Analysis of uncertainty is expected to be 









Tornado diagrams, threshold plots or 
simple statements of threshold 
parameter values, are all appropriate. 
Uncertainty of parameters may be 
represented by several discrete values, 
instead of a continuous range, called 
'scenario analyses'. It is a good practice 
to include the specification of 
parameter’s point estimate and a 95% CI 
range.  





The specific distribution (e.g. Beta, 
normal, lognormal) as well as its 
parameters should be disclosed. When 
PSA is performed without an 
accompanying EVPI, options for 
presenting results include CEAC and 
distributions of net monetary benefit or 
net health benefit. When more than two 
comparators are involved, curves for 
each comparator should be plotted on 





Lack of evidence on correlation among 
parameters should not lead to an 
assumption of independence among 
parameters 
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values been tested 
using DSA or PSA?  
  
Calibration is commonly used to estimate 
parameters or adjust estimated values 
such as overall and disease specific 
mortality and event incidence rates 
Structural 
uncertainty 









For example: i) health states and the 
strategies adopted following the 
recurrence of events; ii) length of 
treatment effects; iii) types of adverse 
effects included; iv) duration of 
treatment effects; v) time dependency of 
probabilities (in a time dependent utility, 
the cost of delaying treatment as a 
function of the time a patient has 
remained in an untreated acute 
pathological state); vi) prognostic 
implications of surrogate end points or 
vii) clinical events. Although these 
structural assumptions are not typically 
quantified, it is uncertain whether they 
express reality accurately and for that 
reason they should be assessed as part of 









If the purpose of a PSA is to guide 
decisions about acquisition of 
information to reduce uncertainty in the 
results, EVPI should be presented in 
terms of expected value of information. 
EVPI is commonly reported in monetary 
terms using net monetary benefit or net 
health benefits; EVPI should be reported 
for specified ICER thresholds 
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Has a graphical 




From observation / proof 
reading / peer review 
Has all sources of 
funding and their role 
been identified? 
   From observation / proof 
reading / peer review 
Have all methods the 
used been 
customised to specific 
application(s) and 
settings? 
   As per description in the 
methods section and peer 
review 
Has the report used 
nontechnical 
language and clear 
figures and tables to 
enhance the 
understanding of the 
model? 
  
 From observation / proof 
reading / peer review 





 From observation / proof 
reading / peer review 
Is there any reference 
as to whether 
technical 
documentation 
would be made 
available at request? 
  
 From observation / proof 
reading / peer review 
Validation 
Is there any evidence 
of model’s face 
validity? 
  
Can occur in several ways: the 
group that develop the model 
can appeal to members of the 
modelling group, people in the 
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same organisation who did not 
build the model, or external 
consultants. Any reader can 
perform his/her own 
evaluation. Peer review 
(previous to publication) 
Has internal validity 
been assessed? 
  
Verification or technical 
validity; models should be 
subject to rigorous verification 
and the methods used should 
be described and results made 




It involves examining different 
models that address the same 
problem and comparing their 
results. Its meaningfulness 
depends on the degree to which 
methods and data are 
independent. Modellers should 
search for modelling analyses of 
the same or similar problems 
and discuss insights gained from 
similarities and differences in 
results 
Has external validity 
been assessed?  
  
This compares the model's 
results with actual event data; a 
formal process needs to be 
developed including identifying 
suitable sources of data; results 
of external validation should be 
made available 




If feasible given the decision 





The DAM guidelines identified in this chapter seem to have responded to the need to 
reflect on how good practice in the field has been defined; the need to keep pace with the 
rapid progress in the way that economic evaluation methodology has progressed since the 
1980s; and as a means to ensure that guidelines for good practice remain current, effective, 
and helpful. More comprehensive guidelines, for example, Philips et al26 or the set of the 
International Society for Pharmacoeconomics and Outcomes Research and the Society for 
Medical Decision Making (ISPOR-SMDM) guidelines, have been developed as part of bigger 
projects, that is, an HTA project involving experts from prestigious academic institutions or 
as part of a ‘task force’ respectively.  
Recommendations and statements of good practice have been proposed following the 
application of different methods. For example, Philips et al26 synthesised good practice 
guidance and accompanying checklist resulted after taking each theme and subtheme 
identified in a systematic review of guidelines followed by technical discussions among the 
research team of its relevance in relation to the development of general guidelines26. 
Guidelines produced by ISPOR-SMDM resulted from a ‘task force’ consisting of expert 
developers and experienced users of models from academia, industry, and government, 
with representation from many countries. A decision was made by the task force to divide 
the DAM topic into six components and working groups, respectively; three of these groups 
covered aspects relevant to all models such as the conceptualization of a model, the 
estimation of model parameters and handling of uncertainty, and the validation of models 
and issues of transparency. The other three components considered specific techniques: 
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state-transition modelling, discrete event simulation, and dynamic transmission models. 
The working groups produced draft reports for each section, and in contrast to Philips there 
was no systematic attempt to review the literature. The first draft of recommendations 
represented the opinions of the experts in the Task Force and these were posted on the 
ISPOR and SMDM Web sites for comment by the general membership of the societies. A 
second group of experts—again, with broad representation of modellers and users of 
models—was invited to formally review the articles. Their comments were addressed and 
after receiving additional comments and considering further revisions, the final version of 
each article was prepared and released to the public (see Section 2.3.1). 
This review has critically compared statements of good practice in contemporary 
guidelines and identified areas in which further work may be needed.  
This chapter demonstrates that: 1) good practice guidelines have been developed and 
agreed; adherence to these guidelines is considered as best practice in DAM; 2) guidelines 
should be seen as tools that if followed will lead to the results obtained being more 
credible; 3) there are common grounds in the application of guidelines; and 4) some 
aspects of the guidelines related to DAM require further development, for example, the 
choice of model structure, assessment of structural uncertainty and achieving predictive 
validity. 
Common grounds have been identified for the application of guidelines in aspects such as 
the specification of a model’s structure, the inclusion of incident cases over the time 
horizon of an evaluation, the use of time horizons, parsimonious model structure, and 
subgroup analysis in DAM. 
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Most decision problems can be conceptualized using one of the available model types, 
while the choice of model structure is unlimited. There is general acceptance of the special 
circumstances under which complex modelling needs to be taken into consideration, while 
at the same time, overly complex models should be avoided if a simpler model can 
accurately reflect all aspects of the decision problem. More research should be undertaken 
of case studies comparing the economic efficiency of simple versus complex models, the 
use of hybrid models which are considered to be very flexible and accurate with no 
restriction on how time is handled21, and the trade-off between model complexities versus 
model transparency. This should be done in light of the advances in computing that make 
complex calculations feasible and economically efficient, opening the way for the more 
generalised use of individual-based simulations21.  
Whether model structure should be informed by data availability or not remains another 
conflicting aspect in DAM. Current guidelines have argued the case for building a model 
first and then looking for the data to populate it, as this strategy will result in more 
appropriate and relevant model structures16. An apparent drawback of this approach as 
argued by detractors is data availability. Alternatively, finding the data to populate the 
model might be possible perhaps by adopting more assumptions based on expert 
opinion16, 21. Independent of the assumptions adopted the model parameters should 
reflect the uncertainty due to the gaps in the available data, which in an ideal world would 
trigger the need for value of information analyses to show the value of this required data20. 
Structural uncertainty remains an area of controversy; an inappropriate structure can 
invalidate the conclusions drawn from cost-effectiveness analyses, while choices made 
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when structuring a model can significantly affect its results and the inferences from it. Until 
recently, even the definition of structural uncertainty was a matter of dispute27, 51; 
however, contemporary guidelines have clarified this concept by using an analogy with 
linear regression, and it is now recommended as good practice to factor in structural 
uncertainties into a model20. 
Another area in which issues have been raised has been with model validity. Guidelines 
have recognised that ‘not all models will be able to achieve all these best practices’, p. 
84422 while the ‘inability to do so does not necessarily imply a model is not useful’, p. 84922. 
Recent guidelines, however, seem to have provided a scope for analysts to use their own 
discretion to solve some issues, provided that the use of ‘optimal practices’, as described 
by methods and recommended practice is demonstrated22. Some aspects of model 
generalisability demand further research because it relies on the availability of follow-up 
data ideally from the same source, and follow-up data from other sources may not be 
generalisable to longer follow-up periods or to new contexts61. 
There are some areas in which there is a contradiction between the guidelines; however, 
it is suggested here these issues can be solved at the discretion of the analysts. A good 
example is when guidelines indicate the use of all feasible and practical comparators16, 26. 
The same guidelines indicate that the choice of comparators is governed by the scope of 
the model, which is a direct consequence of the research question. In other words, even 
though a broad range of feasible strategies may be available, the choice of comparators is 
expected to answer to the decision problem. However, the inclusion or exclusion of 
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potentially relevant comparators should be assessed as part of the structural uncertainty 
of the model51. 
Last but not least, this Chapter proposes the use of a practical five-dimension framework 
to improve current standards of reporting results of DAM. This framework consists of a 
single instrument that is comprehensive by synthesizing all contemporary guidelines in a 
single checklist instrument, is user friendly by reducing the extensive and complex amount 
of information in a single checklist tool and is practical by directing researchers towards 
the key elements of good practice in DAM.  
 
2.6.1. Strengths and limitations 
This chapter contains a comprehensive review of more than a decade of developments in 
DAM, including the most contemporaneous guidelines. Although this chapter has 
discussed all available general guidelines in a single document, the breadth of this field 
determined that this review focuses on aspects that are considered general to all models 
(model structure, model conceptualization, model parameters, model uncertainty, and 
model transparency and validation). The exclusion criteria adopted (abstracts, posters, 
conference papers and non-English language studies) may be considered as a limitation of 
this review; however, these were required to guarantee consistency in the analysis; 
furthermore, a negligible number of non-English language studies were identified 
pertaining to applied studies. Some databases such as HEED, Psychinfo and Cinhal were 
not included in this review mainly because the same references would be identified in 
Medline or else their focus was applied research. This review does not address the choice 
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of data and its processing to yield suitable inputs for the model; the view was taken that 
this is a topic that has been extensively developed in other fields such as epidemiology or 
statistics. Finally, as stated in the previous section, applied studies were excluded that are 
important for identifying which elements of guidelines pose greater challenges for analysts 
or correspond to deviances from guidelines in current practice. This undoubtedly triggers 
the need for research on the adherence of current practice to guidelines and its impact on 
results of decision-modelling emphasizing for example, on issues around the reporting of 
uncertainty analysis or the assessment of structural uncertainty or around areas of 
increasing interest such as the practical use and feasibility of generic models.  
It is the purpose of Chapter 3 to demonstrate how this five-dimension framework might be 
used in practice to assess the adherence of published models to contemporary DAM 
guidelines. This type of exercise is more useful if undertaken for a single disease area or for 
one research question at a time, since this makes it possible to remove some of the 
variation between models which is not relevant for the purpose of assessing adherence to 
guidelines prior to comparing results across a disease area. Furthermore, an assessment of 
adherence, as the one proposed here, i.e. covering a disease area or focused on a particular 
research question, has the added value of contributing to improving current standards of 
reporting, identifying methodological challenges faced by modellers (for example, 
assessment of structural uncertainty or model validation), and contributing to identifying 
the methodological issues not covered in existing published guidelines.   
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2.7. Conclusions  
The framework to judge the adequacy of decision analytic modelling has changed 
dramatically since it was first envisioned. Important attempts have been made to keep 
pace with the rapid progress in the way DAM guidelines have been developed. To date, 
ISPOR-SMDM 2012 constitutes the most contemporaneous, up-to date and agreed set of 
good practice guidelines. However, the results of this Chapter indicate that guidelines lack 
practicality due to the extensive amount of information available and its complexity. This 
Chapter proposes the use of a single instrument to aid researchers improving current 
standards of reporting results of DAM.  
As previously stated, this review excluded applied studies that are important for identifying 
which elements of guidelines pose greater challenges for analysts or correspond to 
deviances from guidelines in current practice. This is taken forward in Chapter 3, where 
research is undertaken on the adherence of current practice to guidelines and its impact 
on results of decision analytic modelling.  
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CHAPTER 3. DO ECONOMIC EVALUATIONS IN PRIMARY 
CARE PREVENTION AND THE MANAGEMENT OF 
HYPERTENSION CONFORM TO GOOD PRACTICE 
GUIDELINES? A SYSTEMATIC REVIEW 
 
3.1. Introduction 
Cardiovascular disease, which incorporates coronary heart disease (CHD) and stroke, is the 
main cause of death worldwide35 and in England and Wales63. Hypertension, defined as a 
persistent raised blood pressure of 140/90 mmHg64, has been recognised as the most 
important modifiable risk factor for CVD63, 64. Poorly controlled high blood pressure can 
damage artery walls and increase the risk of developing a blood clot. Moreover, if it is not 
treated it can also damage organs such as the kidneys, heart and brain. DAM guidelines have 
recognised that RCTs are good sources of evidence to judge the effectiveness of treatments; 
however, because the time horizon for trials often does not reflect the full duration of the 
impact of interventions, DAM is typically used to extend the results of a short term trial over 
a longer time horizon65, 66. A primary outcome used in RCTs that are focused on hypertension 
is often change in blood pressure. However, this is only an intermediate outcome and DAM 
can be used to examine the impact of change in blood pressure on the risk of CVD events in 
the longer term.  
Chapter Two and previously published research67 identified the need for further investigation 
into the compliance of DAM to good practice and its impact on the conclusions drawn from 
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economic evaluations. The aim of this Chapter is to critically evaluate how DAM in primary 
prevention of CVD conforms to guidelines and, in doing so, demonstrate the usefulness of the 
five-dimension framework developed in Chapter Two to assess compliance to guidelines in a 
single setting. The focus here is on one particular clinical area since this makes it possible to 
remove some of the variation between models which is not relevant for the purpose of 
assessing compliance (for example, different outcomes, treatment options or sources of 
uncertainty). CVD prevention has been selected due to the wide number of recent and 
available model-based cost-effectiveness studies conducted in this topic area. This chapter 
focuses on interventions aimed at lowering blood pressure, as a modifiable risk factor for CVD, 
and seeks to answer the research question: ‘to what extent do model-based economic 
evaluations of primary prevention interventions aimed at lowering blood pressure in patients 




Studies of interventions aimed at lowering blood pressure were reviewed and the challenges 
faced when applying DAM methods were identified and discussed. A systematic review was 
conducted, meeting the UK Centre for Review and Dissemination guidance and the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for 
reporting68.  
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The review followed a structured approach for framing research questions: patient population 
(P), intervention (I), the comparator group (C), outcome (O) and the study design (S), or 
PICOS68. Papers published from January 2000 to March 2015 and written in English were 
included in this review if they met all of the following inclusion criteria:  
• the target population was individuals presenting with high blood pressure or at risk of 
developing hypertension;  
• the intervention(s) aimed at lowering blood pressure;  
• management of hypertension, as a modifiable risk factor for CVD, was part of a primary 
prevention strategy (when studies also included secondary prevention, we have 
concentrated on the results for primary prevention); and  
• the study was a model-based economic evaluation. 
This review excluded systematic reviews, guidelines, trials, protocols and conference 
abstracts. In addition, studies were also excluded where the interventions: 
• were aimed at screening blood pressure; 
• were part of a polypill strategy;  
• measured non-adherence to treatment; or 
• were part of a secondary prevention and treatment strategy. 
 
Searches were undertaken using terms identified by expert clinical opinion and a list of 
synonyms identified for each term that helped inform the final search terms used in this 
review (“cost effectiveness”, “mathematical model”, “decision analysis”, “Markov model”, 
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“decision tree”, “economic evaluation”, “hypertension” and “lowering blood pressure”). The 
search was undertaken using truncations and wildcards and all synonyms were subsequently 
combined with appropriate medical subject heading terms (MeSH) or subject terms using 
Boolean operators (Appendix 3, Appendix 4). 
The following databases were searched: EMBASE and Medline via the Ovid interface, and the 
Centre for Reviews and Dissemination’s (CRD) NHS Economic Evaluation Database (NHS-EED). 
In addition, the reference lists of the studies included in this review were manually examined. 
All papers identified by database searching were exported into ENDNOTE-X7TM and duplicate 
references were removed. 
Titles identified by the searches were screened by reading the abstract. Articles that appeared 
to be relevant at this point were obtained and screened against the inclusion and exclusion 
criteria; several studies appeared relevant on reading the abstract but were subsequently 
excluded after reading the full paper.  
All studies were manually searched and data were extracted; any point(s) requiring 
clarification were checked with at least one supervisor. The extraction tool consisted of the 
new framework proposed in Chapter 2 that synthesises contemporary DAM guidelines in a 
single checklist instrument. The tool aided the retrieval and organisation of information from 
each study across five dimensions (Table 2-5): 
i) problem concept; 
ii) model concept; 
iii) synthesis of evidence;  
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iv) analysis of uncertainty; and  
v) model transparency and validation. 
This approach ensured that the review did not miss any information related to the model 
building process. Data were extracted as free text and in the form of a ‘yes/no’ response. 
 
3.3. Results 
The database search yielded 2,607 studies; after removing 27 duplicates, 2,580 studies were 
left for screening ( 
Figure 3-1). 2,549 studies were excluded because they did not consider a CVD related 
intervention, were not a model-based economic evaluation, or were focused on screening ( 
Figure 3-1). 31 full-text articles were assessed for eligibility, of which 18 were rejected as a 
secondary prevention strategy. 13 studies were included in this review, none of which were 
identified through other sources ( 
Figure 3-1).  
Only two of the studies included were published prior to 2004. Thus it can be seen that the 
majority of studies (11/13) would have had access to DAM guidelines at the time of their 
publication such as, for example, Weinstein (200318) or Philips (200426).  
Four studies evaluated programmes for the clinical prevention and treatment of 
hypertension39, 69-71 and nine evaluated antihypertensive drug treatments to lower blood 
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pressure (Table 3-1)72-80. Ten studies were cost-utility analyses (CUA) or combined both CUA 
and a cost-effectiveness analysis (CEA)39, 69, 70, 73-75, 77-80 while three studies were CEA71, 72, 76 
(Table 3-1). The intervention target (risk factor) examined was high blood pressure. The 
remainder of this section describes the main findings. 
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Figure 3-1 Flow chart for the identification of applied studies using the PRISMA statement 
# of records identified through 
database searching (2607) 
 
# of additional records 
identified through other 
sources (0) 
# of records after duplicates removed (2580)  
# of records screened (580)  
# of full-text articles assessed 
for eligibility (31) 
# of articles included in the 
systematic review (13)  
# of records 
excluded (2549) 
• Not CVD 
related (1607) 












Table 3-1 Characteristics of studies, methods and model features 






















et al. (2014) 39 
LT CE of self-
management of 
HPN 
UK NHS  Self-management of 
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Self-management of HPN 
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ICER £1,624/QALY  
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Stevanovic  
et al. (2014) 72 
CE of lowering 
blood pressure 
in patients with 
HPN and low 
CVD risk 




or HCTZ/ARBs versus 
no-treatment  
Various age 
groups: 40, 50, 







4 % for 
costs and 
1.5 % for 
health 
Systolic blood pressure 
reduction was found CE 
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-10 year lifetime: 
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Dead 
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Note: ACE = Angiotensin-Converting-Enzyme Inhibitor; AMI = Acute Myocardial Infarction; ARB = Angiotensin-II-Receptor Blocker; BP = Blood 
pressure; CCB = Calcium-Channel Blocker; CE = cost-effectiveness or cost-effective; CEA = Cost-effectiveness analysis; CHF = Congestive Heart Failure; 
CUA = Cost-utility analysis; CVD = Cardiovascular disease; EchoCar = Echocardiography; EVPI = Expected Value of Perfect Information; HCTZ = 
Hydrochlorothiazide; HF = Heart Failure; HIS = Health Insurance System; HPN = Hypertension; IHD = Ischaemic Heart Disease; LYG = Life Year Gained; 
MI = Myocardial infarction; NHB = Net Health Benefit; NMB = Net Monetary Benefit; LT = Long term; PAD = Peripheral Artery Disease; T_se = Treated, 
side-effects (health state); U_cve_ua = Untreated, cardiovascular event, unaffected (health state); T_cve_ua = Treated, cardiovascular event, 
unaffected (health state); T_se_cve_ua = Treated, side-effects, cardiovascular event, unaffected (health state); U_cve_af = Untreated, cardiovascular 
event, affected (health state); T_cve_af = Treated, cardiovascular event, affected (health state); T_se_cve_af = Treated, side-effect, cardiovascular 
event, affected (health state) 
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3.3.1. Problem concept and model concept 
The decision problem and study objective(s) were stated in all the studies, and all evaluated 
CE from a health care payer perspective. The target decision-maker audience was made 
explicit in 10/13 studies as that of the health care payer, i.e. including only the health effects 
experienced by patients receiving the intervention and costs for the medical services required 
to provide the intervention16. For the remaining studies69, 72, 77 the perspective was left 
implicit. Ekman77 commented that the analysis was “in a Swedish health-care setting”, while 
Stevanovic72 was interested “in the Dutch setting” and Gandjour69 focused on those “insured 
by the German SHI”, where SHI refers to the German Statutory Health Insurance. 
For all studies, the target population was individuals with hypertension or at risk of developing 
hypertension (Table 3-1), frequently stratified by gender, presence of hypertension, age 
groups, and mean age. The target population was always modelled as closed thus reflecting 
patients entering only at the start of the analysis (Table 3-2). 
Despite all the studies sharing a common aim, namely primary prevention of CVD via lowering 
blood pressure, these economic models compared a wide range of interventions and 
presented their results using outcome measures such as QALYs39, 69, 70, 73-75, 77-80, life years 
gained (LYG)71, 72, 74, 76, 78, 80, net health benefits (NHB)76, net monetary benefits (NMB)75 and 
expected value of perfect information (EVPI)75 (Table 3-1).  
Side effects were modelled in only one study73. Four studies39, 69, 72, 80 acknowledged the lack 
of adverse events as a limitation of their results due to lack of data. Two studies argued that 
since ‘previous clinical trials found that first-line hypertensive drugs do not have more side 
effects than placebo’71 or they have ‘mild side effects’77 there was no need to model adverse 
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effects. Similarly another study argued that fatal side effects would have been already 
captured in the clinical trials via the measure of effectiveness76.   
All the studies commented on the reasons for the selection of their comparators, where their 
choice of comparators seems to have been governed by the scope of the study. Two studies 
acknowledged as a limitation the exclusion of relevant comparator(s) arguing that there may 
be more relevant comparators not included77, 79. Furthermore, the ‘do nothing’ option was 
considered in four of the studies69, 72, 76, 77. 
All the studies used Markov models and included a figure showing the model structure; in one 
study71 the structure of the Markov model shown in the figure did not seem to reflect the 
structure of the model described in the text (Table 3-3). The model structures accounted for 
both acute and chronic health states. Five studies made explicit reference to how the structure 
of their models was defined either by using an existing generic model76, being based on 
disease progression39, 69 or consisting of health states designed to reflect the course and 
history of CVD events80. One study reported that ‘health states in the Markov model are based 
on cardiovascular events measured in the previously reported registry study’79. For the 
remaining studies it was inferred that the model structure was based on disease progression. 
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Table 3-2 Dimension 1 - Problem concept 





















Is there a clearly written decision 
problem? Yes Yes Yes Yes Yes Yes 
Are the study’s objective(s) consistent 
with the decision problem and the 
study’s scope? Yes Yes Yes Yes Yes Yes 
Analytical 
perspective 
Has the perspective being stated? 
Yes Yes Yes Yes Yes Yes 
Target 
population 
Has the target population being 
identified? Yes Yes Yes Yes Yes Yes 
Health 
outcomes 
Are the model’s outcome(s) consistent 
with the perspective, scope and 
objective(s)?  Yes Yes Yes Yes Yes Yes 
Have any adverse effect(s) been 
captured? No No Yes No No No 
Interventions 
modelled 
Are the options under evaluation 
clear?  Yes Yes Yes Yes Yes Yes 
Were the inclusion/ exclusion of 
feasible options justified? Yes Yes Yes Yes Yes Yes 
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Is the model time horizon sufficient to 
reflect all important differences 
between options? Yes Yes No Yes Yes Yes 
Have time horizon, duration of the 
treatment and the treatment effect(s) 






























Is there a clearly written decision 
problem? 
Yes Yes Yes Yes Yes Yes Yes 
Are the study’s objective(s) 
consistent with the decision 
problem and the study’s scope? 
Yes Yes Yes Yes Yes Yes Yes 
Analytical 
perspective 
Has the perspective been stated? 
Yes Yes Yes Yes Yes Yes Yes 
Target 
population 
Has the target population been 
identified? 
Yes Yes Yes Yes Yes Yes Yes 
Health 
outcomes 
Are model’s outcome(s) 
consistent with the perspective, 
scope and model’s objective(s)?  
Yes Yes Yes Yes Yes Yes Yes 
Have any adverse effect(s) been 
captured? 
No No No No No No No 
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Are the options under evaluation 
clear?  
Yes Yes Yes Yes Yes Yes Yes 
Were the inclusion/ exclusion of 
feasible options justified? 
Yes Yes Yes Yes Yes Yes Yes 
Time horizon 
Is the model time horizon 
sufficient to reflect all important 
differences between options? 
Yes Yes Yes Yes Yes Yes Yes 
Have time horizon, duration of 
the treatment and the treatment 
effect(s) described and justified? 





Table 3-3 Dimension 2 - Model concept 





















Was the unit of representation given?  Yes Yes Yes Yes Yes Yes 
Does interaction(s) among individuals 
need to be model? If yes, was this 
described? 
No No No No No No 
Does the decision problem require a 
short time horizon? 
No No No No No No 
Is it necessary to model time in 
discrete cycles?  
Yes Yes Yes Yes Yes Yes 
Was the type of model discussed and 
chosen?  
Yes Yes Yes Yes Yes Yes 
Model 
structure 
Was the starting cohort defined by 
demographic and clinical 
characteristics affecting transition 
probabilities or state values?  
Yes Yes Yes Yes Yes Yes 
Were health states and transitions 
reflecting the biological or theoretical 
understanding of the disease 
modelled? 
Yes Yes Yes Yes Yes Yes 
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Continuation 

























Was the unit of representation 
given?  
Yes 
Yes Yes Yes Yes Yes Yes 
Does interaction(s) among 
individuals need to be model? If 
yes, was this described? 
No No No No No No No 
Does the decision problem 
require a short time horizon? 
No No No No No No No 
Is it necessary to model time in 
discrete cycles?  
Yes Yes Yes Yes Yes Yes Yes 
Was a type of model discussed 
and chosen?  
Yes Yes Yes Yes Yes Yes Yes 
Model 
structure 
Was the starting cohort defined 
by demographic and clinical 
characteristics affecting transition 
probabilities or state values?  
Yes Yes Yes Yes Yes Yes Yes 
Were health states and 
transitions reflecting the 
biological or theoretical 
understanding of the disease 
modelled? 
Yes Yes Yes Yes Yes Yes Yes 
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A lifetime time horizon was adopted in all but two studies: of these, one used a five-year73 
time horizon for a population aged 65 years whilst the second used 20-years for a population 
aged 18 and over80. The five-year time horizon was justified as matching the five-year time 
span given to social security authorities in China for budget planning73 whilst the 20-year time 
horizon was not discussed80. Cycle length, though rarely justified in the studies, was always 1 
year. Only one study69 justified their choice of time horizon as most of the data used in their 
model referred to a 1-year period.  
 
3.3.2. Synthesis of evidence 
Patient heterogeneity was considered in most of the studies; results were presented by age 
cohorts69, 70, 72, 73, 76 and gender39, 69, 70, 72-74, 76, 77, 79. Some studies added further analyses based 
on the risk of CVD69, 70, 75, scenarios of SBP reduction72, 77 smoking72 and patient adherence72, 
80. The risks of secondary events were modelled in seven of the studies, e.g. the risk of a 
further stroke after a first stroke70-72, 76-79. In some instances, assumptions were 
acknowledged; for example, the study by Stevanovic72 assumed the risk of secondary events 
to be equal to the risk of a first non-fatal CVD event. The authors acknowledged that this would 
lead to an under-estimation of the CVD risk, and so an increased risk of death in patients 
experiencing non-fatal CVD events was adopted72. In Wisloff76, secondary non-fatal events 
were allowed, and a patient experiencing a secondary event was assumed to be in a health 
state which was worse than the state they were already in. For example, a patient with stroke 
sequelae that experiences a MI will have the risk and costs associated with the stroke sequelae 
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and not those related to MI). Perman71 used expert opinion in the assessment of the risk of 
secondary events. Montgomery70, due to a lack of data assumed that any second 
cardiovascular event was fatal and acknowledged this as a limitation. Some studies that did 
not use separate states to model secondary events39, 69, 80 captured the increased mortality 
from secondary events through the mortality rate of patients surviving CVD events. Few of the 
studies acknowledged the lack of epidemiological data to model secondary events as a 
limitation (Table 3-4)39, 80. 
All studies applied discounting to their results: a discount rate of 3% was most common for 
costs and benefits69, 73, 75, 77, 79, 80; two studies used a different discount rate for costs and 
benefits (Stevanovic used 4% and 1.5%72 while Montgomery used 6% and 1.5%70) (Table 3-1). 
Information on the parameters used as inputs were most frequently presented in tables 
showing mean values and the type of distribution(s) while some studies also included 95% 
confidence intervals or range intervals39, 69, 78. The methods used to report the sources of 
information varied from reporting a detailed list of sources per parameter in a table to 
mentioning the sources of data in the main text.  
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Table 3-4 Dimension 3 - Synthesis of evidence 





















Was patient heterogeneity 
required/considered? 
Yes Yes Yes Yes Yes Yes 
Data sources 
Were transition probabilities and 
intervention effects derived from 
representative data sources?  
Yes Yes Yes Yes Yes Yes 
Were (all) methods and assumptions used 
to derive the model's inputs described? 
Yes Yes Yes Yes Yes Yes 
Were parameters derived from 
observational studies controlled for 
confounding?  
NA NA NA NA NA NA 
Was data quality discussed? Yes Yes No Yes Yes Yes 
If expert opinion was used, was its methods 
described and justified? 




Are the utilities incorporated into the model 
appropriate?  
Yes NA Yes Yes Yes NA 
Was the source for the utility weights 
referenced? 
Yes NA Yes Yes Yes NA 
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Was the use of a half cycle correction 
stated? 
Yes No No No No No 
Resources 
including costs 
Were the costs used in the model justified 
and its sources described? 
Yes Yes Yes Yes Yes Yes 
Were discount rates reported and justified? Yes Yes Yes Yes Yes Yes 
Communicating 
results 
Did the report present results using non-
technical language aided by figures or 
tables? 
Yes Yes Yes Yes Yes Yes 
Parameter 
precision 
Were mean value(s), distribution(s), 
source(s) of data and rationale for the 
supporting evidence described? 




















r et al. 
(2007) 69 
Montgomery 







Was patient heterogeneity 
required/considered? 








Yes Yes Yes Yes Yes Yes Yes 
Were (all) methods and 
assumptions used to derive 
the model's inputs 
described? 
Yes Yes Yes Yes Yes Yes Yes 
Were parameters derived 
from observational studies 
controlled for 
confounding?  
NA Yes NA NA NA Yes NA 
Was data quality 
discussed? 
Yes Yes Yes Yes Yes Yes Yes 
If expert opinion was used, 
were its methods 
described and justified? 
NA NA NA NA No NA Yes 
86 














r et al. 
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Montgomery 









Were the utilities 
incorporated into the 
model appropriate?  
Yes Yes NA Yes Yes Yes Yes 
Was the source for the 
utility weights referenced? 
Yes Yes NA Yes Yes Yes Yes 
Half cycle 
correction 
Was the use of a half cycle 
correction stated? 




Were the costs used in the 
model justified and its 
sources described? 
Yes Yes Yes Yes Yes Yes Yes 
Were discount rates 
reported and justified? 
Yes Yes Yes Yes Yes Yes Yes 
Communicatin
g results 
Did the report present 
results using non-technical 
language aided by figures 
or tables? 
Yes Yes Yes Yes Yes Yes Yes 
Parameter 
precision 
Were mean value(s), 
distribution(s), source(s) of 
data and rationale for the 
supporting evidence 
described? 




3.3.3. Analysis of uncertainty 
The studies examined and reported uncertainty surrounding their identified outcomes 
through sensitivity analysis. Uncertainty in parameter estimates was most commonly handled 
through deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). Five 
studies used only one-way DSA70, 73, 77, 78, 80, whilst another four39, 74-76 only used PSA. Only one 
study measured EVPI75 (Table 3-5).    
Elements pertaining to structural uncertainty were acknowledged as such in six studies39, 69, 71, 
72, 77, 78. Most commonly structural uncertainty was assessed through sensitivity analysis by 
varying the time horizon39, the duration of the effectiveness of the treatment39, 72, the 
discount rate71, 77 or by using alternative measures of outcomes77. One study examined the 
impact of assumptions related to secondary events76. Lack of clinical evidence for key 
parameters such as the treatment effect of drugs39, 69, 72 was identified as a source of structural 
uncertainty. Two studies acknowledged that they could have included more relevant 
comparators had they had more information77, 79, and another two acknowledged that they 
had excluded a potentially relevant state due to lack of epidemiological data69 or insufficient 
evidence regarding its relevance78. 
The decision about which events and health states were included was partially discussed. 
Some studies acknowledged that they subdivided a health state39 (CHD into MI, HF and 
angina), or excluded a potentially relevant health state73 (combined stroke and MI event). All 
studies included chronic health states (post events); however, few discussed having modelled 
the progression of disease39, 69, 80. Most frequently, the studies acknowledged the adoption of 
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assumptions, i.e. assuming the duration of treatment effects to be lifetime or as long as the 
time horizon in the model39, 69, 72, or five years77 or varied79.  
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Table 3-5 Dimension 4 - Analysis of uncertainty 


























Was analysis of uncertainty pertaining to 
the decision problem included and 
reported? 





Were one-way or two-way DSA sensitivity 
analysis performed? 
No Yes Yes No No No 
Was probabilistic sensitivity analysis (PSA) 
included? 





Was correlation among parameters 
considered? 
NA NA NA NA NA NA 
Structural 
uncertainty 
Was there any discussion /evidence of 
uncertainty in structural assumptions? 
Yes Yes No No No Yes 
Other 
reporting of 




If model calibration was used to estimate 
parameters, was uncertainty tested?  
NA NA NA NA NA NA 
 
Continuation 






























Was analysis of uncertainty 
pertaining to the decision 
problem included and reported? 





Were one-way or two-way DSA 
sensitivity analysis performed? 
Yes Yes Yes Yes Yes Yes Yes 
Was probabilistic sensitivity 
analysis (PSA) included? 






Was correlation among 
parameters considered? 
NA NA NA NA NA NA NA 
Structural 
uncertainty 
Was there any discussion 
/evidence of uncertainty in 
structural assumptions? 






Was EVPI measured/ discussed? No No No No No No No 
If model calibration was used to 
estimate parameters, was 
uncertainty tested?  
NA NA NA NA NA NA NA 
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3.3.4. Model transparency and validation 
All the studies included a graphical description of the Markov model they used (Table 3-6). 
Sources of funding were identified in 11 studies: five were funded by the pharmaceutical 
industry72-74, 77, 79, 80, one benefited from joint funds from government and pharmaceutical 
sources76, three were exclusively government-funded39, 70, 78, and one was privately funded75. 
None of the studies stated any means for accessing more detailed information about the 
model. All the studies had a clear policy context with an explicit statement by the funder and 
developer.  
Validation according to guidelines22 is a set of methods for judging the accuracy of a model in 
making relevant predictions, in other words, validation helps readers understand what a 
model does and how it does it. This review checked for five main types of validation. All the 
studies were subjected to face validity checks (having been peer reviewed and published in a 
journal) and they were subjected to verification (internal validity checking). The methods used 
were justified to a greater or lesser extent in each study. All studies undertook sensitivity 
analysis of parameters as a way to double check that the direction and magnitude of their 
outputs were as expected.  
In terms of cross validation, results were mixed. Eight studies39, 69-72, 75, 77, 78 examined different 
models that addressed the same problem and compared their results; however, the level of 
detail provided varied. Five studies presented limited or no evidence of cross-validation73, 74, 
76, 79, 80; only Wisloff76 undertook an exercise of external validation by comparing their 
estimated lifetimes to those reported by Statistics Norway and in doing so they found that the 
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input into their model needed to be adjusted to fit Norwegian mortality data. An assessment 
of predictive validity was not included in any of the studies considered.     
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Table 3-6 Dimension 5 - Model transparency and validation 


























Were the purpose, type and graphical 
description of the model provided? 
Yes Yes Yes Yes Yes Yes 
Was the source(s) of funding and its role 
identified? 
Yes Yes Yes Yes Yes Yes 
Were data sources identified/ described? Yes Yes Yes Yes Yes Yes 
Were methods customised to specific 
application(s) and settings? 
Yes Yes Yes Yes Yes Yes 
Were the effects of uncertainty measured? Yes Yes Yes Yes Yes Yes 
Were limitations acknowledged/ discussed? Yes Yes Yes Yes Yes Yes 
Was any reference made to the availability of 
the model's documentation at request or the 
terms and conditions to access it? 
No No No No No No 
Validation 
Was there any evidence of the model’s face 
validity? 
Yes Yes Yes Yes Yes Yes 
Was internal validity (verification or technical 
validity) assessed? 
Yes Yes Yes Yes Yes Yes 
Was cross-validation (external consistency) 
assessed? 
Yes Yes No Yes Yes No 
Was external validity assessed? No Yes No No No No 

































Were the purpose, type and 
graphical description of the 
model provided? 
Yes Yes Yes Yes Yes Yes Yes 
Was the source(s) of funding and 
its role identified? 
Yes Yes No Yes No Yes Yes 
Were data sources identified/ 
described? 
Yes Yes Yes Yes Yes Yes Yes 
Were methods customised to 
specific application(s) and 
settings? 
Yes Yes Yes Yes Yes Yes Yes 
Were the effects of uncertainty 
measured? 
Yes Yes Yes Yes Yes Yes Yes 
Were limitations acknowledged/ 
discussed? 
Yes Yes Yes Yes Yes Yes Yes 
Was there any reference to the 
availability of the model's 
documentation on request, or 
No No No No No No No 
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the terms and conditions to 
access it? 
Validation 
Was there any evidence of the 
model’s face validity? 
Yes Yes Yes Yes Yes Yes Yes 
Was internal validity (verification 
or technical validity) assessed? 
Yes Yes Yes Yes Yes Yes No 
Was cross-validation (external 
consistency) assessed? 
No No Yes Yes Yes Yes Yes 
Was external validity assessed? No No No No No No No 
Was the model’s predictive 
validity assessed? 
NA NA NA NA NA NA NA 
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3.4. Discussion 
Using the practical framework described in Chapter 2, 13 published economic evaluations 
were evaluated to judge whether they conformed to contemporaneous good practice 
guidelines. It was found that published economic evaluations of interventions aimed at 
lowering blood pressure in patients with hypertension, as part of a primary prevention 
strategy of CVD, demonstrate limited compliance to DAM guidelines which has usually been 
justified by lack of data or imperfect data. This was particularly apparent in the assessment of 
structural uncertainty (or lack of) and model external validation.  
This review identified common grounds in terms of the adherence to, and use of, guidelines. 
The conceptual modelling in all the studies included in this review was based on a disease 
process where the focus was on the definition of the health states (conditions) as opposed to 
treatment (pathways) received and where the decision problem posed required the 
evaluation of the reduction in the risk of developing hypertension, thus explaining the use of 
Markov models. 
It has been argued that alternative model structures can lead to variations in model 
predictions27, most importantly, in the context of a primary prevention strategy, an 
inappropriate model structure may lead to poorly informed policy decisions, resulting in 
inefficient allocation of scarce resources81. Models are by nature sensitive to choices made at 
every single stage during the model development process (i.e., model concept, model 
structure). There will almost always be more than one set of choices, for this reason, 
guidelines have suggested assessing the extent to which model predictions are influenced by 
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the choices made during the model development process, and have suggested methods to do 
so, such as scenario analyses20, 82.  
Lifetime time horizons should be adopted (or be justified when constrained by the cohort’s 
lifetime) or at the very least, time horizons should be ‘long enough’ to capture relevant 
differences in outcomes across strategies16. Lack of data or imperfect data still poses 
important challenges for researchers - for example, when modelling the risk of secondary 
events and disease progression or to attempt the assessment of model validity. Even though 
elements pertaining to structural uncertainty were identified by various authors, the 
assessment of structural uncertainty cannot be considered common practice in this particular 
clinical area and additional guidelines are still needed to aid researchers identifying and 
quantifying structural uncertainty.  
External validity still poses a challenge to researchers and more importantly, to future 
guidelines due to the apparent unavailability of actual extra data (from RCT or patient level 
data) to undertake the exercise. It has been suggested that instead of using all the data 
available to create a model, some data be set aside to use during the validation process (for 
example, one-third of the data)30. This may or may not always be possible, and will depend on 
how much data a researcher has to build a model.  
Studies included in this review shared similar research questions and yet there was a great 
diversity in the structures of the Markov models used. Some of these were simple and some 
more complex, and were generally developed with limited justification81. These indicate, as 
suggested by Squires et al83, that the methods for the development of the model structure are 
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still underdeveloped. This can lead to errors including poor validity, credibility, and no basis 
for model verification and the analysis of structural uncertainty. 
Caro and Möller30 described the above as the ‘disposable approach’ to modelling: models are 
built for a single use, focused on a particular product for a relatively short time. This explains 
to some extent the reduced motivation for undertaking model validation30. Future research 
should examine whether the development of ‘generic models’, or, as proposed by Caro and 
Möller, the development of multi-use models over time, can capture sufficient detail to be 
realistic and to avoid these aspects for which there are no data. This would allow the economic 
evaluation of interventions targeting CVD in any setting, and bridge the knowledge gap and, 
most importantly, allow ease of comparison between the results obtained from different 
studies.  
 
3.4.1. Strengths and limitations 
This is the first study that has critically reviewed compliance to DAM guidelines using a 
previously developed practical framework. It has covered more than a decade of published 
DAM studies of interventions aimed at lowering blood pressure in patients with hypertension. 
The inclusion of recent studies from European, American and Asian countries has helped to 
reflect current practice worldwide.  
The exclusion criteria adopted may be considered as limitation; however, these were required 
to guarantee consistency in the analysis. Furthermore, a negligible number of non-English-
language studies were identified pertaining to applied studies. The fact that none of the 
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studies included was published after the release of the ‘five-dimension framework’ and the 
selection of one particular clinical area (and any impact on generalisability this may have) may 
also be considered a limitation. 
These findings seem in line with the recent debate around the methodological challenges 
being faced by DAM where model validation and structural uncertainty have been identified 
as fundamental problems due to the lack of motivation, time and data to validate models and, 
in the case of structural uncertainty, a lack of methods30.   
 
3.5. Conclusions 
This Chapter, focusing on one particular clinical area, found limited compliance to DAM of 
economic evaluations, which was most commonly explained by lack of data or imperfect data. 
This result was particularly apparent in the assessment of structural uncertainty or lack of 
assessment of structural uncertainty.  
Model predictions are influenced by choices made during the process of model development, 
in particular the choice of model structure. The results of this review indicate that model 
structures used by studies that shared similar research questions varied from simple to more 
complex and most importantly, that model structures were generally developed with limited 
justification. Chapters 4 to 6 take the findings of this chapter forward and explore the effect(s) 
of the choice of model structure on cost-effectiveness results; starting with Chapter 4, which 
outlines the issue of structural uncertainty in the decision analytic modelling process.     
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CHAPTER 4. OVERVIEW OF STRUCTURAL UNCERTAINTY IN 
DECISION ANALYTIC MODELLING 
 
Chapters 2 and 3 identified good practice guidelines and critically assessed compliance of 
published model-based economic evaluations to DAM guidelines for primary care prevention 
and the management of hypertension. Main findings in Chapter 3 indicated that even though 
DAM guidelines are available, compliance to guidelines in one particular clinical area was 
limited, particularly when identifying structural uncertainty arising from the choice of model 
structure.  
4.1. Introduction  
The UK National Institute for Health and Care Excellence (NICE) has recommended that formal 
decision analytic processes rely on results of decision analytic modelling (DAM) as the 
standard framework for health technology assessment11. Mathematical models applied in 
cost-effectiveness or cost-utility analysis aim to examine whether an intervention is cost-
effective when compared to one or more alternatives; to do so, models estimate the 
population mean costs and health effects. Results of such forms of analysis are most helpful 
when they are unbiased and uncertainty about estimated costs and consequences is properly 
specified27, 28. The main sources of uncertainty in model predictions are related to the model 
input values and model structure20, 28-30 (see Section 1.2.4). 
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As demonstrated in Chapter 2 there are statistical literature and other sources of information 
available on structural uncertainty, including ISPOR-SMDM20 and other individual articles27, 28, 
31, 51 which propose a set of guidelines for the analysis of structural uncertainty. However, 
when current DAM practice was assessed against compliance to good practice DAM 
guidelines, the findings in Chapter 3 have indicated that although elements pertaining to 
structural uncertainty are at times identified, the characterisation of structural uncertainty is 
not ‘common practice’ and in fact, it was shown that current DAM practice tends to omit 
testing for structural uncertainty. These findings are in line with those from Bojke et al51, Afzali 
et al29, and Caro and Moller30.  
The aim of this chapter is to outline the ways in which structural uncertainty has been 
described, characterised and assessed within the DAM process. 
 
4.2. Methods  
A review of literature using the best evidence was undertaken to identify the various ways in 
which structural uncertainty has been described and understood within DAM. Following the 
snowball technique of reference identification, relevant studies were identified that 
examined the following: 
• Definition and/or characterisation of structural uncertainty 
• Sources of structural uncertainty 
• Quantification or assessment of structural uncertainty  
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Initial references were identified from personal and supervision team knowledge; references 
from serendipitous discovery, such as identifying a relevant paper when looking for 
something else, were included as well.  
 
4.3. Definition and characterisation of structural uncertainty 
Structural uncertainty has been referred to in a number of ways in the DAM literature. 
Manning84 used the term ‘model uncertainty’ to refer to structural uncertainty and defined it 
as situations when there is uncertainty about the mathematical forms by which the 
parameters are combined. For example, is the response to a treatment linear with regards to 
increasing dose levels, or does it exhibit decreasing effects as dosage increases?  
Bojke et al51 referred to structural uncertainty as uncertainty that is not easily described as 
parameter or methodological uncertainty and indicated that the sources of structural 
uncertainty are ‘the different types of simplifications and scientific judgements that have to 
be made when constructing and interpreting a model of any sort’ (p. 739). Briggs et al20 used 
an analogy with a simple regression model to explain structural uncertainty: ‘just as a linear 
regression imposes a structural relationship between independent and dependent variables, 
a decision analytic model is characterized by assumptions reflected in its structure but not 
formally expressed numerically (types of adverse events, duration of treatment effects or 
time dependency of probabilities)’ (page 837). For Strong et al85 structural uncertainty relates 
to whether or not all relevant processes are represented in a model and asks: “does the model 
adequately reflect reality?” Health economists build deterministic models that can be 
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represented by 𝑦 = 𝜂(𝑋), where the model is a function 𝜂(. ) that takes a vector of input 
parameters X and generates an output y. Whilst uncertainty in input parameters X is usually 
considered and acknowledged through sensitivity analysis, uncertainty about output y due to 
uncertainty about the model’s function, 𝜂(. ), is not frequently considered. When the answer 
to the question “does the value of 𝑦 = 𝜂(𝑋) represent the ‘true’ target value Ÿ?” is negative, 
there is model structural uncertainty85. NICE defines structural uncertainty as the uncertainty 
relating to the range of assumptions and judgements necessary in constructing a model. This 
can include designed features of the model (for example, the assumed standard pathway of 
care) as well as judgements about the relevance of evidence, assumptions about appropriate 
distributions for parameters, and alternative methods of estimation11. Structural uncertainty 
has been more generally used to describe all structural aspects of a model (conceptual 
framework, implementation platform) or the mathematical representation of a decision 
problem29, 33. 
Independently of its definition, structural uncertainty will almost always arise once a choice 
of model structure or choice of relationships between inputs and outputs is defined within 
the model development process. In other words, in a health economics context it is not safe 
to assume that one of a plausible set of model alternatives is necessarily correct. 
Furthermore, there should be an acceptance that, in words of Strong et al85 ‘we will almost 
never have adequate data against which to calibrate the output of a health economic decision 
model’ p. 9. Therefore it is essential to assess the extent to which model predictions are 




4.4. Sources of structural uncertainty 
The results of a review of 241 HTA reports commissioned by the NHS-HTA programme from 
1997 to 2005 to examine how structural uncertainty had been described and resolved in the 
literature found that only 15% of the reports discussed issues pertaining to structural 
uncertainty51. Among the reports discussing structural uncertainty, the most common 
sources of structural uncertainty identified were:  
i) selection of comparators including the do nothing alternative;  
ii) decision about which events, stages or health states to include;  
iii) uncertainty about the correct statistical method to use to estimate parameters, 
and  
iv) lack of clinical evidence from randomised control trials triggering the use of 
expert opinion51.  
For Afzali & Karnon29 (p. 436), sources of structural uncertainty can include:  
i) “health states and events represented in a model;  
ii) transitions between health states;  
iii) the choice of modelling technique;  
iv) the relationship between a transition probability and time (time dependency);  
v) the relationship between a transition probability and the clinical profile or 
baseline characteristics of a patient; and  
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vi) the choice of a particular functional form used to estimate model inputs (for 
example, the choice of alternative survival models to estimate time-to-event 
parameters)”29. 
Structural uncertainty arises from the different types of simplifications and judgements that 
researchers make when building a model. For example, hazard functions may be estimated 
as either multiplicative or additive functions of risk factors. The choice between multiplicative 
or additive functions, in absence of evidence, may be based on mathematical convenience. 
However, the choice of functional form affects the resulting hazard estimate, which in turn 
affects the cost-effectiveness results84. Clinical trials provide estimates of relative risk or risk 
reduction during the follow-up period. However, a trial restricted to a particular demographic 
or clinical group may give little or no indication on how to estimate the survival curve for 
individuals beyond the end of the trial, or of different age and/or sex, or for individuals with 
comorbidities. In this case, the researcher would need to adopt assumptions regarding the 
appropriate basis for extrapolating beyond the period of observation and to the population 
with different survival curves. A straightforward assumption could be that the age and sex-
specific risk of death is modified by the disease in question, the intervention being evaluated 
and any comorbidity relative to the general population. A key choice to make is whether these 
three effects are to be considered as additive or multiplicative. The choice made, in absence 




Other issues leading to structural uncertainty include the effect of the intervention versus 
current practice on, for example:  
i) mortality in the immediate year after the end of trial data;  
ii) the effect of an intervention versus current practice on the long-term 
cardiovascular mortality;  
iii) the types of adverse effect(s) included or ignored;  
iv) assumptions regarding the duration of treatment effects;  
v) time dependency of probabilities (in a time dependent utility, the cost of 
delaying treatment as a function of the time a patient has remained in an 
untreated acute pathological state); and  
vi) prognostic implications of surrogate end points or clinical events. 
Jackson et al27 demonstrated that alternative plausible model structures, combining 
hypothetical scenarios and expert opinion, can lead to wide variation in model predictions 
with potential impact on funding decisions. The authors suggested that appropriate 
characterisation of structural uncertainty should consider the parameterisation of structural 
choices27. Results of a systematic review of structural model properties for cost-effectiveness 
analysis indicated that the associated impact of differences in model structure and 
parameterisation had a substantial effect on outcomes87. An important challenge in 
addressing structural uncertainty seems to be posed by the many elements that are grouped 




4.5. Assessment of structural uncertainty in decision analytic modelling 
In an ideal world, an approach to DAM would consider identifying a set of plausible models 
as providing useful simplifications of the process being investigated. Parameters in each of 
the identified models be estimated and the fit of each model investigated using relevant 
statistical criteria. Ideally, these different statistics will consistently identify the same model 
as having the best fit, and then this model would be shown as the best option.   
In DAM a set of alternative model structures would always be plausible because of inherent 
uncertainty about the structure of the model (lack of complete knowledge of the system), or 
because decisions have been adopted to simplify other rather complex models. Strong et al85 
defined the following formulation for describing a set of possible models as M-Closed or M-
Open85.  
Assume that the complete set of plausible models is denoted as (𝑀𝑖, 𝑖 = 1, … 𝐼). The set of 
models (𝑀𝑖, 𝑖 = 1, … 𝐼) is described as M-Closed if there is a belief that one of the models in 
(𝑀𝑖) is the ‘true’ model, but it is not known which one. In this framework, a Bayesian would 
use probabilities 𝑝(𝑀𝑖) to represent prior beliefs about the ‘truth’ of model (𝑀𝑖). In contrast, 
a set of models is described as M-Open if there is a belief that none of the models in (𝑀𝑖) is 
the correct one85. 
Methods for quantifying structural uncertainty are less well described compared to methods 
for characterising parametric or methodological uncertainty27, 29, 51, 85. Whilst standard PSA 
will typically be undertaken to quantify parametric and methodological uncertainty, PSA does 
not take into account any structural uncertainty that may be present, potentially leading to 
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spuriously precise estimates of the model results85. This section discusses strategies that have 
been proposed to aid researchers in resolving the problem of model structural uncertainty. 
 
4.5.1. Scenario analysis 
Scenario analysis (sometimes considered a form of deterministic sensitivity analysis) is 
perhaps among the most widespread methods in the assessment of structural uncertainty. 
Scenario analysis requires the modeller to identify competing and credible model structures 
and to compute results for each alternative model specification, representing alternative sets 
of judgements or assumptions that are plausible. Briggs82 has suggested running repeated 
analysis using different models with specified prior probabilities of different models across 
this model space. If different credible scenarios suggest conflicting decisions, then structural 
uncertainty is important. But, even if this is not the case, structural uncertainty will affect 
decision uncertainty and value of information in ways that are difficult to assess51.  
A weakness of this approach is that there are no established methods to formally assess the 
plausibility of alternative models and it is not clear which type of, or how many, scenarios 
should be considered. Furthermore, it is not possible to establish the value of conducting 
further research to resolve the source of these structural uncertainties51. Presenting multiple 
model structures to the decision maker may lead to inappropriate decisions by implicit 





Some approaches to structural uncertainty have sought to parameterise the source of 
structural uncertainties into a model by adding uncertain parameters to represent the choice 
between multiple model scenarios. This approach, sometimes referred to as an expanded 
model20, is analogous to model averaging, where weights are given to the parameterised 
structural assumptions depending on what prior knowledge is known about the likelihood of 
the scenarios representing the ‘true’ scenario. However, unlike model averaging where the 
objective is to synthesise all evidence on the structure of a decision model to assess if a 
treatment is cost-effective, by parameterising the uncertainty directly in the model, estimates 
of the value of further research on uncertain parameters can also be made. Parameterisation 
of structural uncertainty may be trivial for a nested structure, where a model is a restricted 
version of another, but challenging for non-nested model structures that require a re-building 
of the model20. 
For notational convenience, consider a model with four states. Given the transition 
probabilities from the multinomial likelihood for a homogeneous Markov model (where the 
transition parameters are independent of time and dependent only on an observed cycle 
length), assume homogeneity of the transition parameters across subjects (this is because the 
data are assumed to be in aggregate form) and let 𝑝𝑘𝑖𝑗(𝑡) denote the probability of making a 
transition from state 𝑖 to state 𝑗, where: 
𝑖, 𝑗 𝜖 [1,2,3,4] where numbers 1 to 4 refer to the different health states in a model 
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The data are usually in aggregate form 𝑦𝑘𝑖𝑗, which represents the total number of observed 
transitions from state i to state j in any given period, for each treatment k. The data are 
observed over the cycle period providing direct information on 𝑝𝑘𝑖𝑗(1). The likelihood for the 
data is given by: 
(𝑦𝑘𝑖1, 𝑦𝑘𝑖2, 𝑦𝑘𝑖3, 𝑦𝑘𝑖4) ∼ 𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑝𝑘𝑖1(1), 𝑝𝑘𝑖2(1), 𝑝𝑘𝑖3(1), 𝑝𝑘𝑖4(1); 𝑛𝑘𝑖) 
Subject to: 
∑ 𝑝𝑘𝑖𝑗(1) = 1,
4
𝑗=1




It is possible to parameterise structural uncertainty using transition rates and convert these 
to transition probabilities using Kolmogorov’s forward equations, to conform to the 
multinomial likelihood88 of the data: 
𝑑
𝑑𝑡
pk(𝑡) =  pk(𝑡). Gk 
Here pk(𝑡) is the transition probability matrix and Gk is the transition rate matrix. Transition 
rates have the advantage of being specified as hazard ratios, which are transportable across 
trials, rather than relative risks that depend on the Markov cycle length88.  
Parameterisation of structural uncertainties seems a preferred option if it is feasible to 
internalise structural uncertainty by adding parameters into the model. However, researchers 
have been advised to be explicit about the structural assumptions that might have an impact 
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on the findings and to suggest alternative assumptions that future modelling exercises might 
employ20, 51. 
 
4.5.3. Model averaging  
The model averaging approach takes an M-Closed view and considers that (M𝑖, i ∈ I) 
represents a set of plausible models, and the best approximation of the true value of the 
target parameter Ÿ corresponds to a weighted mean value of the individual model output. 
Weights can be assigned with differing criteria, for example by choosing the model from the 
set that is believed to be the ‘correct’ while discarding the rest (effectively placing all the 
weight on a simple model), or alternatively assigning weights to the competing structures 
based on beliefs about how likely the different models are to be the ‘correct’, and weight the 
outputs by these probabilities. Weights could be based too on some measure of model 
adequacy, for example, AIC or the Bayesian framework85.  
Measures of model adequacy require data availability, D, to weight the model outputs by 
some function of the adequacy measure. Within a Bayesian framework prior model 
probabilities, 𝑝(𝑀𝑖), could be specified to calculate posterior probabilities via: 




leading to a weighted mean output85 
114 
 
𝑝(Ÿ|D) =  ∑ 𝑝(Ÿ|
𝑖∈𝐼
𝑀𝑖 , 𝐷)𝑝(𝑀𝑖|𝐷) 
It is important to note that model averaging methods can be used to assess structural 
uncertainty if a complete set of plausible competing models can be built and weighted 
according to some measure of model adequacy as previously described28.   
In practice, model averaging approach has some limitations. The first difficulty is that of the 
M-Closed assumption. In reality researchers believe that none of the models is correct, and 
they have instead an M-open set in which they do not believe Y=𝜂𝑖 (𝑋) for any i. 
Another limitation is the form of the data available, D. Model averaging involves evaluating a 
likelihood function for each model, however, the data will not typically be in the form where 
a likelihood p(D|fi (X)) could be identified and this would have been the reason for building 
the model in the first place. 
 
4.5.4. Model selection 
An alternative to model averaging is to choose the ‘best’ model on the basis of some measure 
of predictable performance. The model selection criteria can take either M-Closed or M-Open 
view and consists of selecting a set of credible and plausible models which are then ranked 
according to measures of goodness-of-fit (representing the fit of the model predictions to the 
observed data). There exist a number of measures of goodness-of-fit to discriminate and 
select among alternative fitted models. For nested models measures like an F-test or 
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likelihood ratio test can be used. Nested and non-nested models can be ranked according to 
the Akaike information criterion (AIC), the Deviance information criterion (DIC), among 
others89.  
The AIC is calculated as: 
𝐴𝐼𝐶 = −2 log(𝐿) + 2𝑃, 
where L is the maximum likelihood estimate of parameters by the model fitted to the 
observed data, and P is the number of parameters in the model. Models are ranked comparing 
the value of the AIC for each model, the model with the best approximation (smallest value 
of AIC) is selected29. The maximised likelihood is a measure of fit to the sample data. The 
penalty size 2P has an information-theoretic justification and ensures that over-complex 
models, which cannot be generalised outside the observed data are not chosen27. 
However, in an M-Open scenario, candidate models are chosen to approximate a true model 
of unknown form. The true model may be extremely complex, and more complex models 
would give better predictions in large samples but complex models would be over penalised 
by, for example, the AIC.  
In the view of Jackson et al32 an optimal model choice criterion could be derived by 
approximating the true model. In the context of health economics, models approximate the 
highly complex processes of progression of disease and response to treatment. An 
assumption is made that the true process underlying the data is too complex to be completely 
identified even in the presence of large sample data. Instead of using, for example, AIC, the 
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authors suggest taking a predictive approach by judging model adequacy by the expected 
utility of predicting a replicate data set y based on model Mk fitted to data x.  
A Bayesian model assessment measure of this type is the DIC32, a Bayesian extension to the 
AIC that can be used to compare the fit of the different models either nested or non-nested. 
The DIC is an estimate of an expected predictive utility E[U. y | 𝑥, 𝑀𝑘/] defined as: 
𝐷[𝑦𝐸. 𝜃 /, 𝑥, 𝑀𝑘] =  −2𝑙𝑜𝑔 [𝑓(𝑦|𝐸. 𝜃 /, 𝑥, 𝑀𝑘)], the predictive deviance based on ‘plugging 
in’ the expected parameter values of model Mk. This method assumes that the models under 
consideration are reasonable approximations to the true process, and that the posterior 
distribution of 𝜃 is approximately normal. A parameterisation should be chosen so that 𝜃 has 
an approximately normal posterior. 
It has been seen so far that the best model, among a set of alternative models, is selected on 
the basis of how well a model’s outputs match observed data for one or more model outputs. 
After putting each model through a validation process, the best-validated model is chosen. 
However, to some critics, even if models can be hypothetically ranked according to some 
criterion, it may not be advantageous to determine the “best” model. By choosing the best 
model, useful evidence may be discarded violating the requirements of the DAM process; in 
addition, uncertainty relating to the choice of the best model would also be ignored51. Last 
but not least, the need for additional resources to build alternative models has been identified 




4.5.5. Discrepancy approach 
This method assesses the difference between the model run as its ‘best’ or ‘true’ input, and 
the value of the output quantity. This method assumes that models will always be an 
imperfect description of reality, and makes judgements about the discrepancy between the 
model output and the true costs and consequences of interest defined via the following 
function: 
𝑍 = 𝑓(𝑋) + 𝛿z 
where 𝛿z corresponds to the discrepancy term. The beliefs about the discrepancy term are 
quantified via a weight based on a probability 𝑝(𝛿z). The aim is to assess how large an error 
might be due to the structure of the model at hand (as opposed to making assessments about 
a ‘true’ model structure)85. 
While PSA quantifies input uncertainty, the discrepancy approach quantifies uncertainty 
about the costs and health effects of the various decision options (uncertainty in the model 
structure). Rather than focusing on generating weights for models within some set, this 
method makes inferences about model ‘discrepancy’: the difference between the model run 
at its best or true input and the true value of the output quantity (structural error). 
This method recognises that a given model may be deficient, not in the sense of mistakes, 
‘slips’, ‘lapses’ or other errors of implementation, rather these errors refer to deficiencies 
arising as a result of the gap between any model of reality and reality itself28.  
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For a decision maker to base their decision on the model output, the model must have 
credibility. The model must be judged to be sufficiently good to support the decision being 
made. The primary goal of this analysis is therefore to provide a means for quantifying 
judgements about structural error and specifically to determine the relative importance of 
structural compared with input uncertainty in addressing a decision problem. If it can be 
demonstrated that the uncertainty about the structural error is small in comparison with that 
due to input uncertainty, then a claim can be made that a model is credible28.  
Making meaningful judgements about the model discrepancy is difficult (and would require 
some form of elicitation of beliefs). For that reason this method proposes instead, to make 
judgements about this discrepancy indirectly, or at the sub-function level by decomposing the 
model into a series of sub-functions that link the model inputs to the model output. The idea 
is that, because each sub-function represents a much simpler process than the full model f(X), 
making judgements about discrepancy in fi will be easier than making judgements about 
discrepancy in f( ). It should be noted that not all sub-functions are required to have a 
structural error and similarly there is not a unique decomposition of the model f into a series 
of sub-functions. Once discrepancy terms have been introduced within a model, judgements 
about the size of the discrepancy should be made via the specification of the joint probability 
distribution 𝑝(𝑋, 𝛿) where it is assumed that discrepancies are independent of inputs 
henceforth the joint density 𝑝(𝑋, 𝛿) = 𝑝(𝑋)𝑝(𝛿)28.  
A main advantage of this approach is that only one model needs to be developed and this 
allows analysts to determine the relative importance of the alternative structural 
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assumptions and estimating EVPI surrounding decision uncertainty. However, the discrepancy 
approach requires a subjective estimation of the magnitude and variance of the discrepancy 
between model predictions from the sub-function and reality and the elicitation of expert 
judgements to quantify structural errors may introduce additional uncertainties29. 
 
4.6. Discussion  
Structural uncertainty arises because of the nature of models being mere simplifications of 
reality. Many assumptions need to be adopted during the process of building a model such 
that the distance between a model and reality will always be unknown, or whether other 
plausible models would be a better alternative. This can potentially lead to a wide variation 
in model predictions with potential impact on funding decisions27. 
Even though the impacts of structural uncertainty on cost-effectiveness results have been 
thoroughly documented, the availability of guidelines providing in-depth guidance on how to 
characterise, address, and report this type of uncertainty seems less apparent and may 
explain the findings in Chapter 3 that the assessment of structural uncertainty is not common 
practice.  
Various alternative statistical methods have been proposed to address the impact of 
structural uncertainty on the results of cost-effectiveness20, 27-29, 31, 32, 51, 53, 82, 85, 88, 90, 91 whilst 
some other authors have provided examples on how to implement some of these methods in 
different clinical areas87, 92, 93.  However, it has been recognised that methods for quantifying 
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structural uncertainty are less well described if compared to methods for characterising 
parametric or methodological uncertainty27, 29, 51, 85.  
A main challenge in addressing structural uncertainty is posed by the many issues that have 
been identified as ‘structural uncertainty’ making it a complex task (which may not even be 
cost-effective) to address properly30. Structural uncertainty will almost always arise once a 
choice of model structure or choice of relationships between inputs and outputs is defined 
within the model development process85. Therefore, it is essential to assess the extent to 
which model predictions are influenced by such choices within the model development 
process29. Consequently, in this thesis structural uncertainty is defined as the uncertainty 
associated with all aspects of model structure, i.e., health states and the relationships 
between health states. This is in contrast to parameter uncertainty, which is very much 
focused on the parameters used in a model and their uncertainty. Differences in model 
structure are dependent on the importance given to various aspects of the process being 
modelled, allowing in some instances for model simplifications. In some cases, these originate 
when data are not available, although their inclusion could potentially still be relevant for the 
analysis.  
The challenges posed by the assessment of structural uncertainty might be overcome if 
additional research is undertaken on an experimental basis. Case studies aimed at measuring 
the impact of changing or adapting chosen model structures on previous results of cost-
effectiveness could provide insightful evidence of how much results would be altered when 
alternative model structures are implemented. This would also provide evidence of what 
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other elements, besides the model structure, may be critical in affecting results of cost-
effectiveness.  
This thesis aims to contribute towards that end by presenting two case studies in Chapters 5 
and 6. The aim is to assess the extent to which model predictions are influenced by the choice 
of model structure within the model development process. These chapters aim to provide 
practical illustrations of the impact of changing or adapting model structures on the results 
of cost-effectiveness.  
The focus of the first case study is on the prevention of cardiovascular disease whilst the 
second case study focuses on the optimisation of treatment after a stroke. These case studies 
are focused on one particular clinical area, cardiovascular disease, since this makes it possible 
to remove some of the variation between models which is not relevant for the purpose of 
assessing structural uncertainty (for example, sources of uncertainty).  
 
4.7. Conclusions 
The aim of this chapter was to present an overview of structural uncertainty in DAM. This 
chapter has reviewed what has been understood by structural uncertainty. It has discussed 
the sources of structural uncertainty and methods that have been employed to deal with 
issues pertaining to structural uncertainty. Given the inherent uncertainty in estimates 
produced in DAM, the assessment of structural uncertainty is an essential part of the DAM 




Many issues has been identified as pertaining to structural uncertainty, additional guidelines 
are needed in order to aid researchers identifying what elements are of greater importance 
and how best to identify, address and report results of structural uncertainty. 
Statistical methods to assess structural uncertainty have been proposed and developed, 
however, all of them have been subjected to criticism rendering uncertainty as to whether it 
is good value for money to attempt to address it.    
The results of this overview will contribute towards the design and development of case 
studies aiming to explore the effect of choice of model structure in results of cost-
effectiveness in the following two chapters. Chapters 5 and 6 of this thesis constitute research 
on the effects of structural uncertainty arising from the choice of model structure and are 
aimed at providing practical illustration, through two case studies, of the impact on results of 
cost-effectiveness of changing or adapting model structures. These case studies will also 
provide evidence on whether other elements besides the model structure affect the results 




CHAPTER 5. THE IMPORTANCE OF MODEL STRUCTURE ON 
RESULTS OF COST-EFFECTIVENESS: A CASE STUDY OF 
PRIMARY CARE INTERVENTIONS FOR THE MANAGEMENT 
OF HYPERTENSION 
 
Chapter 4 outlined the ways in which structural uncertainty has been described and 
understood within the decision analytic modelling process. This chapter aims to provide a 
practical illustration of the impact on the results of cost-effectiveness of changing or adapting 
model structures in a model-based economic evaluation. Structural uncertainty arising from 
the model structure is assessed for a Markov model first used to measure the cost-
effectiveness of self-management of blood pressure as a strategy in the prevention of 
cardiovascular disease via management of hypertension. Evidence of whether other elements 
besides the structure of a model may affect the results of cost-effectiveness are also 
examined.  
 
5.1. Introduction  
High blood pressure (hypertension, defined as blood pressure persistently 140/90mmHg) is 
one of the most important but preventable causes of premature morbidity and mortality in 
the UK and worldwide7, 8, 64. Hypertension is a major risk factor for ischaemic and 
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haemorrhagic stroke, myocardial infarction (MI), heart failure (HF), chronic kidney disease 
(CKD), cognitive decline and premature death. It has been estimated for England that a 2 
mmHg reduction in average systolic blood pressure for 40-69 year olds could save 1,500-2,000 
lives per year94. One of the most common interventions in primary care is the management 
of hypertension. Self-management of hypertension, in which individuals monitor their own 
blood pressure and adjust their own medication, has been shown to lead to significantly lower 
blood pressure in hypertension, including individuals with higher cardiovascular risk37, 39, 40.  
Economic evaluations can be undertaken alongside randomised controlled trials (RCTs) where 
costs and health outcomes are measured. The primary outcome of RCTs in hypertension is 
often a change in blood pressure. However, a change in blood pressure corresponds to an 
intermediate outcome, and the final outcome of interest, in this case, is the risk of CVD. As 
RCTs rarely follow patients over the long-term or lifetime, Decision analytic modelling (DAM) 
provides a vehicle to extrapolate the impact of a change in blood pressure on the risk of CVD 
events in the long-term. Modelling the course of CVD can be challenging, requiring CVD risk 
factors (smoking, cholesterol, and diabetes), interactions among the risk factors, adverse 
events and the resulting health states (e.g. stroke sequelae and angina) to be considered. 
Structural uncertainty is defined in this chapter as uncertainty associated with all aspects of 
model structure, i.e., health states and relationships between health states. This is in contrast 
to parameter uncertainty, which is very much focused on the parameters used in a model and 
their uncertainty. Structural uncertainty reflects the extent to which a given model differs 
from the real system it is intended to reflect29, 33. Differences in model structure are 
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dependent on the importance given to various aspects of the process being modelled, 
allowing in some instances for model simplifications. In some cases, these originate when 
data are not available, although their inclusion could potentially still be relevant for the 
analysis.  
The fact that a model is a simplification of reality means that many assumptions need to be 
adopted during the model building process84, 85, 95. This can potentially lead to a wide 
variation in model predictions with potential impact on funding decisions 27.  
Various alternative statistical methods have been proposed to address the impact of 
structural uncertainty on the results of cost-effectiveness (Chapter 4) whilst some other 
authors have provided examples on how to implement some of these methods in different 
clinical areas87, 92, 93. However, it has been recognised that methods for quantifying 
structural uncertainty are less well described when compared to methods for characterising 
parametric or methodological uncertainty27, 29, 51, 85. The main challenge in addressing 
structural uncertainty is posed by the many issues that have been identified as ‘structural 
uncertainty’ making it a complex task (which may not even be cost-effective) to address 
properly30.  
Previous studies51, 67, 96, 97 indicate that even though elements pertaining to structural 
uncertainty are occasionally considered, the assessment of structural uncertainty is not 
common practice and most modelling tends to omit testing for structural uncertainty. 
However, it is essential to assess the extent to which model predictions are influenced by 
such choices made within the model development process96.  
126 
 
Case studies aimed at measuring the impact of changing or adapting chosen model structures 
on previous results of cost-effectiveness could provide insightful evidence of how much 
results would be altered when alternative model structures are implemented. This would also 
provide evidence of what other elements besides the model structure might be critical in 
affecting the results of cost-effectiveness. 
Structural uncertainty will almost always arise once a choice of model structure or choice of 
relationships between inputs and outputs is defined within the model development process85. 
Therefore it is essential to assess the extent to which model predictions are influenced by 
such choices within the model development process29.  
The TASMIN-SR37 trial aimed to determine the effect of self-monitoring with self-titration 
(self-management) of antihypertensive medication on systolic blood pressure among 
hypertensive patients with suboptimal blood pressure control and pre-existing CVD, diabetes 
mellitus and CKD compared to usual care. The trial involved 552 patients at 59 UK primary 
care practices and it was conducted between March 2011 and January 2013.  
A model-based economic evaluation was undertaken to assess the cost-effectiveness of the 
self-management intervention compared with usual care40. The main results indicated that 
self-management of blood pressure in high risk patients with poorly controlled hypertension 
not only reduced blood pressure compared to usual care, but also represented a cost-
effective use of healthcare resources. 
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The case study developed in this chapter is based on the results of the TASMIN-SR study40 and 
aims to provide a practical illustration of the impact, on results of cost-effectiveness, of 
changing or adapting model structures in a model-based economic evaluation on the primary 
prevention of CVD.  
 
5.2. Description of the TASMIN-SR model 
The economic evaluation in the Tasmin-SR study consisted of a model-based cost-utility 
analysis40. The aim of the model was to assess the long-term cost-effectiveness of the self-
management intervention in a ‘high risk’ patient population compared with usual care. A 
Markov model was built to extrapolate the results of the TASMIN-SR trial37, given in terms of 
blood pressure, to the long-term risk of cardiovascular endpoints. The study considered a 
cohort of 70 year old patients (39% female) with sub-optimal hypertension (BP>= 130/80 
mmHg at baseline), combined with a history of stroke, diabetes, CHD, and CKD. The model 
was run over a lifetime time horizon using a six-month time cycle, with results presented from 
a UK National Health Service (NHS) and Personal Social Services (PSS) perspective.  
The structure of the TASMIN-SR model is shown in Figure 5-1. Patients start in an initial ‘HR’ 
or high risk health state representing individuals with hypertension and a history of stroke, 
CHD, diabetes and CKD. The model simulates the lifetime of these patients until any of three 
possible events occur (stroke, myocardial infarction (MI) and unstable angina (UA)) or the 
patient dies from other causes. Individuals that survive an acute phase in any of the health 
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states progress into a post event or chronic phase for that condition until death, with no 
recurrences of cardiovascular events being possible. A lower quality of life was permanently 
applied until death in all chronic health states.  
The CVD history of patients entering the model was informed by the TASMIN-SR 37 trial data. 
Transition probabilities of suffering a stroke, MI, or UA were obtained from the literature for 
each of the high risk conditions. Age-related risk reductions from treatment for MI, UA, and 
stroke were estimated using trial based systolic blood pressure reductions at 6 and 12 months 
(Appendix 5). Resource use and costs were obtained from trial data and published studies 
(Appendix 6).  
 
5.3. Methods 
Taking the TASMIN-SR as the case study, the research methods of this chapter are outlined as 
follows: 
• systematic review to identify plausible alternative model structures to TASMIN-SR  
• definition and implementation of changes to the structure of the TASMIN-SR model   
• inclusion of secondary events in the TASMIN-SR model  
• identification of alternative model inputs 
5.3.1. Alternative model structures 
Structural uncertainty was addressed here by assessing issues such as the adequacy of the 
type of model used (Markov), the structure of the model (health states and transition 
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probabilities) that translates into plausible alternative model structures, and data availability 
to inform input parameters, for example the risk of secondary events.  
The results of the systematic review developed in Chapter 3 were used to inform plausible 
alternative model structures in this chapter (see Section 3.2). Thirteen model-based economic 
evaluations identified from the literature in Chapter 3 were used to inform the changes 
implemented to the TASMIN-SR model. A data extraction instrument was developed to 
extract information from each paper. This included the inclusion or exclusion of potentially 
relevant comparators, type of model used, health states included, recurrence of events, 
choice of covariate effects used in the transition probabilities, and the inclusion or exclusion 
of any other assumption(s) pertaining to structural uncertainty (see Table 5-1). 
The review indicated that all thirteen included studies used Markov models but only two 
justified their use. Kourlaba74 justified the use of a Markov model in his study by saying that 
it is ‘a conventional model that describes restricted transition probabilities between 
important health states’ (p.87). Kaambwa39 indicated that ‘the Markov model overcame 
limitations associated with within-trial analyses’ (p.1527). In the TASMIN-SR40 study, it was 
stated that ‘arguably, a more complex model such as individual patient level simulation could 
be more appropriate’ (p.9) by incorporating patients' histories more efficiently. The use of 
Markov models can overcome limitations associated with within-trial analyses, specifically by 
allowing the modelling of effects and costs of long-term events and the assessment of the 
long term cost-effectiveness beyond the trial period9. Even though individual patient level 
simulation models have long been praised for their flexibility and ability to record patient 
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attributes41, because cardiovascular diseases are chronic with recurring events and often 
result in health states with persistently reduced quality of life, the use of a Markov model is 
often preferred as a more parsimonious approach13, 49. 
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Table 5-1 Data extraction instrument for the assessment of structural uncertainty 
Author 
 
Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 




Yes Yes Yes 
Authors argued that self-monitoring of 
hypertension (as a means to lower blood 
pressure) has been largely evaluated; previous 
CE results found to be inconsistent plus not 
been extrapolated to the longer term. Their 
study examined the long-term cost-effectiveness 
of self-monitoring combined with self-titration 
(i.e., self-management) of blood pressure 
Four acute health states (Stroke, MI, Angina, and HF) and 
death were considered. It was not mentioned how 
health states were identified; authors acknowledged to 
have made an assumption that CHD consisted of MI, HF 
and angina (this was reflected in the structure of their 
Markov model); the risk of secondary events, including 
progression of disease, was not modelled and was 
acknowledged as a weakness 
Adverse effects such as anxiety or 
drug side effects were not 
modelled due to lack of data, 
however, trial data found minimal 
differences; effectiveness of the 
intervention after the year of the 
trial was unknown however the 
effect of various potential 
reductions in efficacy was tested in 
SA. Lifetime time horizon was 





Yes Yes Yes 
Authors argued that health and economic 
consequences of newer anti-hypertensive 
agents such as ACEIs and ARBs were not 
available at the time of the study in 
Netherlands. As a result, authors compared HCT 
25 mg (diuretics) versus HCT/ACEIs versus 
HCT/ARBs versus no treatment 
One acute health state (Acute CVD), a chronic health 
state (Stable CVD) and death were considered. The 
inclusion of states in the Markov model was not justified. 
Risk of secondary events was assumed to be equal to the 
risk of a first non-fatal CVD event. This assumption was  
acknowledged to lead to an under-estimation of the CVD 
risk and compensated with the adoption of an increased 
risk of death in patients experiencing non-fatal CVD 
events 
Adverse effect(s) from 
antihypertensive treatment was 
not considered; large uncertainty 
ranges around the expected values 
of the SCORE input parameters 
(model for ten year risk of fatal 
cardiovascular disease) used in the 
model for both 10-year and 
lifetime horizons, as tested 






Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
Wu et al73 
  
Yes No No 
Comparators resulted from the results of a 
meta-analysis study indicating that Norvasc 
(Amlodipine) was superior to ARBs in the 
prevention of stroke and MI in hypertensive 
patients. 
Two acute (Stroke and MI) and its corresponding chronic 
health states were considered. No justification was given 
for the inclusion of states in their Markov model; authors 
did not discuss the possibility of recurrent events, 
however they acknowledged as a weakness in the model 
not including the risk of patients having both stroke and 
MI due to lack of data 
Even though an assumption was 
adopted that the risk of stroke or 
MI and the mortality risk during 
the lifetime of the model (5-years) 
will remain fixed, this assumption 




Yes No No 
Comparators resulted from answering the 
research question in light of recent guidelines in 
Greece for the use of combined therapy to treat 
hypertension 
Two acute (MI and Stroke) health states and its 
corresponding chronic health states were modelled. No 
movement from MI to stroke was assumed; it was 
acknowledged as a limitation; risk of secondary events in 
their Markov model was not considered; same risk of 
CVD death was assumed (independently of whether a 
patient has experienced a previous CVD). None of these 
assumptions was tested in SA 
No evidence or discussion 
presented on this respect 
Ekwunife et 
al75 
Yes Yes No 
Comparators were identified from hypertension 
guidelines in Nigeria 
Two acute health states (Stroke and CHD) were modelled 
and two chronic post event health states. The model 
reflected the pathway of patients with hypertension 
starting in an asymptomatic health state, and then 
moving to a cardiovascular state (CHD or stroke) and 






Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
and this was not discussed. The authors used a Markov 
model  
Wisloff  et 
al76 
  
Yes Yes No 
Alternatives were aimed at contribute towards 
the discussion around intervention thresholds 
and the choice of first-line drug and 'add on' 
drugs 
Four acute health states (Stroke, AMI, Angina and HF) 
and two post event health states (Post-Stroke and Post-
CVD) were considered. Health events in the Markov 
model reflected the asymptomatic stages, cardiovascular 
life and death of patients; the model allowed for 
secondary events after which the model assumed 
patients will move to the worst health state; some 
assumptions regarding risk of secondary events were 
based on expert opinion. These assumptions were not 
tested in SA 
The authors used observed 
incidence rates to reflect risk 
factors using registry data; this 
was acknowledged as a limitation 




Yes Yes No 
Justified on the grounds that no head to head 
randomised comparative studies were 
previously performed comparing Candesartan 
and Losartan; authors acknowledged as a 
limitation that there may be ARB comparators 
more relevant to Candesartan than Losartan in 
other health care setting 
The authors considered health states (HF, PAD and 
Arrhythmia), post event health states (post-MI and post 
Stroke) and a chronic health state (IHD). Health states in 
the Markov model, including post MI and post stroke 
were based on CVD events measured in a registry study 
(authors commented and acknowledged a potential risk 
of confounding); after a CVD event an increased risk of 
mortality was applied (no SA to test for these 
assumptions) 
  
Baker et al80 
 





Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
Comparators were justified in view of the 
concerns surrounding non-medical ARB 
switching after Simvastatin became a generic 
product leading to a number of patients being 
switched from branded atorvastatin to generic 
Simvastatin for economic rather than medical 
reasons 
Health states were designed to reflect the course and 
history of CVD events in a typical patient with 
hypertension (CVD event free, post CVD, and death). 
Although secondary CVD events were not explicitly 
considered in the model, patients in the post-event state 
were subject to an increased risk of death reflecting their 
disease state 
The model assumed that Valsartan 
remained on patent for the first 
2.75 years of the model time 
horizon and Losartan for only 4 
months after which generic 
formulations would become 
available. No side effects were 
modelled, which was 





Yes Yes Yes 
Justified on the basis that previous evidence was 
favourable for hypertension programmes as 
compared to drug treatments 
The health states were: an acute MI event, no event and 
death. The inclusion/exclusion of health states in the 
Markov model was not discussed but rather just 
introduced; an interesting assumption in the model was 
that patients presenting an acute CVD event could have 
or not have hospital attention? Risk of secondary events 
was considered. This was not tested in SA 
The discount rate was considered 
as a structural variable and thus 
analyses were performed with 
different discount rates ranging 
from 0%-12% 
Ekman et al77 
  
 





Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
The comparators corresponded to those found 
to have mild side effects as per previous clinical 
trials; it was acknowledged as a weakness not to 
include other comparators such as diuretics 
Four acute health states (Angina, MI, CHF and stroke), a 
post MI, and post stroke health state were modelled. No 
particular explanation was given for the 
inclusion/exclusion of health states. The Markov model 
assumed that patients may undergo revascularization 
procedures while in the MI or angina health states; 
recurrence of events was modelled however 
acknowledged that data was limited to reflect how risks 
of recurrent strokes or MIs vary depending on various 
disease histories. 
Treatment effects were supposed 
to last five years; SA tested the 
sensitivity of the model to changes 
in the duration of the 
antihypertensive treatment and 
variation of discount rate 
(between 0% to 8%) and measure 











Comparators resulted from the research 
question which is whether the health service can 
reduce the underuse of hypertensive medication 
among the German population through a 
national programme 
Three acute health states (MI, stroke and renal failure) 
were modelled. No particular reason argued for the 
inclusion/exclusion of health states in the Markov model; 
treatment and its effect were assumed to last a lifetime; 
secondary events were not modelled but captured 
through the mortality rates of patients after a CVD event. 




Yes No No 
Comparators resulted from the research 
question which is whether incorporating 
patients’ preferences into the decision-making 
process may have an important influence on 
treatment recommendations for individual 
patients 
A single acute CVD health state was considered with 
variations to account for the impact of side effects and 
treatment or lack of it. No explanation was given for the 
inclusion/exclusion of health states in the Markov model; 
secondary events were not modelled and the 





Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 





Yes No No 
Comparators were chosen in line with 
hypertension guidelines for first-line 
antihypertensive therapy from both, the Joint 
National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood 
Pressure (JNC-VI) and the World Health 
Organization (WHO) 
Three acute health states (CAD, CVD and CHF) were 
considered. Authors argued to have included the most 
common CVD outcomes as health states in the Markov 
model; the model allowed one opportunity to switch 
from conventional therapy to ACE inhibitors in response 
to adverse effects or lack of efficacy; recurrence of 





The complexity of the different model structures considered in this analysis was varied, this 
being due to the different approaches to the inclusion of the acute or post-event health states 
modelled. Model structures were most frequently a reflection of the course and history of 
CVD events or disease progression. The most common initial state was disease-free and the 
most common acute states modelled were stroke and MI followed by angina, heart failure 
and CVD. Few studies modelled only a single health state to describe an acute cardiovascular 
event70-72. Some studies modelled additional states such as congestive HF77, coronary artery 
disease78, renal failure69 or peripheral artery disease79. Absorbing states consisted of death 
and non-CVD death. Some studies acknowledged they had excluded states69, 78 or 
combinations of health states (HF and stroke)76 due to data limitations. Compared to the 
TASMIN-SR model, the review identified a variety of model structures ranging from a 
simplistic (single CVD morbidity)71, 72, 80 to more complex approaches (four states including 
stroke, MI, HF, angina)76, 77, 79. 
The risk of secondary events was modelled in seven70-72, 76-79 of the studies reviewed. It could 
be argued that some of these studies adopted assumptions which would add extra 
uncertainty to the results. These included assuming that the risk of secondary events was 
equal to the risk of a first non-fatal event72, assuming that the patient with a second event 
will be in a health state worse than the state prior to the event76, or using expert opinion to 
inform risks of secondary events71. Lack of epidemiological data was acknowledged as the 
main reason for the exclusion of secondary events by some authors39, 80. The TASMIN-SR 
model assumed no recurrence of CV events due to the lack of data describing secondary 
events for a high risk population. The choice of modelling approach should be considered as 
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part of the investigation into the impact of structural uncertainty. However in this Chapter, 
only the Markov model structure is considered as informed by the results of the review. 
 
5.3.2. Implementation of model structures 
Alternative Markov model structures were primarily identified based on the findings of the 
systematic review. Validation of the adequacy of this type of model over competing 
structures such as decision trees, DES or individual sampling model was checked using a 
framework to select the appropriate model type13. The validation check indicated that 
Markov was just the right type of model, considering that estimating interactions between 
individuals was not necessary whilst modelling health states was important (patient 
pathways would not be adequately represented by decision trees) and an excessive number 
of health states was not required (excluding the option of individual sampling model). 
These alternative model structures, were labelled Model 1 through Model 3, were developed 
by varying the number of health states used from a simplistic structure to one of increased 
complexity (Figure 5-1). Model 1 uses a simplified approximation of the TASMIN-SR model 
structure. It was informed by Stevanovic72 and consists of a single CVD state with progression 
to a chronic state (Figure 5-1). Following NICE Statin guidelines98 it was assumed that CVD is 
a combined state consisting of CHD (MI and UA) and stroke. Assumptions were adopted to 
estimate transition probabilities, utilities and costs due to lack of data in the literature to 
inform a single CVD health state (Table 5-2). Parameters for the CVD state correspond to a 
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weighted average of input parameters used in the case study model for the states stroke, MI 
and UA (Table 5-2). 
Model 2 applied the assumption that if the costs and utilities for two health states are the 
same, then it may not be necessary to distinguish between those two states to estimate 




                        




























UA MI ST 
DEA














                        Model 4 TASMIN-SR and the inclusion of secondary events 
 
 
Figure 5-1 Model structures for the TASMIN-SR and models 1 - 4 
HR = High Risk, UA= Unstable Angina; MI= Myocardial Infarction; HF = Heart Failure; ST = 
Stroke;    TIA = Transient Ischemic Attack; CVD = Cardiovascular Disease.  
Names preceded by a ‘P’, for example, PMI refers to a post event (chronic) health state for a 
patient surviving an event (MI)  
Names preceded by ‘2’, for example, 2UA refers to the occurrence of a second event 
consisting of a UA 




In the TASMIN-SR model, treatment effects and the long-term costs and utilities for states MI 
and UA were assumed to be the same due to lack of data on UA (Table 5-2). Under these 
circumstances, it may not be necessary to include a state UA. Model 2 reflects a restricted 
version of the TASMIN-SR model consisting of two health states Stroke and MI. The review 
identified studies using a model structure consisting of two states, named stroke and a MI73, 
74 or stroke and CHD75. Model 2 was implemented consisting of health states stroke and MI 
with progression to a chronic phase for individuals who survive (Figure 5-1 and Table 5-2).  
Model 3 adopted an expanded structure that was informed by the structure of the most 
complex models76, 77, 79, using an increased number of health states (Table 5-1). In Model 3, 
high risk patients can move to one of a number of primary CVD events, MI, stroke, HF, UA and 
transient ischemic attack (TIA) or dead from CVD or other causes. Individuals that survive an 
acute CVD phase naturally progress to a chronic phase where quality of life is lower and where 
they remain until death.  
 
5.3.3. Inclusion of secondary events 
TASMIN-SR did not consider recurrence of cardiovascular events due to the lack of suitable 
epidemiological data to reflect the transition of elderly and high risk patients after a primary 
cardiovascular event. After carefully reviewing sources of data and literature, including 
relevant NICE guidelines, no additional suitable data were identified. Therefore in this 
chapter, assumptions based on expert clinical advice were adopted. In Model 4, individuals 
that survive a primary acute event can either move into a chronic post event phase 
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(asymptomatic) or may experience a recurrent cardiovascular event one year after the first 
event. In Model 4 it was assumed that patients will experience only one cardiovascular event 
per year and following a primary event, patients may experience a second event one year 
after the first event with the same probability as for the first event. Transitions from a more 
severe health state (e.g. stroke) to a less severe state (e.g. unstable angina) were omitted 
from the model because such transitions would imply lower costs and improvements in 
quality of life that may not reflect clinical reality (Figure 5-1)99.  
 
5.3.4. Model input parameters and analysis 
Information from the literature was sought to populate all input parameters for models 1 to 
4 for a UK setting (Table 5-2). When information on transition probabilities or age-related 
relative risks was not readily available, figures were estimated using a weighted average 
based on the distribution of patients to primary CVD events40. Costs were derived from a 
combination of standard unit costs100, 101 and previously published literature and models101, 
102, and were adjusted using the Hospital and Community Health Service index to the price 
year of 2014/15100. The acute and chronic costs of CVD were estimated using a weighted 
average based on the distribution of patients to primary CVD events102. The probabilities of 
death due to cardiovascular events within a year of the event are reported in Table 1 and 
were applied to the first year after an event (first two cycles in the model). Life tables were 
used to determine the overall mortality for each model dependent on age and gender103. Risks 
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of death following a second event and utility values following a second event used in Model 
4 were taken from the literature (Table 5-2). 
A cost-utility analysis was undertaken for all models to calculate the cost per quality-adjusted 
life year (QALY) gained. Results from each alternative model specification are presented as 
scenario analysis. Deterministic and probabilistic sensitivity analysis was conducted to assess 
parameter uncertainty. The PSA was run with 10,000 Monte Carlo simulations allowing cost-
effectiveness planes (CEP) and cost-effectiveness acceptability curves to be constructed to 
estimate the probability of self-management being cost effective at different willingness-to-
pay thresholds.  
Sensitivity analyses were conducted to assess uncertainty in the results of each model 
(TASMIN-SR and Model 1-4). Deterministic sensitivity analysis was undertaken around key 
parameters and assumptions. The time horizon for each model was varied from 30 years 
(lifetime) to 10, 5, 3, 2 and 1 year to determine whether the intervention was cost-effective 
in the shorter and the long-term. All cost variables were increased by 40% and 200% or 
decreased by 40% and 50%. Additional sensitivity analyses for Model 4 was undertaken to 
examine the impact of doubling or halving the probabilities of having a second cardiovascular 
event.   
The impact of structural uncertainty was presented in terms of the impact on the cost-
effectiveness results of a model and expected value of perfect information (EVPI). Including 
different parameters in the model can be expected to alter the extent of uncertainty captured 
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in the EVPI calculation. Because the models have different parameter sets, comparisons of 
expected value of partial perfect information would not be helpful.  
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Table 5-2 Input parameters used in the case study and each one of the alternative model structures 
Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
Annual CVD events for patients with DM 
Stroke       
60-69 years old 0.0196  0.0196 0.0196 0.0196 
NICE, Diabetes 
guidelines104 
70-79 years old 0.0262  0.0262 0.0262 0.0262 
80-89 years old 0.0298  0.0298 0.0298 0.0298 
MI       
60-69 years old 0.0089  0.0089 0.0089 0.0089 
NICE, Diabetes  
guidelines104 
70-79 years old 0.0100  0.0100 0.0100 0.0100 
80-89 years old 0.0111  0.0111 0.0111 0.0111 
UA       
60-69 years old 0.0041   0.0041 0.0041 
NICE, Diabetes  
guidelines104 
70-79 years old 0.0047   0.0047 0.0047 
80-89 years old 0.0052   0.0052 0.0052 
TIA       
60-69 years old    0.0053  
NICE, Diabetes  
guidelines104 
70-79 years old    0.0059  
80-89 years old    0.0066  
HF       
60-69 years old    0.0197  NICE, Hypertension 
Guidelines64 70-79 years old    0.0236  
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
80-89 years old    0.0264  
CVD       
60-69 years old  0.0323    
Added risks* 70-79 years old  0.0405    
80-89 years old  0.0456    
Annual CVD events for patients with CKD 
Stroke       
60-69 years old 0.0072  0.0072 0.0072 0.0072 
Kerr et al105 70-79 years old 0.0147  0.0147 0.0147 0.0147 
80-89 years old 0.0189  0.0189 0.0189 0.0189 
MI       
60-69 years old 0.0051  0.0051 0.0051 0.0051 
Kerr et al105 70-79 years old 0.0113  0.0113 0.0113 0.0113 
80-89 years old 0.0171  0.0171 0.0171 0.0171 
UA       
60-69 years old 0.0024   0.0024 0.0024 
Kerr et al105 70-79 years old 0.0054   0.0054 0.0054 
80-89 years old 0.0081   0.0081 0.0081 
TIA       
60-69 years old    0.0600  
Koren-Morag  
et al106 
70-79 years old    0.1303  
80-89 years old    0.1867  
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
HF       
60-69 years old    0.0269  
Shiba et al107 70-79 years old    0.0585  
80-89 years old    0.0838  
CVD       
60-69 years old  0.0146    
Added risks* 70-79 years old  0.0311    
80-89 years old  0.0435    
Annual CVD events for patients with a previous stroke 
Stroke       




70-79 years old 0.0590  0.0590 0.0590 0.0590 
80-89 years old 0.0715  0.0715 0.0715 0.0715 
MI       




70-79 years old 0.0232  0.0232 0.0232 0.0232 
80-89 years old 0.0232  0.0232 0.0232 0.0232 
UA       
60-69 years old 0.0139   0.0139 0.0139 
PROGRESS (1999) & 
NICE, Lipid 
70-79 years old 0.0232   0.0232 0.0232 
80-89 years old 0.0232   0.0232 0.0232 
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
modification 
guidelines108, 109 
TIA       
60-69 years old    0.5000  
Hankey GL (2003)110 70-79 years old    0.0848  
80-89 years old    0.1027  
HF       
60-69 years old    0.0115  
NICE, Hypertension 
guidelines64 
70-79 years old    0.0193  
80-89 years old    0.0207  
CVD       
60-69 years old  0.0615    
Added risks* 70-79 years old  0.1022    
80-89 years old  0.1141    
Annual CVD events for patients with CHD 
Stroke       




70-79 years old 0.0590  0.0590 0.0590 0.0590 
80-89 years old 0.0715  0.0715 0.0715 0.0715 
MI       
60-69 years old 0.0666  0.0666 0.0666 0.0666 
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 




80-89 years old 0.1112  0.1112 0.1112 0.1112 
UA       





70-79 years old 0.0882   0.0882 0.0882 
80-89 years old 0.0882   0.0882 0.0882 
TIA       
60-69 years old    0.0499  NICE, Lipid 
modification 
guidelines108 
70-79 years old    0.0820  
80-89 years old    0.1046  
HF       
60-69 years old    0.0304  NICE, Lipid 
modification 
guidelines108 
70-79 years old    0.0512  
80-89 years old    0.0653  
CVD       
60-69 years old  0.1467    
Added risks* 70-79 years old  0.2373    
80-89 years old  0.2475    
Probability of death for those who have suffered an event 
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
Fatal Stroke 0.23  0.23 0.23 0.23 Bamford et al111 
Fatal MI       
65-74 years old 0.23  0.23 0.23 0.23 
ONS, Deaths registry 
&  Kerr et al103, 105 
75-84 years old 0.39  0.39 0.39 0.39 
85 and over 0.52  0.52 0.52 0.52 
 
Fatal TIA 
    
0.11 
 Mant et al & 
Gattellary et al112, 113 
Fatal HF       
Male 
   
0.17  NorCAD model 
(2008)99  Female 
   
0.16  
Fatal CVD      
  
65-74 years old  0.20    
Weighted average† 75-84 years old  0.25    
85 and over  0.29    
Probability of death from a second cardiovascular event, one year after the first event 
Stroke after a first stroke     0.34 
NICE, Statins 
guidelines102 
UA after first UA     0.02 
MI after first MI    
 
Same as first 
year event 
Age-related relative risks at 12 months 
MI, UA and HF – self-management  
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
60-69 years old 0.63  0.63 0.63 0.63 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.69  0.69 0.69 0.69 
80-89 years old 0.75  0.75 0.75 0.75 
Stroke and TIA – self-management  
60-69 years old 0.54  0.54 0.54 0.54 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.59  0.59 0.59 0.59 
80-89 years old 0.75  0.75 0.75 0.75 
CVD – self-management  
60-69 years old  0.60    
Weighted average† 70-79 years old  0.65    
80-89 years old  0.75    
MI, UA and HF - usual care  
60-69 years old 0.82  0.82 0.82 0.82 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.85  0.85 0.85 0.85 
80-89 years old 0.88  0.88 0.88 0.88 
Stroke and TIA - usual care  
60-69 years old 0.76  0.76 0.76 0.76 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.81  0.81 0.81 0.81 
80-89 years old 0.88  0.88 0.88 0.88 
CVD - usual care  
60-69 years old  0.80 
   
Weighted average† 
70-79 years old  0.83 
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
80-89 years old  0.88 
   
Age-related relative risks at 6 months  
MI, UA and HF – self-management  
60-69 years old 0.71  0.71 0.71 0.71 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.75  0.75 0.75 0.75 
80-89 years old 0.80  0.80 0.80 0.80 
Stroke and TIA – self-management  
60-69 years old 0.62  0.62 0.62 0.62 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.68  0.68 0.68 0.68 
80-89 years old 0.80  0.80 0.80 0.80 
CVD – self-management  
60-69 years old  0.68    
Weighted average† 70-79 years old 
 0.72    
80-89 years old  0.80    
MI, UA and HF - usual care  
60-69 years old 0.83  0.83 0.83 0.83 
TASMIN-SR trial & 
Law et al37, 114  
70-79 years old 0.85  0.85 0.85 0.85 
80-89 years old 0.89  0.89 0.89 0.89 
Stroke and TIA - usual care  
60-69 years old 0.77  0.77 0.77 0.77 TASMIN-SR trial & 
Law et al37, 114  70-79 years old 0.81  0.81 0.81 0.81 
154 
 
Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
80-89 years old 0.89  0.89 0.89 0.89 
CVD - usual care  
60-69 years old  0.80    
Weighted average† 70-79 years old  0.84    
80-89 years old   0.89      
Costs of acute disease one-off cost (UK 2014/15 £) 
Stroke 11,433 
 
11,433 11,433 11,433 Youman et al115 
MI 5,693 
 
5,693 5,693 5,693 Palmer et al116 
UA 3,416 
  
3,416 3,416 Assumed 60% of MI 
TIA 
   
1,715 
 NHS Reference costs 
2013-14101 
HF 
   
2,797 






 Weighted average‡ 
Costs for long-term (chronic) disease per year (UK 2014/15 £) 
Stroke 2,823 
 
2,823 2,823 2,823 Youman et al115 
MI 593 
 
593 593 593 Cooper et al117 
UA 593 
  
593 593 Cooper et al117 
TIA 
   
333 
 NICE, Statins 
guidelines102  
HF 
   





 Weighted average† 
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
Utilities for initial health states 
Self management & Usual care       
65-74 years old 0.81 0.81 0.81 0.81 0.81 
TASMIN-SR trial37 75-84 years old 0.74 0.74 0.74 0.74 0.74 
85 and over 0.71 0.71 0.71 0.71 0.71 
Utilities for acute events 




TASMIN-SR trial37, 64, 
102, 108 
MI 0.76  0.76 0.76 0.76 
Stroke 0.63  0.63 0.63 0.63 
TIA    0.90  
HF    0.68  
CVD  0.76    
Stroke after stroke     0.479 
Ara, et al119 
UA after UA     0.615 
MI after MI     0.700 
MI and Stroke     0.479 
Angina and Stroke     0.596 
Angina and MI     0.541 
Utilities for long term (chronic) disease 
UA 0.88   0.88 0.88 NICE, Lipid 
modification and 
Statins guidelines, 
MI 0.88  0.88 0.88 0.88 
Stroke 0.63  0.63 0.63 0.63 
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Parameter TASMIN-SR Model 1 Model 2 Model 3 Model 4 Sources 
TIA    0.90  TASMIN-SR trial37, 
102, 108  HF    0.68  





Dead 0 0 0 0 0 By definition 
Annual discount rate for costs and 
utility 
0.035 0.035 0.035 0.035 0.035 Gray et al1 
*The probability of CVD was estimated as the added risks of the individual risk probabilities for stroke, MI and UA 
†Weighted averages were estimated based on the distribution of patients to primary event health states in the ScHARR economic model  




The main cost-effectiveness results obtained in the TASMIN-SR study were found to be robust 
to changes in model structure (Table 5-3) and to the inclusion of secondary events. Self-
management of blood pressure remained dominant (more effective and cheaper than usual 
care) for all models. Expected costs for each intervention were noticeable higher for Model 4 
while the expected QALYs for both interventions were noticeably lower for Model 3. 
The highest QALY outcomes for both interventions were found by implementing Model 2 
(restricted version). Higher incremental QALYs were found for Models 3 and 4 between self-
management and usual care. Differences found between incremental QALYs for TASMIN-SR 
and Models 2 and 3 were marginal (0.0001 and 0.0002 respectively) (Table 5-3).   
The cost effectiveness plane (CEP, Figure 5-2) shows the results from the Monte Carlo 
simulation for 10,000 replications. All the results were in the north-east and south-east 
quadrants indicating that self-management was always more effective but may be more or 
less costly. The cost-effectiveness acceptability curves (CEAC) shown in Figure 5-3 were 
derived from the joint density of incremental costs and incremental QALYs for the self-
management of blood pressure. Each CEAC presents the probability that the self-
management intervention is cost-effective for the different model structures. For a 
willingness to pay of £20,000 per QALY, the proportion of model replications that were cost-
effective was higher than 99% for all model structures (Figure 5-3).  
All sensitivity analyses undertaken appear to indicate that individual results for the various 
models remained aligned after increasing or decreasing all costs (Table 5-4), varying the 
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length of time horizons (Table 5-5), and varying transition probabilities to secondary events 
(Table 5-6), in other words, self-management of hypertension always remained dominant. 
Self-management in Models 1-4 was found to be dominant if the time horizon was two years 
or more (Table 5-5). Per-patient lifetime EVPI for alternative model structures compared to 
TASMIN-SR was reduced substantially for Model 1 at all willingness to pay thresholds. For all 






Table 5-3 Cost-Effectiveness results for the case study and each one of the alternative model 
structures 





 TASMIN-SR model       
Usual care 
        
9,860  7.0946    
Self-management 
        
8,997  7.4390 -864 0.3444 Dominant 
 Model 1       
Usual care 
        
9,452  6.9102    
Self-management 
        
8,813  7.2311 -639 0.3210 Dominant 
 Model 2       
Usual care 
        
9,854  7.1612    
Self-management 
        
8,858  7.5057 -996 0.3445 Dominant 
 Model 3       
Usual care 
        
9,696  5.9274    
Self-management 
        
9,156  6.2721 -539 0.3446 Dominant 
Model 4       
Usual care 11,651 7.0704    















































































































Figure 5-3 Cost-effectiveness acceptability curve (CEAC) for the probability that self-
management of blood pressure is cost-effective compared to usual care – TASMIN-SR and 




































































Figure 5-4 Per-patient expected value of perfect information (EVPI) across varying willingness 





Table 5-4 Results of cost-effectiveness after increasing and decreasing total costs  






          
Increasing costs 200%       
Usual care 
       
19,728  
            
7.0946        
Self-management 
       
17,899  
            
7.4390  -1,829 0.3444 Dominant  
Increasing costs 40%       
Usual care 13,805       7.0946      
Self-management 12,596  7.4390  -1,209 0.3444 Dominant  
Decreasing costs 40%       
Usual care    5,917  7.0946      
Self-management 5,398  7.4390  -518 0.3444 Dominant  
Decreasing costs 50%       
Usual care 
        
4,931  
            
7.0946        
Self-management 
        
4,550  
            
7.4390  -382 0.3444 Dominant  
Model 1 
      
Increasing costs 200%      
Usual care 18,905  6.9102             
 
Self-management 17,528     7.2311            -1,376 0.3210 Dominant  
Increasing costs 40% 
    
  
Usual care 13,234  6.9102  
  
  
Self-management 12,339  7.2311  -895 0.3210 Dominant  
Decreasing costs 40% 
    
  
Usual care   5,671  6.9102  
  
  
Self-management 5,287  7.2311  -384 0.3210 Dominant  
Decreasing costs 50% 
    
  
Usual care 4,726         6.9102                   
Self-management     4,455   7.2311 -271 0.3210 Dominant  
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Increasing costs 200%      
Usual care 19,717    7.1612           
 
Self-management 17,626     7.5057              -2,091 0.3445 Dominant  
Increasing costs 40%       
Usual care 13,797  7.1612      
Self-management 12,402  7.5057  -1,394 0.3445 Dominant  
Decreasing costs 40%       
Usual care   5,913  7.1612      
Self-management 5,315  7.5057  -598 0.3445 Dominant  
Decreasing costs 50%       
Usual care 4,928        7.1612                   
Self-management  4,479         7.5057              -449 0.3445 Dominant  
Model 3 
      
Increasing costs 200%      
Usual care 19,396         5.9274                  
 
Self-management 18,218         6.2721              -1,179 0.3446 Dominant  
Increasing costs 40%       
Usual care       
Self-management 13,574  5.9274    Dominant  
Decreasing costs 40% 12,819  6.2721  -755 0.3446   
Usual care       
Self-management   7,069  5.9274    Dominant  
Decreasing costs 50% 6,607  6.2721  -462 0.3446   
Usual care 4,848          5.9274                    
Self-management  4,628         6.2721              -220 0.3446 Dominant  
Model 4 
      
Increasing costs 200%      
Usual care 31,071         7.0489      
 
Self-management 27,771         7.4085  -3,301 0.3596 Dominant  
Increasing costs 40%       
Usual care 16,097  7.0489        
Self-management 14,464  7.4085  -1,633 0.3596 Dominant  
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Decreasing costs 40% 
Usual care 6,899  7.0489        
Self-management 6,199  7.4085  -700 0.3596 Dominant  
Decreasing costs 50%       
Usual care 7,766          7.0489        





Table 5-5 Results of cost-effectiveness after altering the time horizon 






          
10 years       
Usual care 5,860  5.1741      
Self-management 5,237  5.3506  -623 0.1765 Dominant  
5 years       
Usual care 3,109  3.2475      
Self-management 2,753  3.3079  -356 0.0605 Dominant  
3 years        
Usual care 1,792  2.1372      
Self-management 1,626  2.1564  -166 0.0192 Dominant  
2 years       
Usual care  1,173  1.4889      
Self-management  1,110  1.4957  -63 0.0068 Dominant  
1 year       
Usual care     629  0.7791      
Self-management     652  0.7797  23 0.0006     35,391  
Model 1 
      
10 years       
Usual care 5,729  5.1310      
Self-management 5,231  5.3029  -498 0.1719 Dominant  
5 years       
Usual care  3,066   3.2371      
Self-management   2,762  3.2955  -304 0.0584 Dominant  
3 years        
Usual care   1,772   2.1331      
Self-management   1,630  2.1516  -141 0.0185 Dominant  
2 years       
Usual care   1,162   1.4871      
Self-management   1,111  1.4937  -51 0.0066 Dominant  
1 year       
Usual care     624  0.7788      
Self-management     650  0.7795  25 0.0006      40,799  
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10 years       
Usual care   5,738   5.2904      
Self-management   5,045  5.4608  -692 0.1704 Dominant  
 
5 years       
Usual care  2,923  3.3047      
Self-management  2,565  3.3580  -357 0.0533 Dominant  
3 years        
Usual care  1,644   2.1624      
Self-management 1,492  2.1786  -152 0.0161 Dominant  
2 years       
Usual care  1,066  1.5018      
Self-management  1,014  1.5075  -52 0.0056 Dominant  
1 year       
Usual care     566  0.7830      
Self-management     593  0.7835  27 0.0005      50,960  
Model 3 
      
10 years       
Usual care   6,114  4.4454      
Self-management   5,641  4.6811  -473 0.2357 Dominant  
5 years       
Usual care  3,481   2.9515      
Self-management   3,132  3.0489  -348 0.0974 Dominant  
3 years        
Usual care  2,100  2.0112      
Self-management  1,903  2.0448  -197 0.0336 Dominant  
2 years       
Usual care   1,402  1.4255      
Self-management  1,314  1.4378  -89 0.0123 Dominant  
1 year       
Usual care      771  0.7607      
Self-management     785   0.7619  14 0.0012      11,701  
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10 years       
Usual care 6,880  5.2107        
Self-management 5,975  5.3803  -905 0.1696 Dominant  
5 years       
Usual care 3,470  3.2711        
Self-management 2,985  3.3237  -485 0.0527 Dominant  
3 years        
Usual care 1,889  2.1446        
Self-management 1,685  2.1611  -203 0.0165 Dominant  
 
2 years       
Usual care 1,194  1.4907        
Self-management 1,123  1.4969  -71 0.0062 Dominant  
1 year       
Usual care 629  0.7791        






Table 5-6 Results of cost-effectiveness after increasing and decreasing the probability of 
having a second event 





Model 4            
Doubling the probability of having a second event  
Usual care 15,528 6.0034    
Self-management 13,925 6.3859 -1,603 0.3825 Dominant  
Halving the probability of having a second event  
Usual care 8,213 7.9957    




Decision-analytic modelling represents an organised way to synthesise the evidence currently 
available on the outcomes and costs of alternative health care interventions12, 14. The results 
obtained from a DAM will depend on how the model structure has been defined and the data 
used to populate the model. The analysis of uncertainty in DAM has mainly focused on 
parameter uncertainty, taking account of any uncertainties in the data inputs27, 29, 51, 85, 97. 
Such analyses are usually based on the premise that the model has been correctly specified. 
However, an inappropriate model structure can potentially invalidate estimates of cost-
effectiveness and, therefore, is also of little value to a decision maker27, 29, 51. Although 
limitations in model structure are usually acknowledged, there is a lack of clarity about the 
methods used to evaluate structural uncertainty27, 29, 51. 
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This chapter identified and implemented alternative model structures in the assessment of 
the cost-effectiveness of primary care interventions for the management of hypertension in 
patients at risk of or with established CVD. The results of each alternative model structure, 
including the results of EVPI, were presented and compared. 
The main cost-effectiveness results obtained in the TASMIN-SR study did not change when 
alternative model structures (Model 1 to 3) were implemented or after adjusting the TASMIN-
SR model for the effect of secondary events (Model 4) suggesting that structural uncertainty 
was not important in this model. This case study gave similar results for EVPI across the range 
of model structures, except for Model 1, where the restricted parameter set meant that a 
large part of the decision uncertainty was not apparent in the model. 
The illustration of various scenarios representing structural uncertainty offers the decision 
maker the opportunity to decide on which model structure or assumption(s) he/she believes 
and make policy decisions on that basis. However, it does not provide any explicit framework 
for quantifying the uncertainty or offer any guidance to decision makers that have no clear 
preferences over alternative model assumptions.  
The assessment of structural uncertainty shown in published studies in the area of primary 
prevention of CVD has mainly focused on assessing parameter uncertainty and there have 
been relatively few studies that have attempted to examine structural uncertainty in the 
extent that this study has done. Studies that considered the assessment of structural 
uncertainty varied in scope39, 71, 72, 77 however none attempted to show the effect of different 
model structures on the cost-effectiveness of anti-hypertension treatments.  
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Model 1 (single CVD state) produced lower QALYs and lower costs compared to TASMIN-SR 
and this can be explained by the increased overall risk of CVD due to the added individual 
risks of stroke, MI and UA used to estimate the risk of CVD and the lower weighted average 
acute and chronic costs of CVD. The findings in terms of the highest QALY outcomes and 
reduced costs found by implementing Model 2 may be explained by the fact that when 
compared with TASMIN-SR, the population entering Model 2 was exposed to an overall 
reduced risk of CVD and reduced acute and chronic costs due to the exclusion of the angina 
state, thus leading to increased QALYs and reduced overall costs.  
The lowest QALY gained and higher self-management costs from Model 3 (more complex 
model) can be explained by the additional burden of mortality for patients presenting with 
HF and TIA. The results of Model 4 show self-management to be even more cost-effective 
than usual care when compared with results from the case study and alternative Models 1-3. 
This can be explained by the increased overall risk of CVD due to the occurrence of additional 
events, and therefore more scope for preventing these events. The fact that expected costs 
for each intervention were noticeable higher for Model 4 can be explained by the acute costs 
of having experienced a second CVD event while lower expected QALYs for both interventions 
in Model 3 are explained by the additional burden of mortality for patients presenting HF and 
TIA. 
The main conclusions drawn from the cost-effectiveness analyses were not altered when 
alternative model structures were implemented or in the presence of secondary events, and 
were driven by greater uncertainty around costs, reflected in the CEP where the results from 
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the Monte Carlo simulations were in the north-east and south-east quadrants indicating that 
self-management was always more effective but could be more or less expensive.  
These results may well lead to the conclusion that the use of a simple model will suffice when 
examining the potential impact of anti-hypertensive strategies on the primary care 
prevention of CVD.  
This case study reflects the level of the complexities typically faced in current practice when 
undertaking an assessment of structural uncertainty. Currently, guidance regarding the 
assessment of structural uncertainty in DAM by bodies such as ISPOR and NICE (in the UK) 
goes as far as recommending that modellers should parameterize uncertainties20 and, if this 
is not possible, use sensitivity analysis and scenario analysis11, 20.  
The wide variation in the model structures that were identified by the systematic review 
supports the need for improved guidance to handle the implications of potential sources of 
structural uncertainty. Most importantly, this may be an indication that disease-specific or 
generic models to examine the cost-effectiveness of self-management of hypertension in 
patients with established CVD may need to be considered.  
Challenges across different disease areas are so varied that it may well be the case that only 
studies such as this can shed any light on the importance of model uncertainty in different 
settings. In fact, there is evidence from UK HTA appraisals of metastatic end-stage cancer of 
biases associated with the use of models such as state transition versus partitioned survival 
analyses (PartSA), leading NICE to recommending120 that further research is warranted to 
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understand the conditions under which the PartSA and state transition modelling approaches 
perform well. 
Current practice seems bound by data availability whilst methods proposed to assess 
structural uncertainty, borrowed from other disciplines, seem oblivious to the needs in a 
health care setting where patient level data is most of the time not readily available. 
 
5.5.1. Limitations  
A limitation of the approach adopted in this Chapter to assess structural uncertainty is that 
there are no established methods to formally assess the plausibility of alternative models and 
it is not clear which type of, or how many scenarios should be considered.  
The choice of model type in this case study was limited to a cohort Markov model. Some may 
argue that a microsimulation or Discrete Event Simulation (DES) may offer some advantages 
such as flexibility in incorporating individual heterogeneity and tracking individual event 
history. However, the review indicated that all economic evaluations in this disease area had 
used Markov models, presumably based on the trade-off between model flexibility and 
analytical input49. Furthermore, chronic and recurring diseases are often reflected by using 
Markov models in which individuals move between clinical states of interest in discrete time 
periods, and each state is associated with a cost and utility9. In addition, giving the 
information available for a UK setting to populate the model, developing a more complex 
model structure would have required the adoption of additional assumptions and therefore 
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would have meant adding more uncertainty to the model. Due to a lack of epidemiological 
data, Models 1 to 3 did not capture structural uncertainty arising from the exclusion of 
secondary events of CVD for high risk patients. However, using assumptions based on expert 
opinion, the risk of secondary events in Model 4 were assessed. The exclusion of secondary 
events in Models 1 to 3 was a conservative assumption, as a reduction in blood pressure was 
expected to reduce the risk of these events in addition to the primary events already 
considered, making self-management even more cost-effective as demonstrated in Model 4.  
More sophisticated methods could not be implemented, for example, model selection, model 
averaging, or discrepancy approach to select the best model on the basis of how well the 
model’s output match observed data (commonly judged by the likelihood-based information 
criteria). This was because only single point estimates were available for key parameters 
(transition probabilities) taken from the literature. These do not allow the estimation of the 
maximum likelihood of parameters: for that, actual patient level data is required. 
Furthermore, results of previous research seem to indicate that the standard likelihood-based 
approaches may be unsuitable when the underlying datasets are different93. Renal failure and 
peripheral artery disease were not considered in this case study. These additional health 
states are part of the broader set of diseases that may indirectly lead to CVD and data to 
populate input parameters for these states was not available. 
The results of cost-effectiveness for self-management of blood pressure in this case study 
were of dominance for all competing model structures. For this reason it is difficult to draw 
conclusions regarding the importance of correctly exploring structural uncertainty in this 
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setting. It may be that if the results were near the £20,000 threshold, changes in model 
structure could have led different results of cost-effectiveness and possible EVPI.  
The assessment of structural uncertainty shown in published studies in the area of primary 
prevention of CVD has mainly focused on assessing parameter uncertainty and there have 
been relatively few studies that have attempted to examine structural uncertainty in the 
extent that this study has done, showing the effect of different model structures on the cost-
effectiveness of anti-hypertension treatments and implementing extensive sensitivity 
analyses and EVPI. 
5.6. Conclusions 
The results of this chapter indicate that the main conclusions from the TASMIN-SR cost-
effectiveness model are robust to changes in model structure. The cost-effectiveness results 
and the EVPI were not sensitive to model structure specification. 
Even though the results from Model 1 were not similar to those of TASMIN-SR, the fact that 
the main conclusions were the same raises the question, whether in this particular case study 
a more parsimonious model would have sufficed. Currently there are no available guidelines 
indicating how structural uncertainty, in particular structural uncertainty arising from the 
structure of a model, should be identified, assessed, and reported. Therefore, further 
research should focus on the strengthening of generally agreed guidelines on how to address 
issues pertaining to structural uncertainty and, more specifically, how to deal with challenges 
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across different disease areas, perhaps incentivising the development of analyses such as that 
presented in this chapter, focusing on disease specific areas.  
Based on the findings of this chapter, the following recommendations are put forward:  
1. The assessment of structural uncertainty should not be ignored as it is an integral part 
of good practice in DAM 
2. The reasons why an assessment of structural uncertainty is not possible or not needed 
should be always stated as a limitation of the research 
3. Data limitations to undertake an assessment of structural uncertainty should be 
clearly stated and discussed 
4. If there is a reason to believe that structural uncertainty is an issue that may have 
affected the results of CE, then an assessment of structural uncertainty should be 
included 
5. Ideally, sound statistical methods should be used in the assessment of structural 
uncertainty e.g. the discrepancy approach, model averaging, parameterization, model 
selection, scenario analysis, etc. but if none of these are possible due to data 
limitations, then at the very least, appropriate sensitivity analysis should be routinely 
conducted, as per current ISPOR-SMDM guidelines  
Chapter 6 develops a similar analysis to assess the structural uncertainty arising from the 
model structure of a decision tree.  
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CHAPTER 6. IMPORTANCE OF MODEL STRUCTURAL 
UNCERTAINTY FOR THE RESULTS OF COST-EFFECTIVENESS: A 
CASE STUDY OF OPTIMISING ACUTE STROKE CARE SERVICES 
FOR THROMBOLYSIS 
This chapter builds on the results of Chapter 5 by considering the issue of model structural 
uncertainty for another case study. This chapter provides another practical illustration of the 
impact on results of cost-effectiveness, of changing or adapting model structures in a model-
based economic evaluation. Structural uncertainty arising from model structure is assessed 
for a decision tree used to measure the cost-effectiveness of alternative strategies aimed at 
increasing thrombolysis rates among patients who have suffered a stroke. This case study also 
examines whether there is evidence of other elements, besides the structure of a model, that 
affect the results of cost-effectiveness. 
 
6.1. Introduction  
The most important public health measurements of stroke impact are mortality and its 
sequelae. Resulting from the sequelae are a loss of productivity, reduced quality of life, and 
productivity. It has been estimated that 87% of strokes are of ischaemic origin, with the 
remainder being haemorrhagic strokes or transient ischaemic attacks (TIA)5. Mortality during 
the first 30 days after a ischaemic stroke is approximately 10%, and is mainly associated with 
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neurological sequelae, and then 40% in the subsequent 12 months111. As the world population 
ages, the burden of disease from stroke is expected to increase over the coming decades35.  
A previous study aimed at quantifying the annual cost of illness of stroke to the UK in 2009 
found that the treatment of and productivity loss arising from stroke resulted in total societal 
costs of £8.9 billion a year, with treatment costs accounting for approximately 5% of total UK 
NHS costs. Direct care accounts for approximately 50% of the total, informal care costs 26% 
and indirect costs 24%121. 
Thrombolytic therapy or thrombolysis is a treatment to dissolve clots in blood vessels, 
improve blood flow, and prevent damage to tissues and organs. Thrombolysis may involve 
the injection of clot-busting drugs through an intravenous (IV) line or through a long catheter 
that delivers drugs directly to the site of the blockage. It may also involve the use of a long 
catheter with a mechanical device attached to the tip that either removes the clot or 
physically breaks it up. In patients presenting to hospital with a recent acute ischaemic stroke, 
thrombolysis (for example, alteplase) can dissolve the clot blocking the arteries and cause a 
stroke. Randomised clinical trials have previously shown that if alteplase is given within a 
window timeframe of no more than 4.5 hours of the onset of symptoms, it increases the 
proportion of patients who are free of disability by 3 months, with larger benefits seen when 
alteplase is able to restore the brain’s blood supply earlier38.  
However, the use of thrombolysis in a small proportion of patients comes with the risk of a 




Health economic evaluations in a number of countries have shown that thrombolysis is a cost-
effective treatment for ischaemic stroke. The introduction of thrombolytic therapy with 
recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke 
has resulted in improved patient outcomes for those eligible to receive thrombolytic 
treatment122-124. The treatment is safe and effective if administered within a short window of 
time (4.5 hours and 6 hours post-onset of symptoms depending on a patient’s age). Therefore, 
the early recognition of symptoms, prompt arrival at hospital, and timely computed 
tomography (CT) scanning have been recognised as determinants for successful treatment.  
A previously published economic evaluation of the cost-effectiveness of optimising acute 
stroke care services for thrombolysis123 (referred to as the ‘Stroke study’ in the remainder of 
this chapter) estimated the cost-effectiveness and potential implementation costs of a series 
of interventions aimed at increasing thrombolysis rates through optimisation of the care 
pathway for acute stroke123. A decision tree was used to represent the acute care pathway 
for patients with stroke and lifetime costs and outcomes per 100,000 population. This chapter 
aims to explore whether the results of cost-effectiveness in the Stroke study would have been 
different if the analysis had considered: i) an alternative model structure (for example a 
Markov model or a combined decision tree and a Markov model); or ii) other elements 
pertaining to structural uncertainty. 
6.2. Description of the Stroke study  
Thrombolysis in the context of the Stroke study refers to an intravenous injection of clot-
busting drugs. Thrombolysis in acute stroke is effective up to 4.5 hours after the onset of 
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symptoms but relies on early recognition, prompt arrival in hospital, and timely brain 
scanning. The economic evaluation in the Stroke study aimed to establish the cost-
effectiveness and potential implementation costs of increasing thrombolytic rates through a 
series of hypothetical interventions designed to optimize the acute care pathway for stroke 
(see Appendix 7 for details).  
The Stroke study used a decision tree built in TreeAge PRO Suite 2011 software, to reflect the 
acute care pathway for stroke patients (see  
Figure 6-1 below). The decision tree describes the care pathway of individuals presenting to 
hospital with a suspected stroke123. Routes to hospital and the demographic characteristics 
of patients (age, sex, and ethnicity) were based on patient level data collected from 
participating hospitals. All patients who entered the model were assumed to have been 
admitted via the hospital emergency department and could have arrived via the Emergency 
Medical Services (EMS), been referred by a general practitioner, travelled via private 
transport, transferred from another hospital or had a stroke as an existing inpatient (i.e., 
patient had a stroke as a inpatient during an admission for an unrelated complaint), see Figure 
6-1 below. The study included 488 stroke events in the base-case analysis including 133 
patients presenting with nonvascular disease (stroke mimics). It was assumed that once in 
hospital, all patients with suspected stroke would received a CT scan and the results of the CT 
scan were used to dichotomise patients as having had a stroke (whether ischaemic or 
haemorrhagic) or not having had a stroke (stroke mimics), see Figure 6-1. Those patients 
found to have had a stroke were further dichotomised as having had an ischaemic or 
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haemorrhagic stroke. Those with ischaemic stroke were considered potentially eligible for 







Figure 6-1 Decision Tree model structure 
The Decision-tree model is displayed in vertical format rather than the traditional horizontal 
format. The model is identical at every node ending (grey box with +) with final outcomes 




The cost utility analysis in the Stroke study took a National Health Service (NHS) and Personal 
Social Services (PSS) perspective. Short and long-term costs of initial assessment and 
treatment in hospital along with increased dependency because of stroke-related disability 
were considered and adjusted to a price year of 2010/11. The Stroke study justified the use 
of a decision tree model, as recommended for acute diseases where any intervention 
affecting prognosis is settled in a short time frame1. 
Model pathways were identified by following the care pathway of individuals presenting to 
hospital with a suspected stroke123. Patient level data were collected from patients admitted 
to three participating hospitals with stroke or stroke-like symptoms over a 12-month period. 
Patients in the model were assumed to have been admitted via the hospital emergency 
department and could have arrived via the Emergency Medical Services (EMS), referred by a 
general practitioner (GP), travelled via private transport, transferred from another hospital, 
or have had a stroke as an existing inpatient (Appendix 8). Once in hospital, all patients 
received a CT scan; patients were dichotomised as having had a stroke (either ischaemic or 
haemorrhagic) or a mimic stroke as per the results of the CT scan123. Only patients with 
ischaemic stroke were considered eligible for thrombolysis. Life expectancy and the time 
horizon in the model varied depending on whether an individual had a stroke or not and after 
a stroke whether they were dependent or independent123. 
Several assumptions were made with respect to current practice and the data for the base-
case. The time window for the administration of thrombolysis treatment was set at 4.5 hours 
as this represented current practice at the participating centres at the time of data collection. 
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Patients aged up to 85 years old were considered eligible for treatment; the impact of 
thrombolysis on reducing dependency was modelled using results from a Cochrane Review125.  
The primary outcome measured was changes in QALYs with utilities being identified from the 
literature. The modified Rankin Scale (mRS) – a commonly used scale for measuring the 
degree of disability or dependence in the daily activities of people who have suffered a stroke 
was used to assess dependency. This scale runs from 0 (least dependent) to 5 (most 
dependent) and 6 (dead). Scores of 0-2 were classified as independent and 3-5 as dependent. 
QALYs were calculated by multiplying life expectancy by the utility associated with a given 
outcome. Costs and outcomes were discounted at the standard annual rate of 3.5% 1. In the 
case of events that imitated a stroke, only the costs incurred by transport and initial 
assessment in hospital were modelled. The model evaluated a series of hypothetical 
interventions designed to reduce delay to thrombolysis treatment; these interventions were 
identified from the literature (Appendix 7). The results of the Stroke study indicate that all 
intervention strategies that increased thrombolysis rates in acute stroke are cost-effective 
because of a reduction in dependency after stroke and the subsequent reduction in long-term 
care costs.  
 
6.3. Methods 
In order to explore how the results from the Stroke study may have differed if the original 
model was different; this chapter examines the adequacy of the type of model used, the 
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structure of the model as well as changes to other key parameters pertaining to structural 
uncertainty. The resulting cost-effectiveness results are then compared with those from the 
Stroke study. The structure of the model used in the Stroke study constitutes the base-case 
model ( 
Figure 6-1). The analysis of structural uncertainty was performed in three steps: 
• Identification of plausible alternative model structures  
• Definition and implementation of alternative types of model  
• Identification of model parameters 
 
6.3.1. Identification of plausible alternative model structures 
As described in Chapter 5, model structural uncertainty is addressed by assessing issues such 
as the adequacy of the type of model used, the structure of the model (model pathways or 
health states and transition probabilities) and data availability to inform input parameters, 
for example the risk of secondary events.  
In order to identify plausible alternative types of model and model structures, a literature 
review was undertaken.  
 
 
6.3.1.1. Methods of the literature review 
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The literature review identified studies of interventions aimed at increasing or optimising 
thrombolysis in acute stroke care services. The review followed a structured approach to 
identify papers: patient population (P), intervention (I), the comparator group (C), outcome 
(O) and the study design (S), or PICOS68. Studies published from Jan 2000 to June 2016 and 
written in English were included if they met all of the following conditions: 
• Target population was individuals presenting with stroke symptoms 
• Intervention was thrombolysis 
• Study was a model-based economic evaluation 
The review excluded systematic reviews, conference papers, commentaries or letters and 
non-English articles. Studies were also excluded if the interventions were part of an 
intermittent pneumatic compression or stent retrievers or CT perfusion of screening or 
mechanical thrombectomy or other non-thrombolytic therapies. 
Searches were undertaken using reasonable variations of the following terms ‘cost-
effectiveness’ or ‘decision-analysis’ or ‘economic evaluation’ or ‘cost utility’ combined with 
the term ‘stroke’ and the terms ‘thrombolysis’ or ‘rt-PA’ or ‘alteplase’. The search was 
undertaken using truncations and wildcards, and all synonyms were subsequently combined 
with appropriate medical subject heading terms (MeSH) or subject terms using Boolean 
operators (Appendix 9) 
The following databases were searched: the Centre for Reviews and Dissemination’s (CRD) 
NHS Economic Evaluation Database (NHS-EED) and EMBASE and Medline via the Ovid 
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interface. In addition, the reference lists of the studies included in this review were manually 
examined. All papers identified by database searching were exported into ENDNOTE-X7TM and 
duplicated references were removed. 
Titles identified by the searches were screened by reading the abstract. Articles that appeared 
to be relevant at this point were obtained and screened against the inclusion and exclusion 
criteria; several studies appeared relevant on reading the abstract but were subsequently 
excluded after reading the full paper. 
 
6.3.1.2. Results of the literature review 
The database yielded 328 studies; 302 studies were excluded as duplicates, systematic 
reviews, conference papers, commentaries, letters or non-English language papers (Figure 
6-2). 26 full-text articles were assessed for eligibility, of which 8 were rejected as interventions 
that were part of an intermittent pneumatic compression or stent retrievers of CT perfusion 
or screening or mechanical thrombectomy in acute ischaemic stroke or other. 5 further 
studies were excluded as non-economic evaluations. 13 studies (including the Stroke study) 




Figure 6-2 Flow chart using the PRISMA statement 
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All studies were manually searched and data were extracted; any doubtful point(s) were 
checked with at least one of the supervisors. Data were retrieved, and organised across the 
following items: author/year, model comparators, type of model/description and structural 
assumptions. This approach ensured that the review did not miss any information related to 
the model type, model structure, model assumptions, model justification and the assessment 
of structural uncertainty. Table 6-1 summarises the results of the review.  
The included studies aimed to assess the use and cost-effectiveness of thrombolysis for acute 
stroke. The comparators considered were thrombolysis compared with placebo or no 
thrombolysis. One study127 assessed the proportion of patients thrombolysed based on a 





Table 6-1 Overview of published models on thrombolysis treatment for patients presenting with acute ischaemic stroke 
Author, year Model comparators Type of model / description Structural assumptions 
Araujo et 
al122 
Thrombolysis (up to 
3hrs after symptom 
onset) compared to 
placebo from the 
Brazilian Public Health 
System perspective 
Markov model consisting of four health states and a death 
state simulating a patient’s transit from an acute phase of 
coronary vascular accident (CVA) to an intracranial bleeding 
event or no intracranial bleeding and to different levels of 
severity of post-stroke sequelae (Rankin 0 to Rankin 5) or 
death; cycle length varied from 3 months in the first year to 1-
year from year 2 onwards. Used a lifetime time horizon of up 
to 30 years. Outcomes using QALYs; discount rate 5% for costs 
and outcomes  
Side effects of thrombolysis 
modelled were intracerebral 
bleeding (6.4% with rt-PA and 
0.6% with the conservative 
treatment) 




from the perspective of 
the Northern Ireland 
integrated health and 
community social 
services 
Discrete Event Simulation (DES) representing 3 health states, 
death, survival in an independent state or survival in a 
dependent state. Patients were distributed among six 
subgroups reflecting their final destination (home, 
rehabilitation centre or no rehabilitation centre, or 
institutional care). The DES model tracked six groups of 
patients, in which each group represented a patient pathway 
within the simulation and their LOS in hospital. Even though 
SIMUL8 was used, ideal for DES models, authors did not take 
advantage of all its features (queuing /patient competition for 
services). Outcomes were measured as QALYs (discounted at 
3.5% ). No discount rate was provided for costs.  
Side effects of thrombolysis 
were increased risk of 
haemorrhage and death  
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Author, year Model comparators Type of model / description Structural assumptions 
Boudreau et 
al126 
rtPA administered (in 
the 3-to 4.5-hour 
therapeutic window) 
versus rtPA not 
administered. Analysis 
was conducted from 
the payer perspective. 
A short-term disease-based decision tree model to simulate 
90-day outcomes for a hypothetical cohort of patients 
presenting to hospital with acute ischaemic stroke by 
treatment with or without rtPA. Short term outcomes were 
disabled, nondisabled or death. Patients surviving to 90 days 
in the short-term model entered a Markov model to simulate 
long-term clinical outcomes such as disability, recurrent stroke 
and death during the patient’s remaining years of life. 3% 
discount rate for costs and outcomes was applied 
Side effects, a disutility of -0.38 




Secondary events: the risk of a 
recurrent stroke was 1.52-fold 
for disabled patients (2-5 mRS) 
and 1.10 for nondisabled (0-1 
mRS) taken from literature 
 
Model structure: simplified 
model structure was justified 
after evaluating the validity of 
grouping mRS rankings 
compared with using separate 
values by comparing the 
weighted values for costs, 
quality of life and mortality. 
They found that grouping mRS 
lead to similar results for rtPA 
versus no rtPA. Authors verified 
that the weighted utilities for 
the corresponding health states 
were equivalent in both arms 
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Author, year Model comparators Type of model / description Structural assumptions 
Dirks et al127 Breakthrough Series-
based implementation 
programme to increase 
the proportion of 
patients thrombolysed 
compared to a laissez-
faire implementation of 
thrombolysis (both 
within 4hrs from onset) 
from a healthcare 
perspective  
Type of model used not specified, however, it seems a 
modified Markov model or ISM was used. Even though the use 
of this type of model was not justified, presumably it was 
linked to the outcomes measured: thrombolysis rates and 
timing of response to assess health benefits. Patients from 
both arms entered the model at hospital admission. They may 
have a recurrent stroke and be readmitted, become more 
disabled or die. Model used half year time steps until death. 
3% annual discount rate used for costs and health effects. 
Secondary events: the risk of a 
recurrent stroke was considered 
using information from 




3hrs of symptom onset 
by MRI imaging 





Decision tree with Markov modelling  
The decision tree followed the care pathway of individuals 
with acute ischaemic stroke; the model assumed that patients 
could receive either thrombolysis or conservative treatment 
and according to treatment received, patients were at risk of 
haemorrhage 
The Markov model reflects the transition of patients between 
seven post-stroke disability states (R0 to R5 or death) 
according to the functional outcome after 3 months based on 
a mRS. After hospitalization patients are assumed to be 
discharged home, to rehabilitation or to a nursing home 
Time horizons of 1,2,3 and 30 years; 5% discount rate for costs 
and outcomes; outcomes were measured using QALYs 
Side effects: risk of intracranial 
haemorrhage of 5.9% on 
thrombolysis and 1.1% on 
conservative treatment 
Secondary events: the risk of 
recurrence of stroke was 
assumed to be 5.2% per year 
(for survival after first year and 
recurrence an equal rate for all 
patients was assumed). 
Information was taken from the 
NINDS tPA Stroke Study 
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Author, year Model comparators Type of model / description Structural assumptions 
Ehlers et 
al129 
National use of 
thrombolysis with 
alteplase for acute 
ischaemic stroke via 
telemedicine compared 
to conservative 
treatment from a 
Danish National Health 
perspective 
This study used the same Decision tree with Markov model as 
per Ehlers et al (2007); in this case the model was expanded to 
include thrombolysis at satellite clinics linked to a larger 
thrombolysis centre 
Side effects: risk of intracranial 
haemorrhage of 5.9% on 
thrombolysis and 1.1% on 
conservative treatment 
Secondary events: the risk of 
recurrence of stroke was 
assumed to be 5.2% per year 
(for survival after first year and 
recurrence an equal rate for all 
patients was assumed). 
Information was taken from the 
NINDS tPA Stroke Study 
Mar et al130 Thrombolysis versus 
thrombolysis and 
intravenous 
administration of tPA 
(up to 3hrs from 
symptom onset) in 
Spain from the 
perspective of the 
health care system 
Markov model, the initial health state reflects patients 
presenting with stroke, patients can transition after 1-year 
cycle to an autonomous, disabled or death state. The model 
considers the recurrence of stroke. 3% discount rate was 
applied and a lifetime time horizon. Outcomes were measured 
using QALYs 
 
Side effects the risk of 
haemorrhage associated with 
both alternatives refers to the 
number of events that appeared 
in the NINDS study 
Secondary events (recurrent 
stroke was modelled using a 
0.051 probability within a year). 




Author, year Model comparators Type of model / description Structural assumptions 
Pan et al131 tPA treatment versus 
non-tPA treatment 
(within 4.5hrs from 
symptom onset) from 




insurance and patients 
in China 
Decision tree with a Markov model The decision tree followed 
the care pathway of individuals presenting with acute 
ischaemic stroke that would or would not receive intravenous 
tPA. Patients could or could not have been affected by 
symptomatic intracerebral haemorrhage (sICH). The Markov 
model estimated the long-term costs and outcomes per 
disability levels modelling recurrence of stroke. Functional 
states were identified from the mRS. Outcomes were 
measured as QALYs by multiplying years of life by utility scores 
derived from literature. Outcomes and costs were modelled 
over the short-term (2 years) and the long-term (30 years) 
Secondary events: recurrence of 
stroke after the first 90 days and 
assumed an increase in stroke 
recurrence rates by 1.01—fold 
per life year according to the 
relative risk estimated from 
patients of ischemic stroke in 
the China National Stroke 
Registry (CNSR), a nationwide 





treatment for acute 
ischaemic stroke 
compared with 
standard care (within 
3hrs from symptom 
onset), from a broad 
health care and 
personal social services  
perspective in the UK 
Decision tree with Markov model A decision analysis model 
reflected the pathways that acute stroke patients follow after 
being admitted to hospital. A Markov model was used to 
predict the health and economic outcomes of rt-PA after the 
first year. The model used age-specific mortality, risk of 
recurrent stroke and stroke-specific case-fatality to estimate 
the probabilities of being dead, dependent and independent 
at the beginning of each year. One year cycles were assumed. 
Outcomes were measured as QALYs modelled over short-term 
(1 year) and longer-term (lifetime) time horizons. Annual costs 
and health benefits were discounted at 6%. 
Side effects The risk of 
haemorrhage modelled as part 
of the decision tree based on 
data from the Lothian Stroke 
Register 
Secondary events: Recurrence 
of stroke modelled as an annual 
risk stroke recurrence of 0.05 
after 1 year. Information was 




Author, year Model comparators Type of model / description Structural assumptions 
Sinclair et 
al132 
t-PA therapy within 
3hrs of stroke onset 
versus no t-PA from the 
perspective of the 
Canadian healthcare 
system 
Markov model to describe the short and long term outcomes 
associated with treatment versus usual stroke management. 
Patients with ischaemic stroke, presenting to hospital within 3 
hours of the onset of symptoms enter the model. During 
hospitalisation patients could experience a symptomatic 
intracranial haemorrhage. At discharge, individuals within the 
cohort were classified according to the their mRS. Outcomes 
considered were the costs of stroke, management of stroke 
sequelae and 30-year post stroke, quality-adjusted survival 
(measured by QALYs). Costs discounted at an annual rate of 
5% 
Side effects: Major bleeding 
complications were assumed as 
t-PA 6.4% versus no t-PA 0.6% 
Secondary events: The risk of 
recurrent stroke was taken from 
literature (5.2% per annum) 
 
Tan et al133 
 
Intravenous tPA 
treatment (within 4.5 
hrs of symptom onset) 
compared to no-tPA in 
Australia 
 
A decision tree modelled the pathway of patients presenting 
with acute ischaemic stroke that would or would not be 
treated with intravenous tPA. Patients who survived the 
treatment would move to one of six disability levels as per 
mRS (mRS 0 to mRS 5). The time horizon was 1 year after tPA 
treatment, with the assumption that patients’ clinical and 
functional status would remain stable between 90 days and 1 
year. Health benefits were measured using QALYs 
 
Side effects patient level data 
indicated that a substantial 
proportion of patients (7.1% 
experienced haemorrhage after 
tPA – symptomatic intracranial 
haemorrhage or parenchyma 




Author, year Model comparators Type of model / description Structural assumptions 
 
Tung et al134 
 
Intravenous tPA 
administered in the 3-




Decision analytic tree and Markov model, a patient enters the 
model when he/she is admitted to hospital within 3 to 4.5hrs 
after the onset of stroke symptoms. Patients who survived the 
treatment would move to one of six disability levels as per 
mRS. After the end of each annual cycle, patients may remain 
in the same health state, have a recurrent stroke and 
transition to a lower health state, or die. Costs and health 
benefits were discounted at a rate of 3.0%. The analysis was 
conducted from the societal perspective, however, indirect 
economic costs such as lost work productivity were not 
considered in the model. 
 
Side effects: The risk of 
symptomatic intracerebral 
haemorrhage was modelled 
Secondary events: the risk of 
recurrent stroke was assumed 
to be 0.051 per time step and 
the risk of death after a second 
stroke was assumed to be 0.19 
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Six studies124, 126, 128, 129, 131, 134 used decision trees combined with Markov models: a decision 
tree to reflect the pathways that acute stroke patients follow after being admitted in hospital 
and a Markov model to predict the health and economic outcomes in the long-term (or after 
the end of the acute stage). Three studies122, 130, 132 used Markov models to reflect the 
transition from an acute phase to different levels of severity of post-stroke sequelae and/or 
recurrence of stroke. One study133 used a decision tree to model the pathway of patients 
treated with tPA after a stroke and until one year after treatment. Another study15 used a 
discrete event simulation (DES) model to track the final destination (home, rehabilitation 
centre, no rehabilitation centre or institutional care) of patients after stroke. This type of 
model does not seem relevant in this context and this is apparent by the fact that even though 
the authors used SIMUL8 software, ideal for modelling DES models, they did not take 
advantage of all its features, for example, tracking individuals competing for resources. One 
study127 did not specify the type of model used. However, it seems an ISM was used to 
measure thrombolysis rates and the timing of response after the implementation of a 
programme (Table 6-1).  
In terms of model structure, only Boudreau et al126 evaluated the validity of grouping mRS 
values compared with using separate scores by comparing the weighted values for costs, 
quality of life, and mortality. They found that the distribution of mRS within the nondisabled 
and disabled categories was similar on average between rt-PA and no rt-PA, thus justifying 
their simplified modelling approach. 
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Side effect(s) of thrombolysis, for example the risk of intracranial haemorrhage or 
intracerebral bleeding was considered in most of the studies reviewed (Table 6-1). For two 
studies127, 131 it was not possible to establish if the side effect(s) of thrombolysis had been 
considered. One study15 found excess risk of death after thrombolysis via the increased risk 
of haemorrhage; however, the authors did not find statistical support for an increased risk of 
dependency15. 9 studies124, 126-132, 134 modelled the risk of a recurrent stroke (another stroke 
after a first stroke) using data from population registers124, 131, patient level data127, clinical 
trials128, 129 and secondary sources126, 130, 132, 134 (Table 6-1).  
 
6.3.2. Methods - model structure 
Based on the findings of the review, alternative model structures were identified and assessed 
in light of the primary research aim of the Stroke study i.e. estimate the cost-effectiveness of 
alternative strategies aimed at increasing thrombolysis rates through the optimisation of the 
care pathway for acute stroke. As previously described, the review identified three main types 
of model structure that have previously been used in the literature: i) combined decision tree 
and Markov model124, 126, 128, 129, 131, 134; ii) Markov model alone122, 130, 132; or iii) decision tree 
alone133.  
A Markov model alone, such as the structure used by Araujo et al122 who used 1-year cycles 
or Mar et al130 who used 3-month cycles during the first year and 1-year cycles afterwards 
was not considered as a plausible alternative structure to implement in this case study due to 
the short time frame nature of the intervention of interest (thrombolysis). Furthermore, in 
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the Stroke model, critical pathways during the thrombolysis treatment (recognition of 
symptoms, arrival to hospital, computed tomography - CT) occur over an instantaneous 
discrete period of time. In other words, there is no need to measure an explicit time for events 
to occur (for example, time from onset of symptoms to arrival to A&E, to CT scan, etc.). The 
simplified version of a decision tree as per Tan et al133 who focused on final outcomes after 
thrombolysis treatment in terms of disability levels does not seem a plausible alternative 
either because it would not allow for the modelling of critical pathways for the treatment of 
acute stroke such as early recognition of symptoms, prompt arrival in hospital, and timely CT. 
Other types of models identified in the review, for example a DES or ISM were rejected on 
the basis of model parsimony. An essential feature of a DES model is that patients compete 
for limited resources. In the Stroke study patients with stroke symptoms, arriving at A&E 
within the window timeframe and being suitable for thrombolysis would all be thrombolysed. 
ISM on the other hand would be ideal in cases where the aim is mainly to assess the timing of 
the response to an event. However, the aim of the Stroke study was to increase thrombolysis 
rates by expediting the acute care pathway through a series of intermediate hypothetical 
strategies. 
Based on the above considerations this case study used as an alternative model structure a 
combined decision tree and Markov model (Figure 6-3, Part A and Part B). The short-term 
decision tree describes the care pathway up until 12 months after stroke, whilst the Markov 
structure reflects lifetime costs and outcomes (beyond 12 months). Validation of the 
adequacy of this type of model over other competing structures such as DES or individual 
sampling model was checked using a framework to select an appropriate model type13. The 
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validation check indicated that either a decision-tree or a decision-tree followed by a Markov 
model was a correct type of model, considering that estimating interactions between 
individuals was not necessary whilst an excessive number of health states was not required.  
The Stroke study did not model the recurrence of stroke after a primary stroke. This case 
study adopts assumptions based on the literature to reflect the risk of stroke recurrence119. 
Individuals that survived a primary acute event at the end of the 12 months (short term 
decision tree) move into the Markov component of the model as independent or dependent 
survivors (Figure 6-3, Part B). As in the Stroke model, the mRS was used to assess dependency 
where scores of 0 to 2 were classified as independent and 3-5 as dependent. Patients could 
experience a recurrent stroke event one year after the first event. Following a recurrent 












Part B Expansion of the Markov component in the Decision Tree followed by a Markov model 
Figure 6-3 Decision Tree followed by a Markov model 
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6.3.3. Model parameters and analyses 
The model was populated with the dataset used in the Stroke study, that is, patient level data 
collected from 3 participating English NHS hospital Trusts. Information from the literature for 
a UK setting was sought to populate all the input parameters in the Markov component of the 
model. Transition probabilities for patients with a previous stroke, the risk of death following 
a second event, and utility values following a second event were all taken from secondary 
sources (Table 6-2 below).  
One-off costs of acute disease after a second stroke were derived from the literature and 
adjusted using the Hospital and Community Health Service Index (Table 6-2). ONS Life tables 




Table 6-2 Input parameters and distributions 
Variables 
Value 





Patients with symptoms who have suffered a 
"true" stroke             
Percentage who contact ambulance services 




Percentage who contact their GP surgery 
first 16% Beta  n , r 355 57 
Percentage who make their own way to the 
hospital 11% Beta  n , r 355 40 
Percentage of patients who are already 
inpatients 5% Beta  n , r 355 18 
Percentage of patients who are 
referred/transferred 1% Beta  n , r 355 3 
Patients with symptoms who have suffered a 
stroke and contacted 999 services             
Percentage who get to A&E within 4.5h 




Percentage who get a CT scan and results 
within 4.5h of stroke onset  39.8% Beta  n , r 237 94 
Percentage with an ischaemic stroke and 










Percentage who have an ischaemic stroke 
and receive thrombolysis 12.7% Beta  n , r 237 30 
All stroke patients             
Percentage of ischaemic stroke in all stroke 




Percentage within 4.5h of stroke onset who 
have an ischaemic stroke 42.0% Beta  n , r 355 149 
Percentage of death* after stroke due to an 
haemorrhagic infarct  19.4% Beta  n , r 36 7 
Percentage of death* after stroke due to 
ischaemic stroke  19.1% Beta  n , r 319 61 
Percentage of death* after an ischaemic 
stroke and thrombolysis treatment  15.2% Beta  n , r 33 5 
Percentage of being dependent/disabled 
after an ischaemic stroke  35.0% Beta  n , r 545 191 Bamford et al111 
Patients with "true" stroke symptoms             
Percentage with no previous 




Effectiveness of thrombolysis             
















Life expectancy (number of additional years) 
            
Life expectancy for a 72 year old female with 
no history of stroke** 10.8         
ONS, Life tables 
(stroke Study)123 
Life expectancy for a 68 year old male with 
no history of stroke** 11.2         
Life expectancy for a 72 year old female with 
history of stroke** 10.0         
Life expectancy for a 68 year old male with 
history of stroke** 10.7         
Utility score             
Utility score for a dependant stroke patient 38% Beta   41.80 68.20 
Sandercock et al124 
Utility score for an independent stroke 
patient 74% Beta   216.48 76.06 
Resource use             
Cost of a GP home visit  £82         
Curtis et al135 Cost of a GP phone call £15         
Cost of a GP surgery visit £25         
Cost of transportation by ambulance 












Cost of attending A&E leading to admission £237         
Cost of a CT scan £95         
Cost of Thrombolysis (drug only) £720         BNF 2011136 
Stroke costs             
Cost of an independent acute stroke 
£4,100 Gamma 
 1 0.0001 
Sandercock et al137 
Cost of a dependent acute stroke £14,935 Gamma  1 0.0002 
Cost of long-term independent acute stroke £1,341 Gamma  1 0.0001 
Cost of long-term dependent acute stroke £17,651 Gamma  1 0.0001 
Cost of a fatal stroke £9,664 Gamma  1 0.0007 
Stroke recurrence one year after the first stroke       
70-79 years old 5.9% Beta  n , r 75 4 
PROGRESS (1999) 
& NICE, Lipid 
Modification 
Guidelines108, 109 
80-89 years old 7.1% 
Beta  n , r 110 8 
Probability of death from a second stroke, one 







Utility for acute stroke after stroke 0.479     Ara et al119  
Dead 0     By definition 
Annual discount rate for costs and utility 3.5%     Gray et al1 
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*Death within 1 year of stroke 
**Office for National Statistics (ONS); adjusted by mortality rates in post-stroke years 
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This case study implemented four alternative hypothetical interventions, based on the 
strategies implemented in the Stroke study to reduce delay on the current thrombolysis 
pathway. To assess the impact of change to the model structure on the results of cost-
effectiveness, the same alternative hypothetical interventions (scenarios 1 to 4) were 
implemented for each of the two competing model structures (see Table 6-3 below) for 
details: 
• Scenario 1 assumed full (100%) implementation of a timely GP referral consisting of 
diverting GP calls to the ambulance service after stroke recognition  
• Scenario 2 assumed partial (64%) implementation of a timely GP referral consisting 
of diverting GP calls to the ambulance service after stroke recognition 
• Scenario 3 assumed full (100%) implementation of a timely CT scan to ensure that all 
who presents with stroke receive an immediate CT scan  
• Scenario 4 assumed partial (25%) implementation of a timely CT scan to ensure that 
all who presents with stroke receive an immediate CT scan  
The main results of the cost-effectiveness analyses for the hypothetical interventions were 




Table 6-3: Description of hypothetical interventions and scenarios for implementation in the case study 
Area for improvement based on 
baseline data (n=355)  
Hypothetical interventions with reference to 
literature  
(Estimates noted) 
Maximum #  of patients 
benefiting from 
removal of block in 




based on that 
previously recorded 
in the literature n(%) 




16% of patients contacted General 
Practitioner following onset of 
stroke and arrival in hospital was 
delayed compared to those who 
called the emergency services. 
Divert GP calls to ambulance service 
General practice staff are trained to better 
recognise stroke, resulting in patients who 
initially contact their General Practitioner being 
referred immediately to hospital. Up to 64% 
immediately referred to EMS 
 
Scenario 1  
57 patients (100%) 
 
Scenario 2  
36 patients (64%) 
Timely CT scan 
14% of patients who arrived in 
hospital within 4.5 hours of 
symptom onset did not receive an 
immediate CT scan within the time 
window for thrombolysis. 
Ensure all who present with stroke receive 
immediate CT scan 
In-hospital stroke services are reorganised to 
ensure patients with stroke receive a timely CT 
scan (e.g. CT scanner moved closer to the 
emergency department ward). 
Reduce time to CT scan by an hour  
 
Scenario 3  
51 patients (100%) 
 
Scenario 4  
13 patients (25%) 
Note: Scenarios 1 to 4 were run using a decision tree model whilst scenarios 5 to 8 were run using a decision tree followed by a Markov model
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A cost-utility analysis was undertaken for all models to calculate the cost per quality-adjusted 
life year gained. Results from each alternative model specification are presented as scenario 
analyses. One-way sensitivity analyses were undertaken to reflect the uncertainty and 
imprecision surrounding specific costs: CT scan costs were doubled; the cost of an individual 
dose of alteplase was increased by 50%; and long-term care costs (for dependent and 
independent patients) were increased by 20%. The method of recruitment used in the Stroke 
model meant that it was possible for patients with more severe stroke to have been excluded 
from the sample population (because patients who were seriously ill or died in hospital could 
not be approached for consent)123. The impact of this potential bias was examined by 
increasing the proportion of dependent patients with stroke with an mRS score of >=3 by 5% 
and 10%). Probabilistic sensitivity analysis was used to explore the implications of parameter 
uncertainty, where parameter values were sampled from distributions describing each 
variable in the model (Table 6-2). Using 10,000 Monte Carlo simulations, uncertainty was 
propagated through the model by randomly selecting values from distributions describing 
each model parameter (shown in Table 6.2). Cost-effectiveness planes and cost-effectiveness 
acceptability curves were constructed to estimate the probability of the hypothetical 
interventions to be cost-effective at different willingness-to-pay thresholds. 
The impact of structural uncertainty in terms of the impact on the cost-effectiveness results 
of a model and EVPI are presented. Including different parameters in the model can be 
expected to alter the extent of uncertainty captured in the EVPI calculation. As the models 
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have different parameter sets, comparisons of expected value of partial perfect information 
would not be helpful. 
 
6.4. Results 
The main cost-effectiveness results obtained in the Stroke study were found to be robust 
when a new model structure (decision tree followed by a Markov model) was implemented, 
and when secondary events were included. In other words, any intervention that increased 
thrombolysis rates in acute stroke remained dominant, i.e. it was more effective and cheaper. 
All implemented hypothetical interventions (either full implementation or partial 
implementation) reduced costs and increased QALYs (Table 6-4). Both model structures, a 
single decision tree and a decision tree followed by a Markov model, indicated that the 
hypothetical intervention with the largest cost saving was a timely CT scan (Table 6-4). 
The cost effectiveness plane shows the results from the Monte Carlo simulation for 10,000 
replications. The generated estimates appearing as points on the plane for all scenarios 1 to 
4 corresponding to the decision tree and to the decision tree followed by a Markov model are 
scattered across all four quadrants and clustered around the origin. Substantial portions of 
the joint density (C/E) (Figure 6-4) are contained within the NE quadrant (between 45 to 
48 per cent of the points in all scenarios considered) and SW quadrant (between 43 to 45 per 
cent of the points in all scenarios considered). This seems to indicate a strong linear 
correlation between costs and QALYs: to gain an additional extra QALY is increasingly more 
expensive in this setting and vice versa.   
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Table 6-4: Results of cost-effectiveness per patient 






     
    Current Practice    43,954     6.9996     
1. Timely GP referrals (100% implementation)    43,861     7.0105  -93 0.0109  Dominant  
2. Timely GP referrals (65% implementation)    43,888     7.0074  -66 0.0078  Dominant  
3. Timely CT scan (100% Implementation)    43,804     7.0185  -150 0.0189  Dominant  
4. Timely CT scan (25% Implementation)    43,916     7.0042  -38 0.0047  Dominant  
Decision tree plus Markov model 
     
    Current Practice    60,424     6.4595     
1. Timely GP referrals (100% implementation)    60,401     6.4679  -23 0.0085  Dominant  
2. Timely GP referrals (65% implementation)    60,408     6.4656  -16 0.0061  Dominant  
3. Timely CT scan (100% Implementation)    60,390     6.4714  -33 0.0120  Dominant  
4. Timely CT scan (25% Implementation)    60,414     6.4631  -10 0.0036  Dominant  






Decision-tree (scenario 1) 
 
Decision-tree (scenario 2) 
 
Decision-tree (scenario 3) 
 






















































































Decision-tree plus Markov model (scenario 
1) 
 
Decision-tree plus Markov model (scenario 
2) 
 
Decision-tree plus Markov model (scenario 
3) 
 
Decision-tree plus Markov model (scenario 
4) 
 
Figure 6-4 Cost effectiveness plane (CEP) for scenarios 1 to 4 – Decision Tree and Decision 


























































































Lifetime EVPI for the decision-tree followed by a Markov model compared to the base-case 
decision-tree was reduced substantially at all willingness to pay thresholds and under the 
various scenarios (Figure 6-5). 
The cost-effectiveness acceptability curves shown in 
Figure 6-6 were derived from the joint density of incremental costs and incremental QALYs 
for the hypothetical interventions. Each CEAC presents the probability that a hypothetical 
intervention is cost-effective for the different scenarios and under different model structures. 
For a willingness to pay of £20,000 per QALY gained, scenarios 3 and 4 had the highest 
probability of being cost-effective (66%) when the decision tree model was used. This CEAC 
increased and after a threshold of £20,000 per QALY started decreasing. Scenario 3 had the 
highest probability of being cost-effective (62%) if the decision tree followed by a Markov 
model was used. The particular shape of this CEAC is explained by the fact that the confidence 
ellipse lies around the origin with most of the values contained within the NE and SE quadrant 
of the CE plane. In other words, around half of the starting points of the curve are at 50% 
(since half of the circle is below the x-axis) and the limit of the curve is around 50% (since half 
of the circle is left of the y-axis). Since for increasing ceiling ratios around half of the circle is 
below the threshold line (the acceptability curves show little variation in the probability that 
the alternative is cost-effective when the threshold changes quite substantially), the 






Part A Scenarios 1 and 2 
 
Part B Scenarios 3 and 4  
Figure 6-5 Per-patient expected value of perfect information (EVPI) across varying willingness 
to pay values for the Decision-Tree model and the Decision-Tree Followed by a Markov model 
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DT and M CT 100%
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Part A Decision Tree – scenarios 1 to 4 
 
Part B Decision tree followed by a Markov model – scenarios 1 to 4  
Figure 6-6 The cost effectiveness acceptability curves (CEAC) for the probability that 
hypothetical interventions are cost-effective: Part A – Decision Tee model; Part B – Decision 
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The various sensitivity analyses undertaken seem to indicate that individual results from the 
various scenarios for the different model structures remained aligned after doubling the cost 
of a CT scan (Table 6-5), increasing the cost of alteplase by 50% (Table 6-6) and after increasing 
the cost of long-term care by 20% (Table 6-7). Increasing the proportion of patients being 
dependent after stroke by 5% did not change the results of cost-effectiveness (Table 6-8). 
When the proportion of patients being dependent after stroke was increased by 10%, under 
the new model structure (decision tree followed by Markov model), hypothetical intervention 
were not dominant (Table 6-9).  
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Table 6-5: Lifetime costs and outcomes per patient after doubling costs of CT scan 





Stroke Study (decision tree)      
    Current Practice    44,049  6.9996    
1. Timely GP referrals (100% implementation)    43,956     7.0105  -93 0.0109  Dominant  
2. Timely GP referrals (65% implementation)    43,983     7.0074  -66 0.0078  Dominant  
3. Timely CT scan (100% Implementation)    43,899     7.0185  -150 0.0189  Dominant  
4. Timely CT scan (25% Implementation)    44,011     7.0042  -38 0.0047  Dominant  
Stroke Study (Decision tree plus Markov model)      
    Current Practice    60,519  6.4595    
1. Timely GP referrals (100% implementation)    60,496     6.4679  -23 0.0085  Dominant  
2. Timely GP referrals (65% implementation)    60,503     6.4656  -16 0.0061  Dominant  
3. Timely CT scan (100% Implementation)    60,485     6.4714  -33 0.0120  Dominant  
4. Timely CT scan (25% Implementation)    60,509     6.4631  -10 0.0036  Dominant  






Table 6-6: Lifetime costs and outcomes per patient after increasing costs of Alteplase by 50% 





Stroke Study (decision tree)      
    Current Practice    43,978     6.9996     
1. Timely GP referrals (100% implementation)    43,890     7.0105  -88 0.0109  Dominant  
2. Timely GP referrals (65% implementation)    43,916     7.0074  -62 0.0078  Dominant  
3. Timely CT scan (100% Implementation)    43,837     7.0185  -141 0.0189  Dominant  
4. Timely CT scan (25% Implementation)    43,942     7.0042  -36 0.0047  Dominant  
Stroke Study (Decision tree plus Markov model)      
    Current Practice    60,515  6.4595    
1. Timely GP referrals (100% implementation)    60,496     6.4679  -19 0.0085  Dominant  
2. Timely GP referrals (65% implementation)    60,502     6.4656  -13 0.0061  Dominant  
3. Timely CT scan (100% Implementation)    60,487     6.4714  -28 0.0120  Dominant  
4. Timely CT scan (25% Implementation)    60,507     6.4631  -8 0.0036  Dominant  







Table 6-7: Lifetime costs and outcomes per patient after increasing costs of long-term care by 20% 





Stroke Study (decision tree)      
    Current Practice    51,461  6.9996    
1. Timely GP referrals (100% implementation)    51,351     7.0105  -110 0.0109  Dominant  
2. Timely GP referrals (65% implementation)    51,384     7.0074  -78 0.0078  Dominant  
3. Timely CT scan (100% Implementation)    51,283     7.0185  -178 0.0189  Dominant  
4. Timely CT scan (25% Implementation)    51,416     7.0042  -45 0.0047  Dominant  
Stroke Study (Decision tree plus Markov model)      
    Current Practice    70,615  6.4595    
1. Timely GP referrals (100% implementation)    70,588     6.4679  -27 0.0085  Dominant  
2. Timely GP referrals (65% implementation)    70,597     6.4656  -18 0.0061  Dominant  
3. Timely CT scan (100% Implementation)    70,575     6.4714  -40 0.0120  Dominant  
4. Timely CT scan (25% Implementation)    70,604     6.4631  -11 0.0036  Dominant  





Table 6-8: Lifetime costs and outcomes per patient by increasing the proportion of dependent patients by 5% 





Stroke Study (decision tree)      
    Current Practice    45,698  6.9569    
1. Timely GP referrals (100% implementation)    45,631     6.9672  -67 0.0103  Dominant  
2. Timely GP referrals (65% implementation)    45,651     6.9643  -47 0.0074  Dominant  
3. Timely CT scan (100% Implementation)    45,593     6.9747  -104 0.0178  Dominant  
4. Timely CT scan (25% Implementation)    45,671     6.9613  -27 0.0044  Dominant  
Stroke Study (Decision tree plus Markov model)      
    Current Practice    61,775  6.4317    
1. Timely GP referrals (100% implementation)    61,773     6.4398  -3 0.0080  Dominant  
2. Timely GP referrals (65% implementation)    61,774     6.4375  -1 0.0058  Dominant  
3. Timely CT scan (100% Implementation)    61,771     6.4431  -5 0.0114  Dominant  
4. Timely CT scan (25% Implementation)    61,774     6.4352  -1 0.0034  Dominant  





Table 6-9: Lifetime costs and outcomes per patients by increasing the proportion of dependent patients by 10% 





Stroke Study (decision tree)      
    Current Practice    47,458     6.9138     
1. Timely GP referrals (100% implementation)    47,421     6.9233  -37 0.0095  Dominant  
2. Timely GP referrals (65% implementation)    47,433     6.9206  -25 0.0069  Dominant  
3. Timely CT scan (100% Implementation)    47,405     6.9303  -53 0.0165  Dominant  
4. Timely CT scan (25% Implementation)    47,444     6.9178  -14 0.0041  Dominant  
Stroke Study (Decision tree plus Markov model)      
    Current Practice    63,139     6.4037     
1. Timely GP referrals (100% implementation)    63,160     6.4113  20 0.0076         2,688  
2. Timely GP referrals (65% implementation)    63,154     6.4092  15 0.0054         2,803  
3. Timely CT scan (100% Implementation)    63,167     6.4144  28 0.0107         2,626  
4. Timely CT scan (25% Implementation)    63,148     6.4070  9 0.0032         2,760  







This case study was developed in response to findings in Chapters 3 and 4 indicating that: 1) 
the assessment of structural uncertainty is not common practice; and 2) additional research 
on the impact of changing model structures on results of cost-effectiveness is needed. 
Specifically, this chapter has explored whether the cost-effectiveness results from the Stroke 
study would have been different had the structure and type of model been different or had 
other elements pertaining to structural uncertainty been considered. 
This case study identified and implemented a plausible alternative type of model structure 
based on results of a systematic review of economic evaluations focused on a similar research 
question. The selected model type consisted of a decision-tree followed by a Markov model. 
The decision tree reflected the short term care pathway and the Markov structure reflected 
the lifetime costs and outcomes. Other types of models such as a DES or ISM were rejected 
on the basis of model parsimony. The results of cost-effectiveness for each alternative model 
and scenarios specified, including the EVPI, were presented and compared. 
The main cost-effectiveness results in the stroke model did not change when an alternative 
decision-tree followed by a Markov model was implemented, including an adjustment to 
allow for the recurrence of stroke. This may suggest that structural uncertainty was not 
important in the stroke model. Results for EVPI in the decision-tree followed by a Markov 
model decreased for all scenarios, indicating that a large part of the decision uncertainty was 
not apparent in the model.   
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The results here corroborate previous findings indicating that all intervention strategies that 
increase thrombolysis rates in acute stroke are cost-effective because of a reduction in 
dependency after stroke and the subsequent reduction in long-term care costs123. 
The results presented in this chapter for this particular clinical area and research question, 
lead to the conclusion that the simplest model (decision tree) would suffice in projecting the 
potential impact of alternative interventions aiming at increasing thrombolysis rates through 
optimisation of the care pathway for acute stroke.  
However, an important variation in model structures was identified by the systematic review 
for similar research questions, and this corroborates findings in Chapter 5 indicating that 
improved guidance to handle the implications of potential sources of structural uncertainty 
are needed.   
The question remains as to whether this results would have been different, had the research 
question be different, or the clinical area, or the results of cost-effectiveness. Further research 
is required to identify the forms of structural uncertainty analyses that might be relevant to 
best inform decision making according to the characteristics of the disease being modelled. 
 
6.6. Strengths and limitations  
As previously indicated in Chapter 5, a weakness in the approach followed to assess structural 
uncertainty in this chapter is the lack of established methods to formally assess the plausibility 
of alternative models or to start understanding how many scenarios should be considered. 
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More sophisticated methods to assess structural uncertainty such as the discrepancy 
approach were not implemented due to data restrictions to estimate the maximum likelihood 
of parameters. 
This chapter used as a case study a model taken from work previously published on the cost-
effectiveness of optimising acute stroke care services for thrombolysis123. The model 
structure of the decision-tree was affected by some of the nuances associated with the 
pathway (service evaluation) type of models These nuances include the healthcare 
interventions received based upon what was known or believed by healthcare practitioners 
at the time, and the extent of the model complexities which may not or could not be 
appropriately captured by the model.138 However, on building the model, relevant NICE 
clinical guidelines and expert opinion were incorporated.  
The choice of model type for the case study was limited to a decision tree followed by a 
Markov model. Some may argue that a microsimulation or DES may offer some advantages 
in the particular case of the Stroke study. An essential feature of a DES is that patients 
compete for limited resources however, in the Stroke study patients were not competing for 
resources as any patient presenting in A&E within 4.5 hours of the onset of symptoms and 
was found eligible, received thrombolysis. An ISM on the other hand is more useful when the 
aim is to assess the timing of the response to an event. However, the aim of the Stroke study 
was to assess the effectiveness of key hypothetical interventions in increasing the rates of 
thrombolysis among patients who had suffered an ischaemic stroke rather than changes to 
the timing of the intervention. 
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The results of cost-effectiveness analyses indicated that increasing thrombolytic rates via the 
implementation of interventions designed to optimize the acute care pathway for stroke 
patients is clinically superior and cost saving. This case study may have limited ability to be 
generalisable to other disease areas since thrombolysis for acute stroke is associated with 
substantial QALY gains, typically not seen with many other therapies. It may be that if the 
results were near the £20,000 per QALY threshold, changes in model structure could have led 
to different conclusions regarding cost-effectiveness and possible EVPI. 
Other limitations may relate to the model perspective adopted. A National Health Service 
(NHS) and Personal Social Services (PSS) perspective was utilized here meaning that other 
benefits associated with service evaluation, for example, the potential improvement in 
people’s perceptions of urgent care, were not measured.   
The assessment of structural uncertainty shown in published studies in the area of secondary 
prevention of Stroke/TIA has mainly focused on assessing parameter uncertainty. This 
chapter has extensively examined structural uncertainty showing the effect of a plausible 
alternative model structure and scenarios on the results of cost-effectiveness through 
implementing extensive scenario and EVPI analyses.  
 
6.7. Conclusion 
The results in this chapter indicate that the main conclusions of cost-effectiveness analysis 
from the Stroke model are robust to plausible changes to the model structure. The cost-
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effectiveness results and the EVPI were not sensitive to model structure specification. These 
results were also robust to the various sensitivity analyses undertaken which lead to the 
conclusion that, in this particular case study, a parsimonious model would suffice. As is normal 
in the economic evaluation of healthcare technology using decision-analytic modelling, the 
mathematical model represents a simplification of reality and the results presented here need 
to be interpreted in relation to the assumptions used and evidence available. 
The results in this chapter corroborate the findings in Chapter 5 and have demonstrated the 
need to strengthen the current guidelines to indicate more clearly how structural uncertainty 
should be identified, assessed, and reported. Most importantly, in which particular 
circumstances or for which disease areas structural uncertainty arising from the structure of 
a model is more likely to affect the results of cost-effectiveness.  
Based on the findings of this chapter, the following recommendations are proposed:  
1. The assessment of structural uncertainty should not be ignored as it is an integral part 
of good practice DAM 
2. The reasons why an assessment of structural uncertainty is not possible or not needed 
should be always stated as a research limitation  
3. Data limitations that impact on the assessment of structural uncertainty should be 
stated and discussed 
4. If there is a reason to believe that structural uncertainty is an issue that may have 




5. If sophisticated methods to assess structural uncertainty are not implemented due to 
data limitations (e.g. discrepancy approach, model averaging, parameterization, 
model selection), then at least scenario analysis or appropriate sensitivity analysis 





CHAPTER 7. DISCUSSION 
 
The overall aim of this thesis was to examine the understanding of good practice in DAM, to 
assess the extent to which economic evaluations in primary prevention of cardiovascular 
disease and acute care interventions for stroke adhered to good practice guidelines, and to 
assess how structural uncertainty arising from the choice of model structure impacts on cost-
effectiveness results in two alternative settings. 
In particular, this thesis has combined the use of methodological research and quantitative 
analysis to: 
1. Examine all available guidelines and statements of good practice in decision-analytic 
modelling between 1990 to 2012 to identify currently available good practice 
guidelines 
2. Develop a five-dimension framework to assess the compliance of current practice to 
guidelines in decision-analytic modelling 
3. Assess to what extent model-based economic evaluations of primary prevention 
interventions aimed at lowering blood pressure in patients with hypertension or at risk 
of developing hypertension have complied with published decision-analytic modelling 
guidelines using the framework developed in Chapter 2  
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4. Develop two case studies illustrating the assessment of structural uncertainty arising 
from the choice of model structure using scenario analysis and extensive sensitivity 
analysis   
This chapter discusses the key findings, draws conclusions, and make recommendations for 
further research. 
 
7.1. Main Findings 
There is wide acceptance that economic methods such as DAM contribute to the decision 
making process in the health care setting by offering a coherent and theoretically based 
approach to identifying, measuring and valuing resource use, costs and outcomes, and by 
handling uncertainty1, 2, 9. Since the 1990s, DAM has been widely used to synthesise clinical 
and economic evidence and to inform resource allocation decisions for the purpose of 
allowing scarce health care to be allocated more efficiently9.  
The growing use of modelling in economic evaluations has led to increased scrutiny of the 
methods used, including clear requirements for researchers in terms of good practice in DAM. 
Good practice considers factors such as the need to incorporate appropriate evidence, to 




This thesis has demonstrated that even though contemporaneous DAM guidelines have kept 
pace with recent progress in the way economic evaluation methodology has progressed, there 
are aspects of DAM that require further development and/or strengthening.  
 
7.1.1. Contemporary understanding of ‘good practice’ in decision analytic modelling 
A comprehensive review of DAM guidelines was undertaken that included 33 studies, and was 
the first to critically assess all available guidelines and statements of good practice since 2006. 
The results of the systematic review have demonstrated that contemporaneous DAM 
guidelines have kept pace with recent progress in the way economic evaluation methodology 
has progressed and have ensured guidelines remain current, effective and helpful. 
Furthermore, DAM guidelines should be seen as tools that if followed will lead to the results 
obtained in economic evaluations being more credible, and adherence to these guidelines is 
considered as best practice in DAM. 
The review identified some aspects of DAM guidelines that require further development. The 
choice of model structure: whether model structure should be informed by data availability 
or not remains an ongoing issue. Structural uncertainty remains an area of controversy. An 
inappropriate structure can invalidate the conclusions drawn from cost-effectiveness 
analyses, while choices made when structuring a model can significantly affect its results and 
the inferences from it. Model validity, in particular some aspects of model generalisability that 
require examining whether model’s predictions are reliable, demands further research. It is 
argued that model external validation be based on new data that is external to the data used 
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for model development. However, most available data will typically be used in model 
development and there will often be relatively little or even no data left available for 
undertaking external validation. 
This thesis found that new sets of guidelines have been developed since 1990, kept up to date 
and are generally available. However, these may at times lack practicality due to the extensive 
amount of reports and information available, making them complex for researchers to follow 
and implement. From the findings of this research it is apparent that standards of reporting 
cost-effectiveness results could be improved if additional effort were made to produce a 
single, comprehensive, user-friendly, up-to-date and practical instrument to direct 
researchers towards the key elements of good practice in DAM. 
Following on from this finding, as part of this thesis, a new DAM framework incorporating and 
reflecting on all the evidence found in the review was developed. The framework synthesised 
current and agreed guidelines in a five-dimensional checklist instrument: problem concept, 
model concept, synthesis of evidence, analysis of uncertainty, and model transparency and 
validation. The framework constitutes the first of its type since Philips et al17. It is 
recommended here that ISPOR, as part of their mission to improve decision making for health 
globally, undertakes a periodic review and update of this framework, whenever new 
statements of good practice are made available or otherwise, at least every two years, as this 





7.1.2. Compliance to good practice guidelines  
The results of the review on DAM guidelines indicated that compliance to guidelines is 
considered best practice. However, few studies in the past have been concerned with 
assessing the extent to which current practice has adhered to DAM guidelines.  
In assessing adherence to DAM guidelines, care was taken to remove all possible variation 
between models which was not relevant for the purpose of assessing compliance (for 
example, different outcomes, treatment options or sources of uncertainty). This was achieved 
by focusing on one particular clinical area. The clinical area of cardiovascular disease 
prevention was selected for the assessment of compliance to DAM guidelines due to the large 
number of recent model-based cost-effectiveness analyses conducted in this area, and the 
fact that CVD is a commonly modelled clinical area where intermediate outcomes such as 
blood pressure reduction can be tracked. The focus here was on interventions aimed at 
lowering blood pressure in patients at risk of developing cardiovascular disease. 
Limited compliance was more commonly justified by a lack of data or imperfect data, and this 
was particularly apparent in the assessment of structural uncertainty and external model 
validation. This appeared to pose challenges to researchers for example, when modelling the 
risk of secondary events and disease progression or when undertaking model external validity. 
Even though elements pertaining to structural uncertainty were acknowledged in some of the 
studies reviewed, the assessment of structural uncertainty was not found to be common 
practice. Guidelines have recommended assessing structural uncertainty as part of good 
practice. Furthermore, this thesis found literature illustrating the assessment of structural 
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uncertainty using various sophisticated statistical methods (Chapter 4). However, it was found 
that these methods are not being implemented in current practice to assess structural 
uncertainty, indicating a possible lack of practicality, excess complexity, or a lack of adequate 
data necessary for them to be implemented. This findings seem to indicate that additional 
guidelines or the strengthening of current guidelines are still needed to aid researchers in 
identifying and quantifying the effect of structural uncertainty on cost-effectiveness results. 
Similarly, model external validity was not found to be common practice and model external 
validation poses important challenges to researchers in terms of actual data or the lack of 
availability of big data, randomised controlled trial, or patient-level data to allow the exercise.  
 
7.1.3. Structural uncertainty surrounding the choice of model structure  
This thesis found that many issues related to structural uncertainty have been identified, 
making it a complex task to address properly. As previously mentioned, statistical methods 
have been developed to address and to report the results of structural uncertainty, however 
most of them have been the object of criticism (Chapter 4). Specific guidelines are needed in 
order to aid researchers in identifying what elements are of greater importance for different 
disease areas, and how best to identify, address and report the results of structural 
uncertainty. Findings in Chapters 5 and 6 have demonstrated that for this particular clinical 
area, disease conditions, and research questions, parsimonious models sufficed and model 
structural uncertainty did not seem to affect the results of cost-effectiveness.  
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The case studies developed in this thesis to assess the impact of choice of model structures 
on cost-effectiveness results modelled the course of prevention and treatment of 
cardiovascular disease. For each case study, alternative model structures were identified from 
the literature, implemented, and then the results of cost-effectiveness analyses compared. An 
important consideration in the assessments of these results was the extent to which cost-
effectiveness results obtained in the case studies were robust to the assumptions adopted 
(for example, the effect of secondary events) and to sensitivity analyses (deterministic and 
probabilistic). 
After implementing competing model structures that varied between a simplified structure 
and a complex one, it was found that the main cost-effectiveness results obtained in the 
TASMIN-SR model and in the Stroke model were robust to changes in model structure and to 
the inclusion of secondary events. In other words, dominance was still demonstrated in the 
results, with higher QALYs and lower costs for the intervention strategy in the case of TASMIN-
SR and for any strategy leading to the increased of thrombolysis rates in the case of the Stroke 
model. For this reason, it is difficult to draw conclusions regarding the importance of correctly 
exploring model structural uncertainty based on the results of the case studies. Therefore, 
these results are not generalisable to other clinical areas or disease conditions for which the 
results may have been different and for which structural uncertainty surrounding model 
structure may still remain an area of controversy, for example, metastatic end-stage cancer 




Inappropriate model structures can invalidate the conclusions drawn from cost-effectiveness 
analyses, while choices made when structuring a model can significantly affect the results 
obtained and the inferences from it.  
It has long been argued14-16 that the art of building models rests on the principle of parsimony, 
according to which model selection should value both accuracy and simplicity. Finding the 
right balance between simplicity of modelling and avoidance of over simplification is difficult. 
However, it is getting this balance right that makes the difference in terms of model 
transparency and model credibility: excessive model details and complexity reduces 
transparency and can lead to distrust in models21. Simplicity in models which relates to the 
size of the model and not to the modelling technique used, has been recognised as an 
advantage because simpler models are usually easier to understand and to validate13. 
Challenges posed by the assessment of structural uncertainty might be overcome if additional 
research were undertaken on an experimental basis, for example by measuring the impact of 
changing model structures on cost-effectiveness results. Case studies aimed at measuring the 
impact of changing or adapting model structures could provide insightful evidence as to how 
much cost-effectiveness results would be altered when alternative model structures are 
implemented. This may or may not be always feasible, depending on how complicated models 




Current practice seems bound by data availability whilst methods proposed to assess 
structural uncertainty have been borrowed from other disciplines oblivious to the needs in a 
health care setting where patient level data is not always readily available.   
 
The main recommendations arising from the case studies are: 
1. The assessment of structural uncertainty should not be ignored as it is an integral part 
of good practice DAM 
2. The reasons why an assessment of structural uncertainty is not possible or not needed 
should always be stated as a research limitation 
3. Data limitations to undertake an assessment of structural uncertainty should be 
clearly stated and discussed 
4. If there is a reason to believe that structural uncertainty is an issue that may have 
affected the results of CE, then an assessment of structural uncertainty should be 
included 
5. Ideally, sound statistical methods should be used in the assessment of structural 
uncertainty (e.g. discrepancy approach, model averaging, parameterization, model 
selection) but if none are possible due to data limitations, then at least scenario 
analysis and appropriate sensitivity analysis should be conducted, as per the case 
studies implemented in this thesis  
6. ISPOR-SMDM guidelines should be followed at the very least by implementing 




7.2. Strengths and limitations 
This thesis has a number of strengths in terms of presenting novel research in three main 
areas. First, it developed, for the first time since Philips et al26 an updated framework to assess 
the quality of decision analytic models. This framework, named the five-dimension 
framework, proposes that the criteria for assessing the quality of model-based economic 
evaluation fall into five areas: problem concept, model concept, synthesis of evidence, model 
uncertainty, and model transparency and validation. Second, it undertook an in-depth 
assessment of the quality of decision analytic models and the value of the five-dimension 
framework in assessing compliance to DAM guidelines. The assessment of compliance to DAM 
guidelines was conducted on economic evaluations of primary prevention interventions 
aimed at lowering blood pressure in patients with hypertension or at risk of developing 
hypertension. Compliance to DAM guidelines was assessed using the five-dimension 
framework. The value of the five-dimension framework was assessed from the point of view 
of its usefulness in reviewing results of DAM. Third, this thesis developed an assessment of 
the impact of model structural uncertainty in the area of prevention and treatment of 
cardiovascular disease. This thesis has demonstrated how structural uncertainty arising from 
model choice can be assessed using scenario analysis, extensive sensitivity analyses and in 
terms of expected value of perfect information. The main results of the cost-effectiveness 
here have indicated that the main conclusions were robust to changes in model structure, and 
thus raise the question, whether in this particular clinical setting, more parsimonious model 
structures suffice.   
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However, there are several limitations of the work presented in this thesis. The exclusion 
criteria adopted for inclusion of studies in the systematic reviews may be considered a 
limitation; however, these were required to guarantee consistency in the analysis. For 
example, the focus on one particular clinical area (CVD prevention) made it possible to remove 
some of the variation between models that was not relevant for the purpose of assessing the 
quality of model based economic evaluations (e.g., different outcomes, treatment options, or 
sources of uncertainty), but meant that these results cannot not be more generalisable to 
other settings. Similarly, the fact that this review did not look for studies published in a non-
English-language may also be considered a limitation. 
The choice of model type used in the case studies was limited to decision tree and Markov 
models and this may also be seen as a limitation. However, as previously defined, model 
complexity is not only related to the type of model used but as well to how complex it is. Some 
may argue that a microsimulation or discrete event simulation may have offered some 
advantages in the case of the TASMIN-SR model, such as the flexibility in incorporating 
individual heterogeneity and tracking individual event history. However, as per DAM 
guidelines, model structure is identified by considering the natural history of the disease and 
the answer to questions: is interaction between patients important? No; do you need to 
model recursive events? Yes; do you require the model to represent a lot of health states? No. 
All of which indicated that a Markov model was the right approach49 13. 
In the case studies considered in this thesis it was not possible to implement a model selection 
method to select the best model on the basis of how well the model’s output matched 
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observed data (judged by the likelihood-based information criteria). This was because only 
single point estimates for key parameters were available, which did not allow the estimation 
of the maximum likelihood of parameters. 
The cost-effectiveness results in both case studies were of dominance. It may be that if the 
results were near the £20,000 per QALY threshold, changes in model structure could have led 
to different conclusions being drawn from the cost-effectiveness analysis.  
 
7.3. Comparison with similar research studies 
There is agreement that the development of good practice guidelines is an ongoing process21, 
and, as such, efforts should be made to review and update DAM guidelines in accordance with 
the methods being used in current practice17, 21, 30. Whilst it is recognised that a single 
framework cannot determine the quality of a model, it can serve as general guidance 
regarding what modelling issues are important and the details of how a model is reported17. 
The use of a framework has the additional advantage of providing a systematic approach to 
the assessment of quality in a model review, allowing the reviewer to focus on the key 
characteristics of a model and thereby identify strengths and weaknesses17, 26. Furthermore, 
the aim of a framework is to synthesise DAM guidelines that are currently available, providing 
pointers towards the particular aspects that require consideration in developing and 
appraising models17, 26.    
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Model validation and the assessment of structural uncertainty represent areas posing key 
methodological challenges in DAM due to the lack of motivation, time and data to validate 
models and in the case of structural uncertainty, the lack of methods21, 29, 30, 96. Model 
structures are commonly described by linking them to the natural history disease, however 
they are less justified from the point of view of the adequacy of the type of model being used 
over competing model structures when reporting cost-effectiveness results. In the other hand, 
concerns have been expressed by the diversity of alternative model structures submitted to 
national reimbursement bodies, such as NICE, for the same disease and to answer similar 
research questions96. This ultimately reduces the comparability of evaluations of competing 
health technologies for the same condition, potentially leading to inconsistent public funding 
decisions96. However, decision problems across different disease areas are so varied that it 
may well be the case that only analysis such as the analysis undertaken in the case studies 
developed in this thesis can shed any light on the importance of model uncertainty in different 
clinical settings.  
 
7.4. What these findings mean and the need for future research 
DAM in health economics has traditionally been used to synthesise best available data or to 
extrapolate beyond the clinical trial to endpoints. Assessing the quality of DAM is paramount 
in light of the unresolved long term concerns regarding DAM. These include less well defined 
methodology, the incorporation of many assumptions and the use of analyst discretion139, the 
increasing use of DAM in the economic evaluation of health care interventions and health 
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technology assessments (HTA), and newer methods being used including more sophisticated 
modelling techniques. 
Good practice guidelines in DAM should aim to reflect the current consensus regarding the 
attributes that characterise a good model in terms of structure, data, and validation. To serve 
as such, DAM guidelines should be subjected to periodic evaluation and update. It is only 
through this means that DAM guidelines would remain, in words of Caro et al21, “current, 
helpful and effective” p. 668.   
Evaluation and the update of DAM guidelines require that reviews of their relevance as in this 
thesis be undertaken periodically. Chapter 2 has shown that since Philips et al17, 26, no further 
attempts have been made to synthesise DAM guidelines in a single framework. To remain 
effective, frameworks such as the five-dimension framework developed in Chapter 2, need to 
be updated and adjusted in response to new developments in current practice. 
Future research should aim to develop a systematic approach to evaluate and update good 
practice frameworks. The options to do so could consider focusing on the following questions: 
firstly, do current results of economic evaluation comply with good practice DAM guidelines? 
The answer to this question would help identify to what extent good practice frameworks are 
considered by researchers prior to submitting their results for publication. However this does 
imply that a view has been established about what is considered good practice in DAM. 
Secondly, do DAM guidelines improve the transparency of published results of economic 
evaluations? The answer to this question would allow the assessment of the transparency of 
reporting results of DAM and would allow users of models to evaluate the quality of models 
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according to criteria of good practice. However some may argue that this would not necessary 
answer the question of whether DAM guidelines have improved the quality of published 
results of model based economic evaluations139.  
Overall, limited compliance in terms of the development of model validation was identified in 
the area of cardiovascular disease, but this has been justified by the lack of sufficient event 
data to undertake the exercise. DAM guidelines have suggested that models should be based 
on the best evidence available at the time they are built, but at the same time, external model 
validity should use actual event data. This poses the difficulty of splitting available data in a 
way that would serve both purposes. Some experts have suggested setting aside one-third of 
the data for the purpose of external validation30. Other issues affecting model validation 
besides data availability are a lack of motivation, time and a short-term vision used during the 
process of building models30. It has been suggested that the development of multi-use 
models30 progressively validated over time would contribute towards solving the issue of 
model validation. 
The wide variations in the model structures identified in the literature to answer similar 
research questions supports the need for improved guidance to handle the implications of 
potential sources of model structural uncertainty. If there is a choice, a model should aim for 
simplicity and how simple a model should be depend upon the sensitivity of the policy 
implications to added complexity139. The best model for a given decision is the simplest model 
that is adequate to represent the decision problem, where adequacy may be defined as 
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allowing the decision maker to make the same decision(s) as would be made with a perfect 
model. 
Modelling in health economics poses the challenge that models are developed for a particular 
decision making context making it difficult for other decision makers to use the published 
results from the modelling. This requires the results to be presented in a way that makes clear 
how much they are dependent on that particular context.  
Model uncertainty is largely related to the choice of appropriate model structure. This thesis 
has demonstrated how it is possible, on a case-by-case basis, to identify and assess model 
adequacy from among both simplistic and more comprehensive model representations of the 
disease area and its impact on cost-effectiveness results. This exercise could be used to serve 
as a basis for the future identification and development of an appropriate common model 
structure for specific diseases. These types of models have been referred to as reference96, 140 
or global models27. The development of reference models would not eliminate structural 
uncertainty particularly if there is insufficient or conflicting evidence to support an 
appropriate model structure96.  
The assessment of structural uncertainty is not common practice and in fact, structural 
uncertainty is rarely addressed when presenting results of economic evaluation. Some of the 
challenges addressing structural uncertainty have been posed by the many elements that have 
been defined as pertaining to structural uncertainty including assumptions about the disease 
process (events and states). The case studies developed in this thesis indicated that many of 
the sophisticated methods proposed to assess structural uncertainty are difficult to 
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implement due to data restrictions. Further research is needed to develop statistical methods 
suitable for a health economics arena where patient level data is insufficient or sometimes 
unavailable in many clinical settings. Similarly, decision-analytic modelling guidelines need to 
be strengthened in order to aid researchers to address structural uncertainty. 
Currently there are no available guidelines indicating how structural uncertainty arising from 
the structure of a model should be assessed and reported. Therefore, further research should 
focus on the development of general guidelines on how to address these issues and more 
specifically, how to deal with challenges across different disease areas, perhaps incentivising 
the development of more case studies focusing on specific areas such as those developed in 




CHAPTER 8. CONCLUSIONS 
 
Good practice guidelines in decision analytic modelling should aim to reflect current 
consensus regarding the attributes that characterise a good model in terms of structure, data 
and validation. To serve as such, DAM guidelines should be subjected to periodic evaluation 
and update. Evaluation and update of DAM guidelines require that exercises such as these 
reflected in this doctoral research be undertaken periodically. It is recommended here that 
ISPOR, as part of their mission to improve decision making for health globally, undertakes a 
periodic review and update of this framework, whenever new statements of good practice are 
made available or otherwise, at least every two years, as this would allow sufficient time for 
the application of any new guidelines to be adopted into practice. 
The wide variations in the model structures identified in the literature for similar research 
questions supports the need for improved guidance to handle the implications of potential 
sources of model structural uncertainty. If there is a choice, a simple model is the preferred 
option and how simple the model should depend upon the sensitivity of the policy 
implications to added complexity139. The best model for a given decision is the simplest model 
adequate to represent the decision problem, where adequacy may be defined as allowing the 
decision maker to make the same decision(s) as would be made with a perfect model. 
This thesis has: 1) responded to the need to update and reflect on current DAM practice by 
developing an up-to-date five-dimensional DAM framework and has demonstrated its 
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usefulness in assessing compliance to DAM guidelines; and 2) answered to the need for more 
case studies comparing the efficiency of simple versus complex model structures in the results 
of cost-effectiveness analyses and by doing so, has set the foundation for the development of 












Appendix 1. Search results for Decision Analytic Modelling guidelines 
EMBASE AND MEDLINE(R) 
Steps Search criteria Number of hits 
1 
(checklist$ or check list$ or standards or 
standardi?ation or peer review or rules or critiquin 
or criteria or good or bad or correct$ or bias or 
fundamentals recommend$ or best or strength$ or 
weakness$ or quality or qualities or validity or 
guideline$ or validation or checkpoint$ or critically 
appraise or problems or limitations or rating scale$ 
or framework$ or protocol$ or audit or principles or 
methodolog$ or validate or validation or evaluating 
or properties or guidance or integrity or evaluation 
or pros or cons).m_titl. 
2261664 
2 limit 1 to abstracts 1470011 
3 limit 2 to English language 1266438 
4 limit 3 to yr="1990 -Current" 1052800 
5 limit 4 to humans 684348 
6 (economic model$ or Markov model$ or 
mathematical model$ or cost model$ or decision 
model$ or pharmacoeconomic$ model$ or decision 
tree$ or decision data or decision analytic$ or 
decision analysis or economic evaluation? or 
economic analysis).m_titl. 
30075 
7 limit 6 to abstracts 24245 
8 limit 7 to English language 21989 
9 limit 8 to yr="1990 -Current" 19501 
10 limit 9 to humans 12259 
11 5 and 10 3930 
12 remove duplicates from 11 2486 
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Appendix 2. Search results Decision Analytic Modelling Guidelines 
from COCHRANE library 
Steps Search criteria Number of hits 
1 
economic model* or economic analysis* or 
economic evaluation* or decision analytic* or 
decision analysis* or economic study* or 
economic submission* from 1990 to 2013, in 
Methods Studies, Technology Assessments and 




2 guideline* 13983 





Appendix 3. Search strategy for the applied economic evaluations 
Cochrane databases (searched 20 March 2015 for the period 2000 to 
2015) and NHS EED (economic evaluations) 
ID Searches - CRD (NHS-EED) 
#1 
MeSH blood pressure EXPLODE PERMUTE  
#2 MeSH hypertension EXPLODE PERMUTE 
#3 cost utility analys*  
#4 mathematical model  
#5 decision analys*  
#6 Markov chain* or Markov process* or decision tree  
#7 Economics 
#8 cost effective* or cost effective* analys*  
#9 #3 OR #4 OR #5 OR #6 OR #7 OR #8 
#10 #1 OR #2  
#11 #9 AND #10 
#12 MeSH primary prevention EXPLODE PERMUTE  
#13 #11 AND #12 




Appendix 4. Search results for case study 1 
EMBASE AND MEDLINE databases  
ID Searches (via OVID) 
#1 
(lowering blood pressure or lowering-blood-pressure or blood pressure 
lowering).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]  
#2 (hypertensi$ or antihypertensi$ or anti-hypertensi$).mp. [mp=ti, ab, sh, hw, 
tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]  
#3 1 OR 2 
#4 (cost effective$ OR cost-effective$ OR mathematical model OR decision-
analys$s OR decision analys$s OR Markov OR decision tree OR economic 
evaluation OR cost utility).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, 
kf, px, rx, an, ui]  
#5 3 AND 4 
#6 limit 5 to English language 
#7 limit 6 to yr="2000 -Current" 
#8 limit 7 to humans 
#9 Exclude conference abstracts, methodological papers, commentaries, 
editorials, notes 
#10 remove duplicates from 9 
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Appendix 5. Model input parameters from the TASMIN-SR model 
Parameter Input Sources 
CVD risk in patients with DM      
Stroke   
60-69 years old 0.0196 
NICE, Diabetes104  70-79 years old 0.0262 
80-89 years old 0.0298 
MI   
60-69 years old 0.0089 
NICE, Diabetes104  70-79 years old 0.0100 
80-89 years old 0.0111 
UA   
60-69 years old 0.0041 
NICE, Diabetes104  70-79 years old 0.0047 
80-89 years old 0.0052 
CVD risk in patients with CKD   
Stroke   
60-69 years old 0.0072 
Kerr et al 105 70-79 years old 0.0147 
80-89 years old 0.0189 
MI   
60-69 years old 0.0051 
Kerr et al 105 70-79 years old 0.0113 
80-89 years old 0.0171 
UA   
60-69 years old 0.0024 
Kerr et al 105 70-79 years old 0.0054 
80-89 years old 0.0081 
CVD risk in patients with stroke   
Stroke   




70-79 years old 0.0590 
80-89 years old 0.0715 
MI   
60-69 years old 0.0139 
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Parameter Input Sources 




80-89 years old 0.0232 
UA   




70-79 years old 0.0232 
80-89 years old 0.0232 
CVD risk in patients with CHD   
Stroke   




70-79 years old 0.0590 
80-89 years old 0.0715 
MI   




70-79 years old 0.1112 
80-89 years old 0.1112 
UA   




70-79 years old 0.0882 
80-89 years old 0.0882 
Age-related relative risks   
MI, UA  – self-management    
60-69 years old 0.63 TASMIN-SR trial & 
Law at al (2009)37, 
114  
70-79 years old 0.69 
80-89 years old 0.75 
Stroke – self-management    
60-69 years old 0.54 TASMIN-SR trial & 
Law at al (2009)37, 
114  
70-79 years old 0.59 
80-89 years old 0.75 
MI, UA - usual care    
60-69 years old 0.82 TASMIN-SR trial & 
Law at al (2009)37, 
114  
70-79 years old 0.85 
80-89 years old 0.88 
Stroke - usual care    
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Parameter Input Sources 
60-69 years old 0.76 TASMIN-SR trial & 
Law at al (2009)37, 
114  
70-79 years old 0.81 
80-89 years old 0.88 
Cost of death 0 By definition 
Utilities   
Utilities for initial health states   
Self-management and usual care   
65-74 years old 0.81 
TASMIN-SR trial37 75-84 years old 0.74 
85 and over 0.71 
Utilities for acute events   





Utilities for long-term (chronic) disease   





Annual discount rate for costs 0.035 Gray et al 1 
Annual discount rate for utility 0.035 Gray et al 1 
Death utility 0 By definition 
Average age of cohort at time of intervention 




Appendix 6. Input parameters and their distributions from the 
TASMIN-SR model 
Description Input Distribution a b 
Probability of death from 
Stroke  0.23 Beta 125 420 
Probability of death from MI 0.23 Beta 155 520 
   alpha lambda 
Cost of well state self-
monitoring 74 Gamma 1 0.0136 
Cost of well state for Usual 
care arm 62 Gamma 1 0.0161 
Cost acute angina 3292 Gamma 1 0.0003 
Cost acute MI 5487 Gamma 1 0.0002 
Cost acute Stroke 11020 Gamma 1 0.0001 
Cost chronic angina 286 Gamma 1 0.0035 
Cost chronic MI 286 Gamma 1 0.0035 
Cost chronic Stroke 1361 Gamma 1 0.0007 
Cost of intervention 35 Gamma 1 0.0286 
   mean s.d. 
Multiplier used to adjust for 




Appendix 7. Hypothetical interventions in the optimisation of acute stroke care for thrombolysis  
 
 
Area for improvement based on baseline 
data (n=355)  
Hypothetical intervention with reference 
to literature  
(Estimates noted) 
Max theoretical number of 
patients benefiting from 
removal of block in pathway 
n(%) – or theoretical 
hypothetical intervention 
(n=355) 
Predicted max benefit 
based on that recorded in 
the literature or estimated 
n(%) – or achievable 
hypothetical intervention 
1.      
  
Timely referral: 
16% of patients contacted a General 
Practitioner following onset of stroke and 
arrival in hospital was delayed compared 
to those who called the emergency 
services. 
Divert GP calls to ambulance service 
General practice staff is trained to better 
recognise stroke, resulting in patients who 
initially contact their General Practitioner 
being referred immediately to hospital. Up 
to 64% immediately referred to EMS 
 
57 patients (100%) 
 
36 patients (64%) 
2.      
  
Wake-up strokes: 
According to previous research, 
approximately 16% (range 8-27%) of all 
stroke patients suffer symptom onset 
upon waking. Currently, these patients 
are ineligible for thrombolysis due to 
unknown onset time. 
Use imaging to estimate onset time for 
wake up strokes 
New imaging techniques are introduced 
which make it possible to estimate onset 
time in wake-up stroke, thus increasing the 
number of patients potentially eligible for 
thrombolysis.  
Estimate that up to 80% feasible with new 
imaging. 
 
57 patients (100%) 
 
45 patients (80%) 
3.      
  
Unknown onset time in stroke: 
Symptom onset time was unknown in 
37% of stroke patients presenting in 
hospital. Approximately 22% (57% of 
those with unknown onset) do not have 
wake-up stroke. These patients are 
ineligible for thrombolysis. 
Improve recognition and recording of 
onset time 
Media campaigns improve public 
awareness of the importance of noting 
onset time in stroke. Additional training of 
healthcare professionals facilitates better 
recording of onset time in patient medical 
notes. 92% known onset time once wake 
up stroke excluded  
 
77 patients (100%) 
 





Area for improvement based on baseline 
data (n=355)  
Hypothetical intervention with reference 
to literature  
(Estimates noted) 
Max theoretical number of 
patients benefiting from 
removal of block in pathway 
n(%) – or theoretical 
hypothetical intervention 
(n=355) 
Predicted max benefit 
based on that recorded in 
the literature or estimated 
n(%) – or achievable 
hypothetical intervention 
4.      
  
Patient delay from onset of symptoms to 
contact with emergency services: 
Approximately 15% of stroke patients had 
a known onset time but arrived in hospital 
greater than 4.5 hours after symptom 
onset. This was often caused by a delay in 
contacting medical services due to lack of 
awareness of stroke as an emergency or 
failure to identify stroke symptoms. 
Reduce time to call emergency services  
Better public awareness of stroke through 
a series of educational interventions result 
in an increase in the proportion of patients 
contacting emergency services 
immediately after the onset of stroke 
symptoms. 
Estimate additional 25% of those arriving 




54 patients (100%) 
 
 
14 patients (25%) 
5.      
  
Timely CT scan 
14% of patients who arrived in hospital 
within 4.5 hours of symptom onset did 
not receive an immediate CT scan within 
the time window for thrombolysis. 
Ensure all who present with stroke 
receive immediate CT scan 
In-hospital stroke services are reorganised 
to ensure patients with stroke receive a 
timely CT scan (e.g. CT scanner moved 
closer to the emergency department 
ward). 
Reduce time to CT scan by an hour  
 
51 patients (100%) 
 
13 patients (25%) 
6.      
  
FAST Acute care pathway: 
22% of patients travelling via ambulance 
and who received a FAST check (or 14% of 
total patients travelling via ambulance) 
were Face Arm Speech Test negative and 
did not have urgent CT scan. 
 
Better stroke recognition tools 
New stroke recognition tools are 
introduced which ensure FAST negative 
stroke patients are recognised by 
emergency services as having stroke. 
Use ROSIER score with sensitivity 93% vs. 
79% for FAST in the present study.  
 
51 patients (100%) 
 
35 patients (68%) 





Area for improvement based on baseline 
data (n=355)  
Hypothetical intervention with reference 
to literature  
(Estimates noted) 
Max theoretical number of 
patients benefiting from 
removal of block in pathway 
n(%) – or theoretical 
hypothetical intervention 
(n=355) 
Predicted max benefit 
based on that recorded in 
the literature or estimated 
n(%) – or achievable 
hypothetical intervention 
7.      
  
Thrombolysis for >85  years old:† 
6% of stroke patients older than 85 years 
old were scanned within 4.5 hours. 
†Current licensing makes these patients 
ineligible for thrombolysis. 
Extend thrombolysis eligibility to over 85s 
New evidence from the International 
Stroke Trial [IST-3] suggests that patients 
over the age of 80 could benefit from 
thrombolysis up to 4.5 hours after 
symptom onset.  
Assume same proportion of those over 85 
who get scan within 4.5 hours receive 
thrombolysis.  
19 patients (100%) 19 patients (100%) 
†In the present CLAHRC cohort, patients up to 85 years were thrombolysed. Note, current guidance indicates that thrombolysis should be administered 
with caution in over 80s from 3 to 4.5 hours from symptoms onset. 
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Appendix 8. Parameters used in the Stroke study 
 
Parameter Value  Distribution Source 
Percentage of patients with symptoms who have suffered a "true" 
stroke and… 
      
contact ambulance services (999) 67% Beta Patient level data 
contact their GP surgery first 16% Beta Patient level data 
make their own way to the hospital 11% Beta Patient level data 
are already inpatients   5% Beta Patient level data 
are referred/transferred   1% Beta Patient level data 
Percentage of patients with symptoms who have suffered a stroke, 
contact 999 services and 
      
get to A&E within 4.5h (hours) of stroke onset 53.4% Beta Patient level data 
get a CT scan and results within 4.5h of stroke onset  39.8% Beta Patient level data 
are suitable for thrombolysis (ischaemic stroke and younger than 
85 years)  30.1% 
Beta Patient level data 
have an ischaemic stroke and receive thrombolysis 12.7% Beta Patient level data 
For all stroke patients, percentage of…       
ischaemic stroke in all stroke patients 89% Beta Patient level data 
ischaemic stroke patients arriving within 4.5h of stroke onset 42% Beta Patient level data 
death* after stroke due to a haemorrhagic stroke  19% Beta Patient level data 
death   after stroke due to ischaemic stroke  19% Beta Patient level data 
death   after an ischaemic stroke and thrombolysis treatment  15% Beta Patient level data 
likelihood of being dependent/disabled after an ischaemic stroke  35% Beta Bamford (1990) 
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Parameter Value  Distribution Source 
Patients with true stroke symptoms 
Percentage with no prior contraindications for thrombolysis 95% Beta Patient level data 
Effectiveness of thrombolysis       
Decrease in dependency after stroke due to thrombolysis treatment 0.67 † Log normal Cochrane Review (2009) 
Life expectancy (in years)       
74 year old female with no history of stroke   9.9 Beta Adjusted ONS, Life 
tables§ 
69 year old male with no history of stroke 10.8 Beta Adjusted ONS, Life 
tables§ 
74 year old independent female with history of stroke    9.6 Beta Adjusted ONS, Life 
tables§ 
69 year old independent male with history of stroke 10.5 Beta Adjusted ONS, Life 
tables§ 
74 year old dependent female with history of stroke    8.7 Beta Adjusted ONS, Life 
tables§ 
69 year old dependent male with history of stroke 10.0 Beta Adjusted ONS, Life 
tables§ 
Utility score       
Dependent stroke patient 0.38 Beta Sandercock (2004) 
Independent stroke patient 0.74 Beta Sandercock (2004) 
Unit costs       
GP home visit  $120    PSSRU 2011 
GP phone call $22    PSSRU 2011 
GP surgery visit $37    PSSRU 2011 
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Parameter Value  Distribution Source 
Transportation by ambulance including paramedics $369    NHS Reference Costs 
2010/11 
Attending A&E leading to admission $348    NHS Reference Costs 
2010/11 
CT scan $140    NHS Reference Costs 
2010/11 
Thrombolysis (drug only) $1,057    BNF September 2011** 
Stroke costs (per year) ¶ 
 
    
Independent acute stroke $6,021  Gamma Sandercock (2002) HTA 
Report 
Dependent acute stroke $21,931  Gamma Sandercock (2002) HTA 
Report 
Long-term independent stroke $1,969  Gamma Sandercock (2002) HTA 
Report 
Long-term dependent stroke $25,919  Gamma Sandercock (2002) HTA 
Report 
Fatal stroke $14,191  Gamma Sandercock (2002) HTA 
Report 
* Death within one year of stroke 
† Odds ratio (95% Confidence intervals 0.61 to 0.75) 
§ Office for National Statistics (ONS); adjusted by mortality rates in post stroke years for each mRS level using published data28 
**BNF, March 2011. Cost refers to intravenous administration over 60 minutes, 900 micrograms/kg (max 90 mg); initial 10% of dose by intravenous 
injection (with diluents), remainder by intravenous infusion (with diluents, transfer device and infusion bag) 
¶ All figures have been adjusted using the Hospital and Community Health Service (HCHS) pay and price Index 2010/11 
NOTE: all figures were converted to US Dollars using the purchasing power parity (PPP) exchange rate 2012 = 0.681 per USD.25 
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Appendix 9. Search results for case study 2  
Search results via Cochrane Library 27/06/2016 
No. Searches Results 
1 MeSH descriptor: [thrombolytic therapy] 
explode all trees 
1764 
2 MeSH descriptor: [Stroke] explode all trees 6543 
3 1 AND 2 246 
Search results via Ovid MEDLINE 27/06/2016 
No. Searches Results 
1 Stroke 69958 
2 Thrombolytic therapy/ or Tissue Plasminogen 
Activator/ 
31876 
3 Rt-PA.mp 2010 
4 2 or 3 32119 
5 1 and 4 5294 
6 Cost-effectiveness.mp or cost-benefit analysis/ 80899 
7 Cost-utility.mp 2768 
8 Economic evaluation.mp or cost-benefit 
analysis/ 
68707 
9 6 or 7 or 8 83115 
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